paclitaxel has been researched along with Prostatic Neoplasms in 541 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (0.37) | 18.7374 |
| 1990's | 67 (12.38) | 18.2507 |
| 2000's | 280 (51.76) | 29.6817 |
| 2010's | 159 (29.39) | 24.3611 |
| 2020's | 33 (6.10) | 2.80 |
| Authors | Studies |
|---|---|
| Chai, H; Cordell, GA; Farnsworth, NR; Hollingshead, MG; Kardono, LB; Kinghorn, AD; Lantvit, D; Lee, IS; Mayo, JG; Mi, Q; Ngassapa, O; Peraza-Sánchez, S; Pezzuto, JM; Reyes-Lim, E; Riswan, S; Zhao, W | 1 |
| Dalton, JT; Gududuru, V; Hurh, E; Miller, DD | 1 |
| Denmeade, SR; Isaacs, JT; Khan, SR; Kumar, SK; Williams, SA | 1 |
| Henne, WA; Kularatne, SA; Low, PS; Santhapuram, HK; Vaitilingam, B; Venkatesh, C; Wang, K | 1 |
| Kim, YJ; Kwon, HC; Lee, KR; Park, HB; Park, JS; Yang, HO | 1 |
| Alaoui-Jamali, M; Bijian, K; Jiang, T; Li, G; Sun, X; Wan, S; Xu, B; Zhang, P | 1 |
| Ahn, S; Chen, J; Dalton, JT; Li, W; Lu, Y; Miller, DD; Wang, J | 1 |
| Dimas, K; Eleutheriades, A; Foscolos, GB; Georgakopoulou, S; Khan, H; Kourafalos, VN; Mantelas, A; Mirjolet, JF; Moutsos, VI; Papanastasiou, I; Pondiki, S; Prassa, M; Riganas, S; Serin, G; Theodoropoulou, M; Tsotinis, A; Vamvakides, A; Zaniou, A | 1 |
| Coelho, MG; Costa, PR; Justo, GA; Magalhães, FC; Martino, T; Netto, CD; Sabino, KC | 1 |
| Cai, S; Cichewicz, RH; Du, L; Hartley, RM; Mooberry, SL; Peng, J; Powell, DR; Robles, AJ; Shaffer, CV | 1 |
| Pham, NB; Quinn, RJ; Tran, TD | 1 |
| Booth, R; Forster, PI; Pham, NB; Quinn, RJ; Tran, TD | 1 |
| Arnst, KE; Banerjee, S; Deng, S; Kumar, G; Li, GB; Li, W; Miller, DD; Wang, Y; White, SW; Yang, J; Yang, L | 1 |
| Arnst, KE; Chen, H; Kumar, G; Li, W; Ma, D; Miller, DD; Wang, Q; Wang, Y; White, SW; Wu, Z; Yang, J | 1 |
| Goto, M; Izumi, K; Mizokami, A; Nakagawa-Goto, K; Saito, Y; Tsurimoto, H | 1 |
| Addo, EM; Anaya-Eugenio, GD; Carcache de Blanco, EJ; Ezzone, N; Henkin, JM; Kinghorn, AD; Ninh, TN; Ren, Y; Soejarto, DD | 1 |
| Aladinskaya, AV; Beloglazkina, EK; Ber, AP; Ivanenkov, YA; Kavalchuk, MV; Koteliansky, VE; Machulkin, AE; Majouga, AG; Nimenko, EA; Plotnikova, EA; Shafikov, RR; Skvortsov, DA; Uspenskaya, AA; Yakubovskaya, RI; Zyk, NU; Zyk, NV | 1 |
| Chen, IC; Chen, MC; Hsieh, CM; Hsu, KC; Lai, RW; Lin, TE; Liou, JP; Nepali, K; Ojha, R; Pan, SL | 1 |
| Akgün, E; Içduygu, FM; Özgöz, A; Oztürk, KH; Samli, H; Vatansever, B | 1 |
| Abasolo, I; Armiñán, A; Bogdanska, A; Borgos, SE; Calzolai, L; Fernández, Y; Foradada, L; Gallon, E; García-Aranda, N; Giménez, V; Gobbo, OL; Hyldbakk, A; Mancilla, S; Movellan, J; Niño-Pariente, A; Paul, A; Ponti, J; Prina-Mello, A; Schwartz, S; Vicent, MJ; Zagorodko, O | 1 |
| Duarte, D; Vale, N | 1 |
| Habrowska-Górczyńska, DE; Kowalska, K; Kozieł, MJ; Piastowska-Ciesielska, AW | 1 |
| Chen, S; Deng, X; Fu, S; He, G; Li, Y; Wu, M; Xue, L; Zheng, C; Zhu, J | 1 |
| Ewert, KK; Fisher, WS; Roberts, L; Safinya, CR; Tchounwou, C; Wei, S | 1 |
| Cao, H; Chen, L; Feng, Y; Gao, R; Wang, D | 1 |
| Ding, Z; Duan, P; Guan, Y; Li, R; Ruan, X; Shi, T; Zhang, D | 1 |
| Chen, C; Wang, YY | 1 |
| Arabzadeh, AA; Arabzadeh, M; Najafzadeh, N; Nejati-Koshki, K; Panahizadeh, R; Vatankhah, MA | 1 |
| Deng, C; Guo, H; Li, Z; Liang, T; Song, W; Yan, D; Ye, X | 1 |
| Tang, X; Tang, Y; Wang, Y; Yang, H; Zhang, Y; Zhang, Z | 1 |
| Abkenar, ZO; Babaei, R; Entezari, M; Hashemi, M; Hushmandi, K; Khorrami, R; Nabavi, N; Nejad, MM; Rahmanian, P; Rajabi, R; Rashidi, M; Ren, J; Rezaei, S; Sadi, FH; Shafiee, SS; Taheriazam, A; Talebi, Y; Zandieh, MA | 1 |
| Cardoso, AM; Coelho, RS; Maia, CJ; Nascimento, D; Passarinha, LA; Rocha, SM; Socorro, S | 1 |
| Aoyama, S; Iwamoto, H; Izumi, K; Kadomoto, S; Kadono, Y; Kamijima, T; Kano, H; Mizokami, A; Naito, R; Nakagawa, R; Nakagawa-Goto, K; Nakata, H; Saito, Y; Shimada, T; Toriumi, R; Yaegashi, H | 1 |
| Banerjee, R; Conn, CE; Drummond, CJ; Kirby, N; Pushpa Ragini, S; Reddy Bathula, S; White, J | 1 |
| Wang, Y; Wu, J; Xu, R; Yang, H; Zhang, S; Zhang, Y; Zhang, Z | 1 |
| Jiang, XZ; Shi, BK; Zhang, ZC; Zhao, HF | 1 |
| Delgado-Carreño, C; Méndez-Callejas, G | 1 |
| Jiao, M; Ju, C; Lin, H; Qu, D; Qu, G; Tian, C; Xue, J; Xue, L; Zhang, C | 1 |
| Biswas, K; Brautigan, DL; Larner, JM; Said, N; Sarkar, S | 1 |
| Chen, J; Jiang, M; Lu, P; Shen, G; Song, R; Xu, C; Zhang, W; Zhou, Y | 1 |
| Han, X; Li, X; Sun, J; Wei, P; Yang, J | 1 |
| Aghajani, M; Aghebati-Maleki, L; Asadzadeh, Z; Baradaran, B; Hajiasgharzadeh, K; Khaze Shahgoli, V; Mansoori, B; Mohammadi, A; Mokhtarzadeh, A; Safaei, S | 1 |
| Chogan, F; Faraji Dizaji, B; Goleij, P; Hasani Azerbaijan, M; Irani, M; Mirmajidi, T; Sharafian, F; Sheisi, N | 1 |
| Fang, K; Guo, Y; Lan, M; Liu, Y; Peng, Y; Qiao, B; Shen, D; Wang, Y; Zhu, L | 1 |
| Beer, TM; Beltran, H; Bergman, AM; Bianchini, D; Castro, E; Chi, KN; Conteduca, V; Cotait Maluf, F; De Giorgi, U; Di Lorenzo, G; Gillessen, S; Hansen, AR; Higano, C; Karalis, K; Klingbiel, D; Kuppen, MCP; Lavaud, P; Le, ML; Ledet, E; Martinez Chanza, N; Mehra, N; Morales-Barrera, R; Oh, WK; Omlin, A; Pezaro, C; Sartor, O; Schär, S; Schmid, S; Suzuki, H; Sweeney, C; Tsao, CK; Tucci, M; Vargas Pivato de Almeida, D; Yip, SM; Zivi, A; Zürrer-Härdi, U | 1 |
| Guo, Y; Leng, W; Liu, Q; Sun, D; Zhang, S | 1 |
| Ayari, J; Balti, M; Ben Abdallah, I; Ben Hassen, M; Ben Nasr, S; Doghri, Y; Fendri, S; Haddaoui, A; Trigui, E; Zribi, A | 1 |
| Chen, C; Chen, M; Dong, Y; Duan, Y; Fu, H; Guo, Q; Shen, M; Wang, L; Yang, X; Yu, J; Zhang, J; Zhang, Y | 1 |
| Gong, C; Qin, J; Yang, J; Yang, X | 1 |
| Jia, H; Jiang, S; Li, R; Lin, P; Liu, C; Wang, N; Wang, W; Xie, H; Yu, X | 1 |
| Chen, YS; Chiou, HL; Hsieh, YH; Hui, SC; Lee, CH; Lin, CY; Wu, MH | 1 |
| Aw Yong, KM; Fu, J; Merajver, SD; Sun, Y | 1 |
| Dai, J; Keller, ET; Lu, Y; Mizokami, A; Shi, J; Wang, L; Wang, W; Zhang, J; Zou, C | 1 |
| Chen, S; Henry, MD; Paudyal, P; Vaddi, PK; Xie, Q | 1 |
| Augsten, M; Bianchi, J; Bykov, VJ; Cheteh, EH; Egevad, L; Östman, A; Rundqvist, H; Sarne, V; Wiman, KG | 1 |
| Chiu, KT; Galimberti, V; Hiramatsu, N; Lin, JH; Mahadevan, NR; Nussbacher, JK; Rodvold, JJ; Willert, K; Zanetti, M | 1 |
| Chen, S; Guo, X; Hu, B; Jiang, W; Jin, X; Li, B; Meng, H; Wang, J; Wang, W; Yu, J; Zhang, T | 1 |
| Hao, L; Luo, Y; Tang, J; Wang, D; Wang, Y; Wang, Z; Wu, M; Zhang, M | 1 |
| Abdalla, MO; Ahmed, MSU; Jaynes, J; Salam, AB; Turner, T; Willian, K; Yates, C | 1 |
| Cao, H; Chen, L; Feng, Y | 1 |
| Dong, J; He, Z; Kan, Q; Lv, Q; Wei, W; Xu, Y; Yang, J; Yang, Z; Zhang, R | 1 |
| He, Z; Lv, Q; Wang, Y; Xu, Y; Yang, J; Yang, Z; Zhang, R | 1 |
| Cui, WG; Gui, SL; Li, W; Ma, HB; Tian, ZS | 1 |
| Cai, DW; Chen, D; Kong, GQ; Liu, F; Liu, ZJ; Sun, SP; Wu, PS; Xian, SZ | 1 |
| Chen, D; Guan, M; Hong, H; Li, R; Shu, C; Wan, LJ; Wang, C; Wang, X; Zhang, G; Zhang, Y; Zou, T | 1 |
| Chen, YY; Guo, H; Guo, R; Li, J; Li, Y; Liu, Y; Su, J; Sun, L; Tang, X; Zhang, P | 1 |
| Mitra, A; Owiti, AO; Pal, D | 1 |
| Ardicli, S; Aztopal, N; Balci, F; Dincel, D; Sahin, A; Samli, H; Samli, M; Vatansever, B | 1 |
| Guo, S; Lei, L; Liu, J; Shen, Y; Wu, K | 1 |
| Chen, W; Deng, J; Fang, Z; Hao, Y; Hu, X; Li, L; Liu, X; Luo, X; Wang, Q; Wu, Y; Xia, D; Xu, J; Yang, X; Zhang, T; Zhou, L | 1 |
| Geng, H; He, J; Sun, M; Tian, S | 1 |
| Guo, R; Li, JL; Li, Y; Liu, YN; Su, J; Sun, LK; Xue, YN; Yu, BB; Zhang, LC | 1 |
| Cong, Z; Guo, J; He, Y; Holmes, JD; Luan, X; O'Driscoll, CM; Rahme, K; Wang, L; Yang, H; Zou, Y | 1 |
| Hu, L; Qin, Z; Wang, X; Wu, Y | 1 |
| Guo, R; Li, JL; Li, Y; Liu, YN; Su, J; Sun, LK; Wu, Y; Xue, YN; Yan, XY; Yu, BB; Zhang, LC | 1 |
| Di, W; Ding, L; Duan, YR; Sun, Y; Wang, L; Wang, Q; Zhang, X; Zhu, WH | 1 |
| Fang, X; Fu, T; He, N; Huang, Q; Peng, Y; Sun, W; Tan, W; Wang, P; Zhang, P; Zhao, Z; Zhou, F | 1 |
| de Lima, MC; Gomes, CP; Gomes-da-Silva, LC; Moreira, JN; Ramalho, JS; Simões, S | 1 |
| Ye, DW | 1 |
| Derenne, A; Goormaghtigh, E; Mignolet, A | 1 |
| Gomes-da-Silva, LC; Moreira, JN; Pedroso de Lima, MC; Ramalho, JS; Simões, S | 1 |
| Hou, X; Huang, W; Kuang, S; Li, J; Li, Z; Liu, X; Ratliff, T; Staiger, C | 1 |
| Betbeder, D; Carpentier, R; Daher, S; Furman, C; Le Broc-Ryckewaert, D; Lipka, E; Vaccher, C | 1 |
| Akino, H; Aoki, Y; Ishida, H; Ito, H; Kusukawa, N; Ooyama, N; Tanase, K; Yokoyama, O | 1 |
| Abdel-Naim, AB; Abdel-Rahman, SZ; Al-Abd, AM; Azab, SS; Esmat, A; Khalifa, AE; Mosli, HA; Tolba, MF | 1 |
| Cascini, GL; Evangelista, L; Luigi, M | 1 |
| Hooper, JD; Lee, ST; Mustafa, MR; Wong, PF | 1 |
| Axiak-Bechtel, SM; Bryan, JN; Clarkson, NA; Dank, KK; Decedue, CJ; Espinosa, J; Kumar, SR; Rosol, TJ; Selting, KA | 1 |
| Ding, X; Jin, P; Xie, J; Yang, L; Zhou, C; Zhu, X | 1 |
| Dong, P; Guo, S; Jiang, L; Liu, J; Liu, Z; Wu, Z; Zhang, Z; Zhou, F | 1 |
| Gao, X; Jing, T; Sun, Y; Wang, F; Xu, C; Zhang, C | 1 |
| Bernie, A; Eastham, JA; Kelly, WK; Konety, BR; Maschino, AC; Poon, SA; Silberstein, JL; Sjoberg, DD; Vickers, AJ | 1 |
| Guo, L; Sun, L; Wang, K; Xiong, W; Zheng, Y | 1 |
| Barile, E; Dahl, R; Das, SK; Fisher, PB; Noberini, R; Pasquale, EB; Pellecchia, M; Stebbins, JL; Wang, S | 1 |
| Cui, J; Gao, Y; Li, C; Li, Y; Wang, C; Wei, N; Xiu, X; Zhao, X | 1 |
| Imada, K; Inokuchi, J; Itsumi, M; Kashiwagi, E; Naito, S; Shiota, M; Takeuchi, A; Tatsugami, K; Uchiumi, T; Yokomizo, A | 1 |
| Gorska, A; Grecka, E; Grygorowicz, MA; Lipiec, A; Malecki, M; Maryan, N; Mikula, M; Omiotek, M; Statkiewicz, M | 1 |
| Bydder, G; Bydder, M; Carmona, R; Gulaya, S; Mell, LK; Pritz, J; Vaida, F; Welch, CS; Williamson, CW; Zhu, H | 1 |
| Bevilacqua, A; Calastretti, A; Gatti, G; Quaresmini, C | 1 |
| Castilla, C; Flores, ML; Japón, MA; Medina, R; Pérez-Valderrama, B; Romero, F; Sáez, C; Tortolero, M | 1 |
| Angelucci, A; Botta, L; Calgani, A; Delle Monache, S; Sanità, P; Schenone, S | 1 |
| Kızılşahin, S; Nalbantsoy, A; Yavaşoğlu, NÜ | 1 |
| Chandratre, SS; Dash, AK | 1 |
| Chen, H; Cui, RJ; Li, D; Li, Y; Lin, F; Lin, P; Yu, XG; Zhao, LN; Zheng, XL; Zou, HF | 1 |
| Chun, YJ | 1 |
| Gao, Y; Li, J; Li, X; Li, Y; Liu, Y; Yuan, L; Zhang, C; Zhao, L; Zhou, Y | 1 |
| Chenchik, A; Kandel, ES; Makhanov, M; Matveev, V; Zynda, ER | 1 |
| Aloysius, H; Hu, L | 1 |
| Hearne, JL; Kiessu, E; Martin-Caraballo, M; Puplampu-Dove, YA; Weaver, EM; Zamora, FJ | 1 |
| Ayala, AG; Choi, EK; Divatia, M; Miles, BJ; Okoye, E; Ro, JY | 1 |
| Guo, F; Li, HZ; Lin, MC; Liu, CM; Qian, BJ; Zhang, C | 1 |
| Chen, CH; Chiu, YH; Chu, IH; Hong, YR; Huang, SB; Hung, SH; Kang, L; Lin, YT; Shen, YN; Wang, C; Yang, MC | 1 |
| Du, AW; Lu, H; Stenzel, MH | 1 |
| Huang, H; Liu, Y; Ren, J; Zheng, X; Zou, Q | 1 |
| Hoffman, RM; Jiang, P; Yang, M | 1 |
| Gao, Y; Li, J; Li, X; Li, Y; Liu, Y; Zhang, C; Zhao, L; Zhou, Y | 1 |
| Beretta, GL; Braunger, JA; Caruso, F; Cavalieri, F; Cui, J; Folini, M; Richardson, JJ; Tinelli, S; Yan, Y; Zaffaroni, N | 1 |
| Kaklamani, V; Siziopikou, K; Uthe, R; Waisbren, J | 1 |
| Dobelbower, M; Donavanik, V; Gomella, L; Grignon, D; Hamstra, DA; Hartford, AC; Hunt, D; Jones, CU; Kerlin, KJ; Kim, H; Kuban, DA; Michalski, J; Moughan, J; Pienta, KJ; Rajan, R; Rosenthal, SA; Rotman, M; Sandler, H; Sartor, AO; Seider, M; Shipley, WU; Zeitzer, K | 1 |
| Adhami, VM; Mukhtar, E; Mukhtar, H; Sechi, M | 1 |
| Bellucci, JJ; Bhattacharyya, J; Chi, JT; Chilkoti, A; Li, X; Lin, CC; McDaniel, JR; Spasojevic, I; Weitzhandler, I | 1 |
| Chang, TC; Chao, CC; Huang, SL; Lu, HP; Sun, NK | 1 |
| Lázaro-Ibáñez, E; Saari, H; Siljander, P; Viitala, T; Vuorimaa-Laukkanen, E; Yliperttula, M | 1 |
| Abasi, M; Abbasi, MM; Akbarzadeh, A; Jahanban-Esfahlan, R; Sani, HM | 1 |
| Getzenberg, RH; Li, Y; Song, Y; Yin, B; Zeng, Y; Zhang, C; Zhang, M | 1 |
| Adjei, IM; Labhasetwar, V; Peetla, C; Sharma, B | 1 |
| Chandra, D; Chaudhary, AK; Dubrovska, A; Goodrich, DW; Kumar, R; Kumar, S; O'Malley, J; Wang, X; Yadav, N | 1 |
| Fu, J; Keller, ET; Lu, Y; Mizokami, A; Wang, L; Yang, Y; Zhang, J | 1 |
| Castilla, C; Flores, ML; Gasca, J; Japón, MA; Medina, R; Pérez-Valderrama, B; Romero, F; Sáez, C | 1 |
| Camussi, G; Chatterjee, D; Chatterjee, DN; DeChalus, A; Keller, ET; Mendelsohn, AR; Mizokami, A; Quesenberry, PJ; Renzulli Ii, JF; Wang, JQ | 1 |
| Bamber, J; Bush, N; de Lange Davies, C; Healey, A; Kvåle, S; Sontum, PC; van Wamel, A | 1 |
| Mahato, RI; Mondal, G; Wen, D; Yang, R | 1 |
| Bazer, FW; Lim, W; Park, S; Song, G | 1 |
| Du, AW; Lu, H; Stenzel, M | 1 |
| He, J; Li, Z; Sun, LQ; Yang, X; Zhang, L | 1 |
| Cardenas, H; Díaz, P; Orihuela, PA | 1 |
| Aoyama, Y; Ichihara, M; Kawamoto, Y; Mizutani, N; Murate, T; Nozawa, Y; Sobue, S; Suzuki, M | 1 |
| Li, J; Song, X; Wen, Y; Zhang, ZX; Zhao, F; Zhu, JL | 1 |
| Kato, Y; Kijima, H; Liu, Q; Morohashi, S; Seino, H; Wu, Y; Yan, X; Yoshizawa, T | 1 |
| Cheng, Y; Ding, X; Jia, X; Jiang, J; Li, Y; Sharma, A; Wang, G; Xie, G | 1 |
| Fazli, L; Gleave, ME; Hayashi, N; Koller, E | 1 |
| Kisielewska, J; Klein, A; Ligeza, J | 1 |
| Azim, HA; Mok, T | 1 |
| Chachoua, A; Formenti, SC; Lepor, H; Sanfilippo, NJ; Taneja, SS | 1 |
| Efferth, T; Fu, Y; Jiang, S; Zhang, Y; Zu, Y | 1 |
| Aragon-Ching, JB; Dahut, WL; Desai, N; Figg, WD; Gardner, ER; Hawkins, MJ; Jones, J; Scripture, CD; Sparreboom, A | 1 |
| Arbini, AA; Greco, M; Marra, E; Moro, L | 1 |
| Bertoni, F; Capri, G; Catapano, CV; Cresta, S; Gallerani, E; Gianni, L; Maccioni, E; Maur, M; Passalacqua, D; Rinaldi, A; Sessa, C; Tosi, D; Viganò, L | 1 |
| Corn, B; Domb, AJ; Gofrit, O; Nyska, A; Shikanov, A; Shikanov, S | 1 |
| Guinan, P; Rubenstein, M; Tsui, P | 3 |
| Ettinger, S; Fazli, L; Gleave, ME; Hayashi, N; Kim, Y; Muramaki, M; Narita, S; So, A | 1 |
| Bogart, J; Elfiky, A; Halabi, S; Kelly, WK; Ou, SS; Small, E; Zelefsky, M | 1 |
| Asbell, SO; Bae, K; Kerlin, KJ; Michalski, JM; Pienta, KJ; Rajan, R; Rosenthal, SA; Sandler, HM; Sobczak, ML | 1 |
| Amato, RJ; Henary, H; Hernandez-McClain, J | 1 |
| Bai, A; Beckham, TH; Bielawska, A; Bielawski, J; Cheng, JC; Elojeimy, S; Garcia, N; Gault, CR; Hammouda, HM; Hannun, YA; Keane, TE; Li, J; Liu, X; Mahdy, AE; McPherson, AS; Meacham, WD; Norris, JS; Saad, A; Taha, MI; Turner, LS | 1 |
| Chen, JL; He, BS; Jiang, HX; Pan, YQ; Wang, B; Wang, SK; Zeng, QD; Zhang, LR | 1 |
| Feng, L; Liu, Q; Liu, Y; Lv, W; Shang, D; Tian, Y; Zhang, F | 1 |
| Fabritius, M; Ip, C; Wu, Y | 1 |
| Dreicer, R; Elson, P; Garcia, J; Klein, EA; Magi-Galluzzi, C; Raghavan, D; Shepard, DR; Stephenson, AJ | 1 |
| Bagley, RG; Crawford, JL; Krumbholz, RD; Kurtzberg, LS; Roth, SD; Rouleau, C; Schmid, SM; Teicher, BA; Yao, M | 1 |
| Fukunaka, Y; Hirano, G; Izumi, H; Kashiwagi, E; Kidani, A; Kohno, K; Masubuchi, D; Miyamoto, N; Naito, S; Nishizawa, S; Sasaguri, Y; Shiota, M; Takahashi, M; Tanimoto, A; Yasuniwa, Y | 1 |
| Kumar, S; Lavhale, MS; Mishra, SH; Sitasawad, SL | 1 |
| Kovel, S; Sella, A; Yarom, N; Zisman, A | 1 |
| He, HW; Li, BW; Shao, RG; Zhang, M; Zhang, SH | 1 |
| Bell, R; Debrincat, MA; Ganju, V; Henry, M; Kosmider, S; Le, B; Sewak, S; Woollett, A; Yeow, EG | 1 |
| Erez, R; Miller, K; Satchi-Fainaro, R; Segal, E; Shabat, D | 1 |
| Alken, P; Bode, C; Kraenzlin, B; Michaelis, U; Michel, MS; Teifel, M; Trojan, L; Weiss, C | 1 |
| Lacko, AG; McConathy, WJ; Mooberry, LK; Nair, M; Paranjape, S | 1 |
| Chen, XG; Liu, JH; Xia, JS; Ye, ZQ; Zhuang, QY | 1 |
| Dai, J; Izumi, K; Keller, ET; Li, Y; Mizokami, A; Namiki, M; Narimoto, K; Shima, T; Zhang, J | 1 |
| Bray, K; Chen, HY; DiPaola, RS; Ganesan, S; Karantza-Wadsworth, V; Karp, CM; May, M; White, E | 1 |
| Agus, DB; Bearss, D; Berk, G; Hodge, A; Jain, A; Kanekal, S; Mumenthaler, SM; Ng, PY; Redkar, S; Taverna, P | 1 |
| Bohrer, L; Chen, S; Gan, L; Huang, H; Sun, Z; Wang, Y; Watahiki, A | 1 |
| Chouai, A; Lim, J; Liu, W; Lo, ST; Simanek, EE; Sun, X | 1 |
| Abbou, CC; Allory, Y; Culine, S; de la Taille, A; Hoznek, A; Paule, B; Ploussard, G; Salomon, L; Terry, S; Vacherot, F; Vordos, D | 1 |
| Alumkal, J; Beer, TM; Eilers, KM; Ryan, C; Ryan, CW; Sun, J | 1 |
| Bekele, NB; Carter, CM; Mathew, P; Pagliaro, L; Tannir, N; Tu, SM | 1 |
| Callari, M; Colecchia, M; Daidone, MG; Folini, M; Gandellini, P; Longoni, N; Pennati, M; Profumo, V; Salvioni, R; Supino, R; Valdagni, R; Veneroni, S; Zaffaroni, N | 1 |
| Cheng, J; Fan, TM; Tong, R; Yala, L | 1 |
| Carducci, M; Chen, YH; DiPaola, RS; Patrick-Miller, L; Roth, B; Stein, M; Vaughn, D; White, E; Wilding, G | 1 |
| Arakawa, S; Fujisawa, M; Matsumoto, O; Shigemura, K; Yasufuku, T | 1 |
| Cai, L; Chen, L; Chen, X; Fu, A; Hu, J; Li, X; Liu, Y; Mao, Y; Shao, X; Wang, X; Wang, Y; Wei, Y; Wu, W; Xiao, W; Yang, L; Ye, X | 1 |
| Deguchi, T; Fujita, Y; Hamada, N; Ito, M; Kitamoto, A; Kojima, K; Kojima, T; Kondo, S; Nozawa, Y; Ohhashi, R; Sato, A | 1 |
| Adiseshaiah, PP; Clogston, JD; Dobrovolskaia, M; Lim, J; Lo, ST; Patri, AK; Simanek, EE; Stern, S; Sun, X; Zheng, J | 1 |
| Chang, YH; Chen, WJ; Chuang, CK; Chuang, HC; Chuang, KL; Hua, MY; Pang, ST; Tsai, RY; Yang, HW | 1 |
| Ding, Y; Yang, L; Zhang, ZY; Zhou, LQ | 1 |
| Deguchi, T; Fujita, Y; Ito, M; Kojima, K; Nozawa, Y | 1 |
| Cho, HS; Dong, Z; Ewing, RC; Gu, H; Huth, C; Pauletti, GM; Shi, D; Wang, F; Wang, L; Xu, H; Zhang, J | 1 |
| Ito, T; Kawashima, H; Nakatani, T; Omachi, T; Tamada, S | 1 |
| Dafni, H; Hu, S; Larson, PE; Ronen, SM; Venkatesh, HS; Vigneron, DB; Wang, C; Ward, CS; Yoshihara, HA; Zhang, X | 1 |
| Abu Ajaj, K; El-Melegy, N; Elsadek, B; Esser, N; Graeser, R; Kratz, F; Madkor, H; Saleem, T; Schäfer-Obodozie, C; Unger, C; Warnecke, A | 1 |
| Jiang, R; Li, J; Zhang, Y; Zhang, Z; Zhao, D; Zhao, X; Zu, Y | 1 |
| Amin, P; Bridges, B; Dawson, N; DiBiase, S; Engstrom, C; Goloubeva, O; Hussain, A; Kwok, Y; Mannuel, H; Mirmiran, A; Wu, Y | 1 |
| Tageja, N | 1 |
| Al-Abed, Y; Caponnetto, S; Donia, M; Fagone, P; Maksimovic-Ivanic, D; McCubrey, J; Mijatovic, S; Miljkovic, D; Mojic, M; Nicoletti, F; Stosic-Grujicic, S; Timotijevic, G | 1 |
| Fu, Y; Jiang, S; Wang, Z; Zhang, Y; Zu, Y | 1 |
| Gao, J; He, Q; Hu, Z; Li, J; Liu, D; Lu, Y; Song, Z; Tang, J; Wang, Z; Wu, D; Yi, T; Yin, W; Zhang, X; Zhang, Z | 1 |
| Golshayan, A; Harrer, GW; Hussain, MH; Mills, GM; Smith, DC; Tangen, CM; Thompson, IM; Van Veldhuizen, PJ; Vogelzang, NJ | 1 |
| Galoforo, S; Krueger, SA; Marples, B; Martinez, AA; Swanson, TA; Thibodeau, BJ; Wilson, GD | 1 |
| Hirsch, HA; Iliopoulos, D; Struhl, K | 1 |
| Getzenberg, RH; Li, Y; Mizokami, A; Mooney, SM; Namiki, M; Yin, B; Zeng, Y | 1 |
| Burt, HM; Chiao, M; Jackson, JK; Pirmoradi, FN; Siu, T; Wan, CP | 1 |
| Babich, JW; Eckelman, WC; Hillier, SM; Joyal, JL; Kern, AM; Maresca, KP; Marquis, JC | 1 |
| Beraldi, E; Gleave, ME; Kumano, M; Naito, S; Nelson, CC; Shiota, M; Sorensen, PH; Zoubeidi, A | 1 |
| Chen, YC; Chiang, PC; Guh, JH; Ho, YF; Kung, FL; Lu, PH; Yu, CC | 1 |
| Deguchi, T; Fujita, Y; Ito, M; Kato, T; Kojima, T; Nakane, K; Nozawa, Y | 1 |
| Chang, YH; Chu, PC; Chuang, CK; Chuang, HC; Hua, MY; Liu, HL; Pang, ST; Tsai, RY; Wu, PY; Yang, HW; Yu, KJ | 1 |
| Hill, S; Lim, J; Lo, ST; Pavan, GM; Simanek, EE; Sun, X | 1 |
| Chen, CS; Guh, JH; Ho, YF; Hsu, JL; Hsu, LC; Leong, PK; Lu, PH | 1 |
| David, A; Journo-Gershfeld, G; Kapp, D; Kopeček, J; Shamay, Y | 1 |
| Koroleva, IA; Mochalova, AS | 1 |
| He, J; Kim, JS; Kim, SJ; Kim, SW; Lee, HJ; Papadopoulos, JN; Park, YK; Yoon, Y; Yu, HK | 1 |
| Adediran, S; Hussain, A; Khan, MA; Livak, F; Ning, Y; Suer, S; Vemula, A; Zhang, B | 1 |
| Bozionellou, V; Georgoulias, V; Giassas, S; Kalykaki, A; Kentepozidis, N; Kotsakis, A; Pantazopoulos, N; Papadimitraki, E; Soultati, A; Vardakis, N | 1 |
| Beraldi, E; Gleave, ME; Li, N; Zoubeidi, A | 1 |
| Albino, D; Carbone, GM; Catapano, CV; Chiorino, G; D'Ambrosio, G; Kunderfranco, P; Longoni, N; Mello-Grand, M; Pellini, S; Pinton, S; Sarti, M; Sessa, F | 1 |
| Behrman, SW; Chitkara, D; Mahato, RI; Mehrazin, R; Singh, S; Wake, RW | 1 |
| Iida, K; Nanus, DM; Shen, R; Zheng, R | 1 |
| Sillerud, LO; Taylor, RM | 1 |
| Hayakawa, Y; Hirano, K; Iguchi, K; Ishii, K; Matsumoto, K; Sugimura, Y; Usui, S | 1 |
| Gao, X; Huang, Y; Li, J; Li, S; Lu, J; Marquez, RT; Meng, X; Venkataramanan, R; Wang, Z; Zhao, W | 1 |
| An, SS; Christudass, CS; Fabry, B; Getzenberg, RH; Kim, JJ; Lee, DY; Mooney, SM; Rajagopalan, K; Shiraishi, T; Terada, N; Veltri, RW; Yin, B | 1 |
| Cameron, KS; Hill, BJ; Howard, CB; Izevbigie, EB; Tchounwou, PB | 1 |
| Logothetis, CJ | 1 |
| Ernst, DS | 1 |
| Bombardelli, E; Cassinelli, G; Cuccuru, G; Laccabue, D; Lanzi, C; Pratesi, G; Supino, R; Zuco, V; Zunino, F | 1 |
| Hsieh, YC; Kies, MS; Kuzel, TM; Rademaker, AW; Wu, N | 1 |
| de Wit, R; Petrylak, DP | 1 |
| Petrylak, DP | 4 |
| Akerley, W; Hixson, DC; Makarovskiy, AN; Siryaporn, E | 1 |
| Avancès, C; Culine, S; Jacot, W; Sénesse, P | 1 |
| Agus, DB; Cordon-Cardo, C; Drobnjak, M; Fox, WD; Higgins, B; Maiese, KM; Scher, HI | 1 |
| Bucana, C; Dinney, CP; Fan, D; Fidler, IJ; Huang, SF; Karashima, T; Kedar, D; Killion, JJ; Kim, SJ; Lee, AT; Mian, B; Shepherd, D; Sweeney, P | 1 |
| Agus, D; Bonham, MJ; Galkin, A; Montgomery, B; Nelson, PS; Stahl, WL | 1 |
| Howard, A; Nicolopoulos, J | 1 |
| Dulin, N; Gabai, VL; Hatch, W; Kolenko, VM; Leavis, P; Uzzo, RG; Zvartau, N | 1 |
| Igawa, M; Kikuno, N; Kishi, H; Shigeno, K; Shiina, H; Urakami, S; Yoshino, T | 1 |
| Kelly, WK; Scher, HI | 1 |
| Chen, J; Lee, F; Scher, HI; She, Y; Sirotnak, FM | 1 |
| Du, W; Fontana, J; Hussain, M; Vaishampayan, U | 1 |
| Kelly, K; Morris, MJ; Santamauro, J; Scher, H; Schwartz, L; Shia, J; Vander Els, N | 1 |
| Capozzoli, MJ; Egorin, MJ; Hershberger, PA; Johnson, CS; Muindi, JR; Peng, Y; Potter, DM; Tauch, JS; Trump, DL | 1 |
| Kondrikov, D; Lin, MF; Rothermund, CA; Vishwanatha, JK | 1 |
| Beer, TM; Egorin, MJ; Eilers, KM; Garzotto, M; Henner, WD; Lowe, BA | 1 |
| Agrawal, S; Wang, H; Yu, D; Zhang, R | 1 |
| Barrett, M; Burnitz, MC; Dipierro, C; Eto, M; Gibson, JJ; Myers, C; Phelps, C; Read, P; Somlyo, AP; Somlyo, AV | 1 |
| Curley, T; Heller, G; Kelly, WK; Regan, K; Scher, HI; Smaletz, O; Verbel, DA | 1 |
| Brewster, SF; Ferguson, DJ; Hellawell, GO; Macaulay, VM | 1 |
| Naito, K | 1 |
| Nishimura, K; Nonomura, N; Okuyama, A; Takahara, S | 1 |
| Cannon, MW; Jones, D; Kuebler, JP; Lee, SJ; Logothetis, CJ; Millikan, R; Thall, PF; Wade, J | 1 |
| Mimata, H; Miyamoto, E; Nomura, T; Nomura, Y; Takeuchi, Y; Yamamoto, H | 1 |
| Arlen, P; Dahut, WL; Figg, WD; Gulley, J; Horne, MK; Lakhani, N; Parker, C; Parnes, H | 1 |
| Apiou, F; Arvelo, F; Bara, J; Boye, K; de Pinieux, G; Dutrillaux, AM; Dutrillaux, B; Legrier, ME; Lidereau, R; Poirson-Bichat, F; Poupon, MF; Sihassen, A | 1 |
| Fidler, IJ; Karashima, T; Killion, JJ; Kim, SJ; Shepherd, DL; Uehara, H | 1 |
| Fan, D; Fidler, IJ; Karashima, T; Killion, JJ; Kim, SJ; Logothetis, C; Mathew, P; Shepherd, DL; Tsan, R; Uehara, H | 1 |
| Guinan, P; Mirochnik, Y; Rubenstein, M; Slobodskoy, L | 1 |
| Du, W; El-Rayes, BF; Fontana, J; Hussain, M; Sakr, W; Smith, DC; Vaishampayan, U; Wood, D | 1 |
| Boyé, K; Bras-Gonçalves, R; De Cremoux, P; De Pinieux, G; Legrier, ME; Oudard, S; Poupon, MF | 1 |
| Eberwein, DJ; Ingram, AC; Knick, VC; Murray, DM; Ryan, CH; Stimmel, JB; Thurmond, LM; Witherspoon, SM | 1 |
| Comninos, A; Day, JM; Leese, MP; Newman, SP; Potter, BV; Purohit, A; Reed, MJ; Solomon, C | 1 |
| Siderov, J | 1 |
| Correale, P; Di Palma, T; Francini, G; Manganelli, A; Marsili, S; Messinese, S; Petrioli, R; Pozzessere, D; Sabatino, M; Salvestrini, F | 1 |
| Beers, S; Capanna, T; DiPaola, RS; Doyle-Lindrud, S; Dvorzhinski, D; Goodin, S; Poplin, E; Rubin, E; Shih, J; Thalasila, A | 1 |
| Curley, T; Fallon, M; Hartley-Asp, B; Kelly, WK; Larson, S; Pellizzoni, C; Rocchetti, M; Scher, H; Schwartz, L; Slovin, S; Tong, W; Zhu, AX | 1 |
| Beer, TM; Eilers, KM; El-Geneidi, M | 1 |
| Widmark, A | 1 |
| Abdel-Mageed, AB; Agrawal, KC; Davis, R; Flynn, V; Moparty, K; Ramanitharan, A; Sikka, S | 1 |
| Chay, CH; Dunn, RL; Esper, P; Fardig, J; Olson, K; Pienta, KJ; Smith, DC | 1 |
| Adinin, RB; Ahmadi, MA; Arbuckle, R; Coats, C; Esmaeli, B; Faustina, M; Hidaji, L; Rivera, E; Tu, SM; Valero, V | 1 |
| Kampel, LJ | 1 |
| Baba, S; Egawa, S; Fujita, T; Kuruma, H; Shitara, T; Yokoyama, E | 1 |
| Beer, TM; Eilers, KM; Garzotto, M; Henner, WD; Wersinger, EM | 1 |
| Davis, TL; Hauke, R; Kakitelashvilli, V; Kellerman, M; Lee, MS; Lin, MF; Lugo, E; Spellman, M; Taylor, R; Zelivianski, S; Zhou, XW | 1 |
| Bardou, VJ; Bladou, F; Camerlo, J; Genre, D; Gravis, G; Macquart-Moulin, G; Maraninchi, D; Salem, N; Serment, G; Viens, P | 1 |
| Budman, DR; Ferrari, AC; Jiang, JD; Liu, XM; Wang, LG | 1 |
| Curley, T; Hartley-Asp, B; Kattan, MW; Kelly, WK; Larson, S; Morris, M; Scher, HI; Schwartz, L; Slovin, S; Solit, DB | 1 |
| Aggarwal, A; Baranda, J; Reed, G; Van Veldhuizen, PJ; Williamson, S; Zulfiqar, M | 1 |
| Syed, S | 1 |
| Butts, JA; Greco, FA; Hainsworth, JD; Meluch, AA; Morrissey, LH; Raefsky, EL; Steis, RG | 1 |
| Bellucci, A; Calvani, M; Camerini, B; Carminati, P; Castorina, M; Cavaletti, G; Cicuzza, S; Galbiati, S; Laccabue, D; Lo Giudice, P; Marmiroli, P; Nicolini, G; Pacifici, L; Pisano, C; Pratesi, G; Tredici, G; Vesci, L; Zunino, F | 1 |
| Cheung, HW; Guan, XY; Lee, DT; Ling, MT; Tsao, SW; Wang, X; Wong, YC | 1 |
| Dang, W; Denmeade, SR; DeWeese, TL; Gady, AM; Lapidus, RG; O'Meally, R; Rosen, DM; Zabelinka, Y | 1 |
| Brown, AW; Harker, WG; Huh, S; Kabbinavar, F; Miller, L; Rinaldi, D; Vaughn, DJ | 1 |
| Cheville, JC; Lingle, WL; Mitchell, RF; Mora, GR; Olivier, KR; Tindall, DJ | 1 |
| Ishida, E; Kishi, M; Konishi, N; Matsuyoshi, S; Nakamura, M; Shimada, K | 1 |
| Dahut, WL; Figg, WD; Retter, AS | 1 |
| Ahmad, I; Dritschilo, A; Gokhale, PC; Kasid, UN; Mewani, RR; Rahman, A; Tang, W | 1 |
| Chapelon, JY; Chesnais, S; Curiel, L; Gelet, A; Paparel, P; Rabilloud, M | 1 |
| Bilkenroth, U; Froehner, M; Fuessel, S; Kraemer, K; Linné, C; Meye, A; Schmidt, U; Wirth, MP | 1 |
| Albertsson, P; Damber, JE; Lennernäs, B; Norrby, K | 1 |
| Horiatis, D; Pinski, J; Wang, Q | 1 |
| Fan, D; Fidler, IJ; He, J; Killion, JJ; Kim, SJ; Langley, RR; Tsan, R; Uehara, H; Yazici, S | 1 |
| Coffey, R; Fitzpatrick, JM; McEleny, K; Morrissey, C; Watson, RW | 1 |
| Cassinelli, G; Lanzi, C; Scovassi, AI; Semple, SC; Supino, R; Zuco, V; Zunino, F | 1 |
| Labhasetwar, V; Ma, W; Sahoo, SK | 1 |
| Beraldi, E; Fazli, L; Gleave, M; Hurtado-Coll, A; Kojima, S; Rocchi, P; Signaevsky, M; So, A; Yamanaka, K | 1 |
| Marumo, K; Mizuno, R; Murai, M; Nakashima, J; Ohigashi, T | 1 |
| Chen, YR; Li, H; Lu, YP; Sun, M; Wang, ZP; Wei, Q; Yang, YR; Yue, ZJ | 1 |
| Bubley, GJ; He, X; Jayaram, DR; Merchan, JR; Sukhatme, VP; Supko, JG | 1 |
| Asmar, L; Berry, WR; Dakhil, SR; Gregurich, MA; Hathorn, JW; Jackson, DV; Loesch, DM; Newcomb-Fernandez, JK | 1 |
| Igawa, M; Kikuno, N; Kishi, H; Moriyama-Gonda, N; Shigeno, K; Shiina, H; Terashima, M; Urakami, S; Yoneda, T; Yoshida, M; Yoshino, T | 1 |
| Chen, Y; Li, H; Lu, Y; Sun, M; Wang, Z; Wei, Q; Yang, Y; Yue, Z | 1 |
| Lee, JT; McCubrey, JA; Steelman, LS | 1 |
| Blanco, J; El Hilali, N; Rubio, N | 2 |
| Bartoletti, R; Cipriani, G; Della Melina, A; Di Cello, V; Dominici, A; Fulignati, C; Maleci, D; Neri, B; Nicita, G; Ponchietti, R; Raugei, A; Turrini, M; Villari, D | 1 |
| Douglas, DA; Gowardhan, B; Leung, HY; Mathers, ME; McCracken, SR; McKie, AB; Robson, CN | 1 |
| Barthomeuf, C; Bay, JO; Cabrespine, A; Chollet, P; Curé, H; Debiton, E | 1 |
| Bermudez, RS; Chakravarti, A; Delaney, MA; Latham, DE; Mukherjee, N; Shipley, WU; Zhang, M; Zietman, AL | 1 |
| Honda, S; Igawa, M; Imai, S; Kikuno, N; Kishi, H; Shigeno, K; Shiina, H; Urakami, S; Yoneda, T; Yoshino, T | 1 |
| Hu, H; Ip, C; Jiang, C; Lü, J; Rustum, YM | 1 |
| Chapelon, JY; Chesnais, S; Curiel, L; Ecochard, R; Gelet, A; Paparel, P | 1 |
| Burt, HM; Gleave, ME; Jackson, JK; Springate, CM | 1 |
| Fan, D; Fidler, IJ; He, J; Kim, SJ; Langley, RR; Mathew, P; Uehara, H; Yazici, S | 1 |
| Johnson, CS; Muindi, JR; Peng, Y; Potter, DM; Trump, DL | 1 |
| Axanova, L; Morré, DJ; Morré, DM | 1 |
| Russell, PJ; Zhang, AL | 1 |
| Altmann, KH; Hattenberger, M; McSheehy, PM; Muller, M; O'Reilly, T; Vaxelaire, J; Wartmann, M; Wenger, F | 1 |
| Busby, JE; Fan, D; Fidler, IJ; He, J; Kim, SJ; Thaker, P; Yazici, S; Yokoi, K | 1 |
| Chan, FL; Chan, KW; Chua, CW; Glackin, C; Kwok, WK; Lau, TC; Lee, TW; Ling, MT; Wang, X; Wong, YC; Zhang, X; Zhou, C | 1 |
| Avila, GE; Chang, RL; Conney, AH; Crowell, P; Cui, XX; Hansson, A; Lin, Y; Lou, YR; Lu, YP; Rabson, AB; Ryan, AD; Shih, WJ; Suh, J; Zheng, X | 1 |
| Baybik, J; Chi, KN; Eggener, SE; Eigl, BJ; Ettinger, S; Gleave, ME; Nelson, C; Wang, Z | 1 |
| Guruli, G; Nelson, JB; Pflug, BR; Udan, MS | 1 |
| Corcoran, NM; Costello, AJ | 1 |
| Chew, HK; DeNardo, GL; Denardo, SJ; Goldstein, DS; Kukis, DL; Lamborn, KR; Lara, PN; Meares, CF; Natarajan, A; O'Donnell, RT; Richman, CM; Shen, S; Tuscano, JM; Wun, T; Yuan, A | 1 |
| Mimata, H; Nomura, T; Nomura, Y; Yamasaki, M | 1 |
| DeNardo, G; DeNardo, S; Lamborn, K; Miers, L; Natarajan, A; Richman, C; Yuan, A | 1 |
| Albrecht, H; Burke, PA; DeNardo, GL; DeNardo, SJ; Gregg, JP; Natarajan, A; O'Donnell, RT; Richman, CM; Yuan, A | 1 |
| Lamph, WW; Yen, WC | 1 |
| Habuchi, T; Higashi, S; Ito, A; Ito, N; Kamoto, T; Kinoshita, H; Kunishima, Y; Nakamura, E; Nishiyama, H; Ogawa, O; Segawa, T; Takahashi, T; Yamamoto, S; Yoshimura, K | 1 |
| Fazli, L; Gleave, ME; Miyake, H; Rocchi, P; Vessella, B; Yamanaka, K; Zangemeister-Wittke, U | 1 |
| Ling, MT; Wang, X; Wong, YC; Zhang, X | 2 |
| Kim, TH; Ren, B; Sun, P; Xiong, H; Zhang, Z | 1 |
| Dewan, P; Lin, DW; Montgomery, RB; Wright, JL | 1 |
| Perez-Stable, C | 1 |
| Kamoto, T; Kinoshita, H; Nakanishi, S; Ogawa, O; Sawada, A; Segawa, T; Yamamoto, S | 1 |
| Chueh, SC; Guh, JH; Huang, DM; Huang, YT; Teng, CM | 1 |
| Guan, JY; Hour, TC; Hsieh, MW; Huang, CY; Lin, CC; Lin, SR; Liu, GY; Pu, YS; Wang, CW | 1 |
| Barthomeuf, C; Bay, JO; Cabrespine, A; Chollet, P; Curé, H; Fleury, J; Guy, L; Khenifar, E; Kwiatkowski, F; Penault-Llorca, F | 1 |
| Bay, JO; Cabrespine, A; Chollet, P; Curé, H; Gachon, F; Guy, L | 1 |
| Eberding, A; Fazli, L; Gleave, M; Goldenberg, L; Guns, ES; Jia, W; Madera, C; Xie, X | 1 |
| Fazli, L; Gleave, ME; Miyake, H; Rocchi, P; So, A; Yamanaka, K; Zangemeister-Wittke, U | 1 |
| Amato, RJ; Sarao, H | 1 |
| Anezinis, P; Castanas, E; Charalampopoulos, I; Gravanis, A; Hatzoglou, A; Kampa, M; Kogia, C; Papakonstanti, EA; Stathopoulos, EN; Stournaras, C; Theodoropoulos, PA | 1 |
| Avila, GE; Chang, RL; Conney, AH; Cui, XX; Garzotto, M; Hebbar, V; Kong, AN; Lin, Y; Lu, SE; Rabson, AB; Shih, WJ; Zheng, X | 1 |
| Busby, JE; Do, KA; Fan, D; Fidler, IJ; He, J; Kim, SJ; Logothetis, C; Mathew, P; Maya, M; Nakamura, T; Uehara, H; Wang, X; Yazici, S | 1 |
| Babcic, V; Harnam, N; Kantoff, PW; Manola, J; Oh, WK | 1 |
| Inui, K; Ito, N; Jiko, M; Kamoto, T; Katsura, T; Masuda, S; Motohashi, H; Nishiyama, H; Ogawa, O; Sato, E; Segawa, T; Takahashi, K; Yano, I | 1 |
| Goto, T; Kadomatsu, K; Muramatsu, T; Takei, Y | 1 |
| Fidler, IJ | 1 |
| Bhagat, S; Cher, M; Chinni, SR; Deng, X; Dong, Z; Mullins, C | 1 |
| Busby, JE; Do, KA; Fan, D; Fidler, IJ; He, J; Kim, JS; Kim, SJ; Maya, M; Nakamura, T; Wang, X; Yazici, S | 1 |
| Asmar, L; Berry, W; Boehm, KA; Fleagle, J; Friedland, D; Ilegbodu, D; Jackson, D | 1 |
| Bekele, BN; Chen, I; Daliani, DD; Dieringer, PY; Logothetis, CJ; Mathew, P; Pagliaro, LC; Zhou, X | 1 |
| Mancuso, A; Oudard, S; Sternberg, CN | 1 |
| Atweh, GF; Mistry, SJ | 1 |
| Benita, S; Gofrit, O; Goldstein, D; Nyska, A | 1 |
| Amalia, A; Azzariti, A; Bruno, P; Calastretti, A; Canti, G; Nicolin, A; Paradiso, A; Priulla, M | 1 |
| Cuccuru, G; Favini, E; Scovassi, AI; Supino, R; Zunino, F | 1 |
| Chen, JW; Meng, QG; Tang, Y; Wang, ZR; Xie, D | 1 |
| Keller, ET; Li, YQ; Mamiya, K; Mizokami, A; Namiki, M; Takeda, M; Zhang, J | 1 |
| Huang, X; Liu, XK; Mu, DZ; Qu, Y; Wu, W; Yang, CL; Zhang, L | 1 |
| Addeo, A; Bertetto, O; Chiappino, I; Cucchiarale, G; Destefanis, P; Ferrando, U; Fontana, D; Galetto, A; Munoz, F; Ricardi, U; Tizzani, A; Zitella, A | 1 |
| Chakrabarti, R; Davila, M; Ghosh, D; Grizzle, WE; Jhala, D | 1 |
| Beer, TM; Garzotto, M; Lin, D; Montgomery, RB; Nelson, PS; Ryan, CW | 1 |
| Brown, PN; Eberding, A; Guns, ES; Madera, C; Wood, CA; Xie, S | 1 |
| Cooney, KA; Dunn, RL; Fardig, JE; Mackler, NJ; Olson, KB; Pienta, KJ; Redman, BG; Smith, DC | 1 |
| Paterlini, M | 1 |
| Burt, HM; Gleave, ME; Jackson, JK; Lu, J | 1 |
| Knittel, T; Milross, C; Russell, PJ; Zhang, AL | 1 |
| Cheung, ALM; Lau, CK; Lee, TK; Leung, SCL; Ling, MT; Wang, Q; Wang, X; Wong, YC; Zhang, X | 1 |
| Daskivich, TJ; Oh, WK; Regan, MM | 1 |
| Downing, KH; Killilea, AN; Killilea, DW | 1 |
| de Korte, FI; Ten Berg, JM; van Werkum, JW; Vijverberg, PL | 1 |
| Brown, MA; Logothetis, C; Millikan, RE; Pagliaro, LC; Thall, PF; Wen, S; Williams, D | 1 |
| Deguchi, T; Ehara, H; Ito, H; Mizutani, K; Nagata, K; Nozawa, Y | 1 |
| Bajgelman, MC; Strauss, BE | 1 |
| Au, JL; Walsh, CT; Wei, Y; Wientjes, MG | 1 |
| Cetnar, JP; Malkowicz, SB; Palmer, SC; Vaughn, DJ; Wein, AJ | 1 |
| Combs, GF; Hu, H; Li, GX; Lü, J; Wang, L; Watts, J | 1 |
| Gerogianni, I; Gourgoulianis, K; Gravas, S; Melekos, MD; Nakou, M; Papadopoulos, D; Terzis, A; Tzortzis, V | 1 |
| Ling, MT; Wang, XH; Wong, YC; Zhang, XM | 1 |
| Gomella, L; Greenberg, R; Hudes, GR; Khater, C; McAleer, C; Nathan, FE; Stern, C | 1 |
| Chapman, A; Gallo, J; Greenberg, R; Hudes, GR; McAleer, C; Obasaju, C | 1 |
| Danesi, R; Figg, WD; Myers, CE; Reed, E | 1 |
| Armour, EP; Corry, PM; Lee, YJ; Martinez, AA; Stromberg, JS | 1 |
| Stearns, ME; Wang, M | 3 |
| Gabel, M; Khil, MS; Kim, JH; Kim, SH; Lee, YJ; Ryu, S | 1 |
| Kasimis, B; Loehrer, PJ; McLeod, D; Roth, BJ; Wilding, G; Yeap, BY | 1 |
| Blagosklonny, MV; Neckers, LM; Nguyen, P; Schulte, T; Trepel, J | 1 |
| Chintapalli, J; Croce, CM; Haldar, S | 1 |
| Lehr, JE; Naik, H; Pienta, KJ | 1 |
| Stearns, ME | 1 |
| Sovak, M | 1 |
| Roth, BJ | 1 |
| Basu, A; Croce, CM; Haldar, S | 1 |
| Dahllöf, B; Hartley-Asp, B; Laing, N; Ranganathan, S; Tew, KD | 1 |
| Palackdharry, CS | 1 |
| Alken, P; Köhrmann, KU; Kreukler, C; Nebe, T; Siegsmund, MJ; Steidler, A | 1 |
| Castillo, M; de Souza, PL; Myers, CE | 1 |
| Corbett, TH; Golakoti, T; Hussain, M; Knight, J; Liversidge, E; LoRusso, P; Moore, R; Panchapor, C; Patterson, G; Peltier, N; Polin, L; Pugh, S; Valeriote, F; White, K | 1 |
| Cornfield, M; Giantonio, B; Gomella, L; Greenberg, R; Haas, N; Hudes, GR; Khater, C; Litwin, S; McAleer, C; Nathan, F; Roethke, S; Ross, E | 1 |
| Pienta, KJ; Smith, DC | 2 |
| Benetatos, CA; Dexter, DW; Hudes, GR; Ranganathan, S | 1 |
| Benetatos, CA; Colarusso, PJ; Dexter, DW; Hudes, GR; Ranganathan, S | 1 |
| Dell, J; Gurnani, M; Hajian, G; Lipari, P; Nielsen, LL | 1 |
| Cho-Chung, YS; Korsmeyer, SJ; Longo, DL; Nesterova, M; Srivastava, AR; Srivastava, RK | 1 |
| Chou, P; Guinan, P; Mirochnik, Y; Ratanawong, S; Ray, V; Rubenstein, M; Shaw, M; Slobodskoy, L | 1 |
| Au, JL; Chen, CT; Gan, Y; Wientjes, MG | 1 |
| Parrish, EA; Rinehart, CA; Watson, JM | 1 |
| Liu, QY; Stein, CA | 1 |
| Budman, DR; Calabro, A; Kreis, W | 1 |
| Orel, NF | 1 |
| Guinan, P; Mirochnik, Y; Ray, V; Rubenstein, M; Shaw, M; Slobodskoy, L | 1 |
| Bombardelli, E; Polizzi, D; Pratesi, G; Riva, A; Supino, R; Tortoreto, M; Zunino, F | 1 |
| Bagiella, E; Balog, J; Benson, M; Fine, R; Heitjan, D; Judge, T; Macarthur, RB; O'Connor, J; Olsson, CA; Petrylak, DP; Pfaff, C; Sawczuk, I; Shelton, G; Zuech, N | 1 |
| Barile, B; Budman, DR; Fetten, J; Gonzales, AL; Kreis, W; Vinciguerra, V | 1 |
| Aisner, J; DiPaola, RS | 1 |
| Ferrari, AC; Gao, M; Ossowski, L | 1 |
| Block, NL; Lokeshwar, BL; Zhu, B | 1 |
| Faircloth, GT; Geldof, AA; Henrar, RE; Mastbergen, SC | 1 |
| Day, KC; Day, ML; Kamradt, JM; Orth, K; Panvichian, R; Pienta, KJ; Pilat, MJ; Yee, C | 1 |
| Agus, DB; Cordon-Cardo, C; Fazzari, M; Fox, WD; Golde, DW; Heller, G; Higgins, B; Scher, HI | 1 |
| Esper, P; Pienta, KJ; Redman, B; Smith, DC; Strawderman, M | 1 |
| DiPaola, RS; Goodin, S; Gupta, E; Hait, WN; Medina, M; Medina, P; Patel, J; Rafi, MM; Rubin, E; Toppmeyer, D; Vyas, V; White, E; Zamek, R; Zhang, C | 1 |
| Arakawa, H; Kodera, T; Morishima, H; Morita, M; Nishimura, S; Ohkubo, M; Okura, A | 1 |
| Vogelzang, NJ | 1 |
| Stein, CA | 1 |
| Earhart, RH | 1 |
| Picus, J; Schultz, M | 1 |
| Cohen, J; Dimitt, B; Friedland, D; Gluckman, R; Keating, M; Lembersky, B; Miller, R; Reilly, N; Voloshin, M; Zidar, B | 1 |
| Bagiella, E; Benson, M; England-Owen, C; Hetjan, D; Judge, T; Macarthur, R; Newhouse, J; O'Connor, J; Olsson, C; Petrylak, DP; Pfaff, C; Sawczuk, I; Shelton, G; Weitzman, A; Zuech, N | 1 |
| Budman, D; Kreis, W | 1 |
| Halabi, S; Hars, V; Kreis, W; Savarese, D; Taplin, ME; Vogelzang, N | 1 |
| Carducci, M; Eisenberger, M; Laufer, M; Sinibaldi, VJ | 1 |
| Kantoff, PW; Oh, WK | 1 |
| Crawford, D; Fisher, E; Hussain, M; Petrylak, D; Tangen, C | 1 |
| Reese, DM; Small, EJ; Vogelzang, NJ | 1 |
| Bishop, WR; Chen, J; Ferrari, E; Gurnani, M; Hajian, G; Lipari, P; Liu, M; Malkowski, M; Nielsen, LL; Shi, B; Yaremko, B | 1 |
| Hussain, M; Jasti, BR; Parchment, RE; Vaishampayan, U | 1 |
| Gleave, ME; Goldie, J; Miayake, H; Nelson, C; Tolcher, A | 1 |
| Gleave, ME; Miayake, H; Tolcher, A | 1 |
| Balczon, R; Chakrabarti, A; Hueser, CN; Ripple, M; Schatten, H; Taylor, M; Weindruch, R | 1 |
| Bagiella, E; Benson, M; Judge, T; Katz, A; Newhouse, JH; Olsson, CA; Owen, CE; Petrylak, DP; Pfaff, C; Sawczuk, I; Shelton, G; Weitzman, AL; Zuech, N | 1 |
| Blagosklonny, MV; Dixon, SC; Figg, WD | 1 |
| Akaza, H; Hattori, K | 1 |
| Hsu, CP; Yang, CC; Yang, SD | 1 |
| Gagnon, GA; Sallah, S | 1 |
| Cal, C; Gunaydin, G; Omay, SB; Ozyurt, C; Uslu, R | 1 |
| Burris, HA | 1 |
| Gleave, ME; Miyake, H; Nelson, C; Rennie, PS | 1 |
| Chi, KN; Gleave, ME; Miyake, H | 1 |
| Boissier, S; Clézardin, P; Colombel, M; Delaissé, JM; Delmas, P; Ebetino, FH; Ferreras, M; Magnetto, S; Peyruchaud, O | 1 |
| Alderson, PO; Cannon, P; Katz, J; Kline, RP; Petrylak, DP; Szabolcs, M; Weisfeldt, ML; Wu, EX | 1 |
| Burt, H; Gleave, ME; Jackson, J; Leung, SY; Miyake, H | 1 |
| Au, JL; Gan, Y; Song, S; Wientjes, MG | 1 |
| Choi, SH; Chun, BG; Chun, YS; Kang, H; Kang, SW; Min, BH; Park, IS; Shin, KH | 1 |
| Budman, D; Kreis, W; Petrylak, D; Savarese, D | 1 |
| Kohl, NE; Rosen, N; Scher, HI; Sepp-Lorenzino, L; Sirotnak, FM | 1 |
| Du, W; Flaherty, LE; Heilbrun, LK; Hussain, M; Kucuk, O; Redman, B; Trivedi, C | 1 |
| Meistrich, ML; Pollack, A; Terry, NH; White, RA | 1 |
| Beraldi, E; Burt, HM; Gleave, ME; Hunter, WL; Jackson, JK; Yago, V | 1 |
| Kamradt, JM; Korenchuk, S; Muenchen, HJ; Pienta, KJ; Williams, JF | 1 |
| Ascherman, JA; Attkiss, K; Knowles, SL | 1 |
| Adams, LM; Budman, DR; Calabro, A; Kreis, W; Liu, XM; Stiel, L; Wang, LG | 1 |
| Bajorin, D; Ciolino, A; Curley, T; George, D; Heller, G; Kantoff, P; Kaufman, D; Kelly, WK; Larson, S; McCaffrey, J; Oh, W; Regan, K; Scher, H; Schwartz, L; Schwartz, M; Slovin, S; Small, EJ; Smith, M; Tong, W | 1 |
| Kris, MG; Miller, VA; Scher, HI; Sirotnak, FM; Zakowski, MF | 1 |
| Muenchen, HJ; Pienta, KJ; Poncza, PJ | 1 |
| Daliani, D | 1 |
| Culine, S; Droz, JP | 1 |
| Amin, P; Chen, Y; Dilley, J; Embry, M; Henderson, DR; Li, Y; Nguyen, N; Oh, J; Yu, DC; Zhang, H | 1 |
| Bhalla, KN; Nguyen, D; Nimmanapalli, R; O'Bryan, E; Orlando, M; Perkins, CL | 1 |
| Gleave, ME; Leung, S; Miyake, H; Tolcher, A; Zellweger, T | 1 |
| Akerley, WL; Godley, PA; Halabi, S; Hars, V; Hussain, A; Savarese, DM; Small, EJ; Taplin, ME; Vogelzang, NJ | 1 |
| Bressi, JC; Douglass, JG; Seligson, AL; Sovak, M; Terry, RC | 1 |
| Small, EJ | 1 |
| Christen, RD; Gerhold, M; Lin, X; Nehmé, A; Niedner, H; Sellakumar, G; Varadarajan, P; Zhang, Q | 1 |
| Bednar, M; Chachoua, A; Ferrari, AC; Mandeli, J; Muggia, F; Rosenthal, M; Singh, H; Taneja, S | 1 |
| Godley, PA; Herndon, JE; Kornblith, AB; Savarese, D; Vogelzang, NJ; Zuckerman, E | 1 |
| Babb, J; Entmacher, M; Flinker, D; Garay, C; Gillon, T; Haas, N; Hudes, G; Minnitti, C; Rogatko, A; Roth, B; Weinstein, A; Yeslow, G | 1 |
| Chi, K; Gleave, ME; July, L; Miyake, H; Nelson, C; Rennie, P; Zellweger, T | 1 |
| Chi, K; Conklin, BS; Cooper, S; Gleave, ME; Miyake, H; Monia, BP; Zellweger, T | 1 |
| Au, JL; Song, S; Walsh, C; Wientjes, MG | 1 |
| Bova, GS; Isaacs, JT; Parikh, A; Pinski, J | 1 |
| Hudes, GR; Obasaju, C | 1 |
| Dexter, DW; Hudes, GR; McCauley, RA; Ranganathan, S | 1 |
| Cassinelli, G; Cuccuru, G; Ferlini, C; Lanzi, C; Scambia, G; Supino, R; Zuco, V; Zunino, F | 1 |
| Haas, NB | 1 |
| Beer, TM; Bubalo, JS | 2 |
| Goldwasser, F; Misset, JL | 1 |
| Pienta, KJ | 1 |
| Asmar, L; Berry, W; Dakhil, S; Gregurich, MA | 1 |
| Bolton, M; Hake, L; Hauke, R; Ledakis, P; Lynch, J; Muhvic, J; Norvell, M; Sitka Copur, M; Tarantolo, S; Wendt, J | 1 |
| Amin, P; Chen, T; Dawson, N; Engstrom, C; Hussain, A; Naslund, M | 1 |
| Bubley, GJ; Ko, YJ; Morganstern, DE; Rajeshkumar, B; Shuster, T; Taplin, ME | 1 |
| George, DJ; Kantoff, PW; Kaufman, DS; Moss, K; Oh, WK; Richie, JP; Smith, MR | 1 |
| Dreicer, R; Klein, EA | 1 |
| Beer, TM; Garzotto, M; Henner, WD; Hough, KM; Lowe, BA | 1 |
| Ryan, CW; Stadler, WM; Vogelzang, NJ | 1 |
| Arlen, P; Dahut, WL; Fedenko, K; Fernandez, P; Figg, WD; Gulley, J; Hamilton, M; Kruger, EA; Noone, M; Parker, C; Pluda, J | 1 |
| Tolcher, AW | 1 |
| Senzer, NN | 1 |
| Bok, R; Frohlich, M; Reese, DM; Small, EJ; Sudilovsky, D | 1 |
| Beer, TM; Henner, WD; Lowe, BA; Pierce, WC | 1 |
| Cabral, F; Finlay, V; Logothetis, CJ; Navone, NM; Newman, RA; Nicolaou, KC; Raymond, M; Stephens, LC; Troncoso, P; Vourloumis, D; Wu, X; Yang, J | 1 |
| Beaucage, SL; Benimetskaya, L; Benimetsky, S; Grajkowski, A; Guga, P; Halperin, AL; Maciaszek, A; Miller, P; Stein, CA; Wilk, A | 1 |
| Frenkel, EP; Hsieh, JT; Li, Y; Lombardi, DP; Okegawa, T | 1 |
| DeNardo, GL; DeNardo, SJ; Kukis, DL; Lamborn, KR; Meyers, FJ; Miers, LA; O'Donnell, RT | 1 |
| Beer, TM; Hayes-Lattin, BM; Henner, WD; Kovach, PA | 1 |
| Agata, N; Bamberg, M; Dickerson, WM; Fram, R; Kalluri, R; Kamphaus, GD; Kharbanda, S; Kufe, D; Milhollen, M; Reimer, CL; Rook, SL; Tammam, JG | 1 |
| Heicappell, R | 1 |
| Mortimer, JE; Picus, J; Read, WL | 1 |
| Aiba, K; Akaza, H; Blackledge, G; Boku, N; Ikeda, T; Isonishi, S; Kato, M; Kawai, K; Mikami, O; Ohashi, Y; Saeki, T; Saijo, N; Sone, S; Stribling, D; Tsukagoshi, S; Tsuruo, T | 1 |
| Asakuma, J; Asano, T; Hayakawa, M; Kuroki, T; Ohba, M; Sumitomo, M | 1 |
| Kelly, WK; Kenneson, K; Morris, MJ; Osman, I; Reuter, VE; Scher, HI; Slovin, SF; Verbel, D | 1 |
| Carducci, MA; Eisenberger, MA; Laufer, M; Moore-Cooper, S; Sinibaldi, VJ; Zahurak, M | 1 |
| Dinney, CP; Fan, Z; Hicklin, DJ; Izawa, JI; Karashima, T; Kedar, D; Kim, SJ; Pettaway, C; Shuin, T; Slaton, JW; Sweeney, P | 1 |
| Beyer, J; Bokemeyer, C; Hartmann, JT; Jonas, U; Kanz, L; Kollmannsberger, C; Kuczyk, MA; Truss, MC | 1 |
| Nathan, C; Shen, C | 1 |
| Chi, K; Gleave, ME; July, L; Kiyama, S; Leung, S; Miyake, H; Zellweger, T | 1 |
| Barone, L; Speicher, LA; Tew, KD | 1 |
| Coffey, DS; Pienta, KJ | 1 |
| Deinum, J; Hartley-Asp, B; Wallin, M | 1 |
| Härkönen, P; Laine, KM; Röyttä, M | 1 |
| Bhukya, B; Chanda, D; Dubey, P; Fatima, K; Khan, F; Kumar, S; Kumar, Y; Lakshmi, V; Luqman, S; Nagar, A; Negi, AS; Shanker, K; Tandon, S | 1 |
| Cong, B; Dong, M; Gu, YC; Huo, CH; Kiyota, H; Ni, ZY; Sauriol, F; Shi, QW; Wang, YF; Wu, YB; Zhang, ML | 1 |
| Delmulle, L; Keukeleire, DD; Vanden Berghe, T; Vandenabeele, P | 1 |
48 review(s) available for paclitaxel and Prostatic Neoplasms
| Article | Year |
|---|---|
FOXO3a and Its Regulators in Prostate Cancer.
Topics: Apoptosis; Cell Proliferation; Cisplatin; Docetaxel; Doxorubicin; Forkhead Box Protein O3; Gene Expression Regulation, Neoplastic; Humans; Male; Oxidative Stress; Paclitaxel; Prostatic Neoplasms | 2021 |
Paclitaxel and docetaxel resistance in prostate cancer: Molecular mechanisms and possible therapeutic strategies.
Topics: Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Paclitaxel; Prostatic Neoplasms; Taxoids | 2023 |
New issues for copper-64: from precursor to innovative PET tracers in clinical oncology.
Topics: Breast Neoplasms; Cell Line, Tumor; Cisplatin; Copper Radioisotopes; Drug Resistance, Neoplasm; Female; Homeostasis; Humans; Male; Neurodegenerative Diseases; Paclitaxel; Positron-Emission Tomography; Prostatic Neoplasms; Radiopharmaceuticals | 2013 |
Chemotherapy plus estramustine for management of castration-resistant prostate cancer: meta-analysis of randomized controlled trials.
Topics: Adenocarcinoma; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Cardiovascular Diseases; Combined Modality Therapy; Docetaxel; Epirubicin; Epothilones; Estramustine; Fatigue; Gastrointestinal Diseases; Hematologic Diseases; Humans; Male; Orchiectomy; Paclitaxel; Peripheral Nervous System Diseases; Prostate-Specific Antigen; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Salvage Therapy; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine | 2014 |
Targeted prodrug approaches for hormone refractory prostate cancer.
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Doxorubicin; Drug Therapy; Humans; Male; Nitric Oxide; Paclitaxel; Prodrugs; Prostate-Specific Antigen; Prostatic Neoplasms; Recurrence; Thapsigargin; Vinblastine | 2015 |
De novo large cell neuroendocrine carcinoma of the prostate gland with pelvic lymph node metastasis: a case report with review of literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Chemotherapy, Adjuvant; Cisplatin; Cystoscopy; Disease Progression; Etoposide; Fatal Outcome; Humans; Immunohistochemistry; Laparoscopy; Leuprolide; Lymph Node Excision; Lymphatic Metastasis; Male; Meningeal Neoplasms; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Paclitaxel; Pelvis; Prostatic Neoplasms; Robotic Surgical Procedures; Time Factors; Tomography, X-Ray Computed; Transurethral Resection of Prostate; Treatment Outcome | 2014 |
Extracellular Vesicle-Mediated Reversal of Paclitaxel Resistance in Prostate Cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Extracellular Vesicles; Humans; Male; Paclitaxel; Prostatic Neoplasms; Signal Transduction; Taxoids | 2015 |
Systemic nonhormonal management of advanced prostate cancer and its likely impact on patients' survival and quality of life.
Topics: Atrasentan; Cisplatin; Diphosphonates; Docetaxel; Humans; Male; Mitoxantrone; Paclitaxel; Prostatic Neoplasms; Pyrrolidines; Quality of Life; Receptors, Calcitriol; Taxoids | 2008 |
Docetaxel in the integrated management of prostate cancer. Current applications and future promise.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Forecasting; Humans; Male; Neoadjuvant Therapy; Paclitaxel; Prostatic Neoplasms; Recurrence; Taxoids | 2002 |
The role of chemotherapy in advanced prostate cancer.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Estramustine; Humans; Male; Paclitaxel; Prostatic Neoplasms; Taxoids | 2002 |
Chemotherapy for androgen-independent prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Docetaxel; Drug Resistance, Neoplasm; Estramustine; Humans; Male; Neoplasm Recurrence, Local; Paclitaxel; Palliative Care; Prostatic Neoplasms; Taxoids | 2002 |
Docetaxel-induced nail dystrophy.
Topics: Acute Disease; Aged; Antineoplastic Agents, Phytogenic; Docetaxel; Humans; Male; Nail Diseases; Paclitaxel; Prostatic Neoplasms; Taxoids | 2002 |
Fatal respiratory failure associated with treatment of prostate cancer using docetaxel and estramustine.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Estramustine; Fatal Outcome; Humans; Male; Paclitaxel; Prostatic Neoplasms; Radiography; Respiratory Insufficiency; Taxoids | 2002 |
[Chemotherapy for prostate cancers].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Administration Schedule; Estramustine; Etoposide; Humans; Male; Paclitaxel; Prostatic Neoplasms; Taxoids; Vinblastine | 2002 |
[Therapy for hormone-refractory prostate cancer].
Topics: Androgens; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Clinical Trials as Topic; Clodronic Acid; Cyclophosphamide; Dexamethasone; Docetaxel; Estramustine; Humans; Male; Neoplasms, Hormone-Dependent; Paclitaxel; Prostatic Neoplasms; Strontium Radioisotopes; Taxoids; Tegafur; Treatment Outcome | 2002 |
[A new model of human prostate cancer, the PAC120 xenograft].
Topics: Adenocarcinoma; Animals; Docetaxel; Gonadotropin-Releasing Hormone; Humans; Male; Mice; Mice, Nude; Neoplasm Transplantation; Paclitaxel; Prostatic Neoplasms; Taxoids; Transplantation, Heterologous | 2003 |
Docetaxel (taxotere) in the treatment of prostate cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Docetaxel; Humans; Male; Paclitaxel; Prostatic Neoplasms; Taxoids | 2003 |
New principles in the treatment of prostate cancer--the oncologist's view.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Clinical Trials as Topic; Combined Modality Therapy; Docetaxel; Humans; Male; Mitoxantrone; Paclitaxel; Prostatic Neoplasms; Radiotherapy, High-Energy; Taxoids | 2003 |
The combination of antiangiogenic and cytotoxic agents in the treatment of prostate cancer.
Topics: Angiogenesis Inhibitors; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Clinical Trials as Topic; Cyclohexanes; Humans; Male; Minocycline; Neovascularization, Pathologic; O-(Chloroacetylcarbamoyl)fumagillol; Paclitaxel; Prostatic Neoplasms; Sesquiterpenes | 2003 |
The current role of chemotherapy in metastatic hormone-refractory prostate cancer.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Estramustine; Humans; Male; Mitoxantrone; Paclitaxel; Prostatic Neoplasms; Taxoids | 2005 |
Effective chemotherapy for hormone-refractory prostate cancer (HRPC): present status and perspectives with taxane-based treatments.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Drug Administration Schedule; Epothilones; Humans; Male; Neoplasms, Hormone-Dependent; Paclitaxel; Prostatic Neoplasms; Taxoids | 2007 |
New therapeutic agents for hormone-refractory prostate cancer.
Topics: Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; Estramustine; Humans; Male; Metalloendopeptidases; Neoplasms, Hormone-Dependent; Paclitaxel; Prostatic Neoplasms; Vinblastine; Vinorelbine | 1996 |
[Taxotere in various solid tumors].
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Docetaxel; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Melanoma; Ovarian Neoplasms; Paclitaxel; Pancreatic Neoplasms; Prostatic Neoplasms; Sarcoma; Skin Neoplasms; Soft Tissue Neoplasms; Taxoids; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms | 1998 |
Paclitaxel in the treatment of hormone-refractory prostate cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Estramustine; Etoposide; Humans; Male; Neoplasms, Hormone-Dependent; Paclitaxel; Prostatic Neoplasms | 1999 |
Overcoming bcl-2- and p53-mediated resistance in prostate cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Drug Resistance, Neoplasm; Gene Expression; Genes, bcl-2; Genes, p53; Humans; Interferons; Male; Mutation; Paclitaxel; Prostatic Neoplasms; Tretinoin | 1999 |
Mechanisms of action of taxanes in prostate cancer.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Cycle; Docetaxel; Gene Expression Regulation, Neoplastic; Humans; Male; Microtubules; Neoplasms, Hormone-Dependent; Paclitaxel; Phosphorylation; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Taxoids; Tumor Suppressor Protein p53 | 1999 |
Docetaxel (Taxotere): preclinical and general clinical information.
Topics: Animals; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Clinical Trials as Topic; Docetaxel; Drug Evaluation, Preclinical; Humans; Male; Neoplasms, Hormone-Dependent; Paclitaxel; Prostatic Neoplasms; Taxoids | 1999 |
Daily oral estramustine and intermittent intravenous docetaxel (Taxotere) as chemotherapeutic treatment for metastatic, hormone-refractory prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Docetaxel; Estramustine; Humans; Male; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Paclitaxel; Prostatic Neoplasms; Taxoids | 1999 |
Docetaxel (Taxotere)-based chemotherapy for hormone-refractory and locally advanced prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Docetaxel; Estramustine; Humans; Male; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Paclitaxel; Prostatic Neoplasms; Taxoids | 1999 |
Hormone-refractory prostate cancer: an evolving standard of care.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Docetaxel; Humans; Male; Neoplasms, Hormone-Dependent; Paclitaxel; Prostatic Neoplasms; Taxoids | 1999 |
Taxanes: an overview of the pharmacokinetics and pharmacodynamics.
Topics: Antineoplastic Agents, Phytogenic; Bridged-Ring Compounds; Docetaxel; Drug Interactions; Humans; Male; Mitosis; Molecular Structure; Paclitaxel; Prostatic Neoplasms; Taxoids | 1999 |
[New combination chemotherapy in urological cancers].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Gemcitabine; Humans; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Male; Methotrexate; Paclitaxel; Prostatic Neoplasms; Taxoids; Testicular Neoplasms; Urinary Bladder Neoplasms; Vinblastine | 2000 |
Docetaxel (Taxotere) in the treatment of cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Lung Neoplasms; Male; Paclitaxel; Prognosis; Prostatic Neoplasms; Taxoids | 2000 |
Docetaxel (Taxotere) in hormone-refractory prostate cancer.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Clinical Trials as Topic; Docetaxel; Drug Resistance, Neoplasm; Drug Therapy, Combination; Humans; Male; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids | 2000 |
Development of angiogenesis inhibition as therapy for prostate cancer.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Chemotherapy, Adjuvant; Estramustine; Humans; Male; Microcirculation; Paclitaxel; Prostatic Neoplasms | 2000 |
Chemotherapy in advanced androgen-independent prostate cancer 1990-1999: a decade of progress?
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Mitoxantrone; Neoplasm Metastasis; Paclitaxel; Palliative Care; Prednisolone; Prostatic Neoplasms; Quality of Life; Randomized Controlled Trials as Topic; Taxoids | 2000 |
Docetaxel in prostate cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Docetaxel; Humans; Male; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids | 2001 |
Paclitaxel and docetaxel in prostate cancer.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carboplatin; Chemotherapy, Adjuvant; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Dexamethasone; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Enzyme Inhibitors; Estramustine; Etoposide; Genes, bcl-2; Humans; Hydrocortisone; Male; Microtubules; Mitosis; Mitoxantrone; Multicenter Studies as Topic; Neoplasm Proteins; Oligodeoxyribonucleotides, Antisense; Paclitaxel; Palliative Care; Prostatic Neoplasms; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Survival Analysis; Taxoids; Treatment Outcome; Tubulin | 2001 |
Can chemotherapy alter the course of prostate cancer?
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Estramustine; Humans; Male; Mitoxantrone; Neoplasm Staging; Paclitaxel; Prostatic Neoplasms; Quality of Life; Taxoids | 2001 |
Complications of chemotherapy for prostate cancer.
Topics: Adenocarcinoma; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Docetaxel; Gastrointestinal Diseases; Humans; Male; Mitoxantrone; Nervous System Diseases; Paclitaxel; Prednisone; Prostatic Neoplasms; Taxoids | 2001 |
[Clinical use of oxaliplatin in solid tumors].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclophosphamide; Female; Humans; Lymphoma, Non-Hodgkin; Male; Neoplasms; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Paclitaxel; Prostatic Neoplasms; Vinblastine; Vinorelbine | 2001 |
Preclinical mechanisms of action of docetaxel and docetaxel combinations in prostate cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-X Protein; Cell Cycle; Docetaxel; Drug Evaluation, Preclinical; Gene Expression Regulation, Neoplastic; Genes, bcl-2; Humans; Male; Paclitaxel; Phosphorylation; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Taxoids; Tubulin; Tumor Cells, Cultured | 2001 |
Prostate cancer: multimodality approaches with docetaxel.
Topics: Antineoplastic Agents, Phytogenic; Combined Modality Therapy; Docetaxel; Humans; Male; Paclitaxel; Prostatic Neoplasms; Radiation-Sensitizing Agents; Taxoids | 2001 |
Controversies in chemotherapy of prostate cancer.
Topics: Adenocarcinoma; Adrenal Cortex Hormones; Androgen Antagonists; Antigens, Neoplasm; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Clinical Trials as Topic; Docetaxel; Estramustine; Humans; Male; Mitoxantrone; Neoplasms, Hormone-Dependent; Paclitaxel; Palliative Care; Prostate-Specific Antigen; Prostatic Neoplasms; Suramin; Taxoids; Testosterone; Treatment Outcome | 2002 |
Recent strategies for the use of paclitaxel in the treatment of urological malignancies.
Topics: Antineoplastic Agents, Phytogenic; Humans; Male; Paclitaxel; Prostatic Neoplasms; Testicular Neoplasms; Urinary Bladder Neoplasms | 1998 |
Effects of docetaxel on pain due to metastatic androgen-independent prostate cancer.
Topics: Aged; Androgens; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetaxel; Humans; Male; Paclitaxel; Pain; Prostatic Neoplasms; Taxoids | 2002 |
Targeting anti-apoptotic genes upregulated by androgen withdrawal using antisense oligonucleotides to enhance androgen- and chemo-sensitivity in prostate cancer.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Apoptosis; Clusterin; Genes, bcl-2; Glycoproteins; Humans; Male; Molecular Chaperones; Oligonucleotides, Antisense; Paclitaxel; Prostatic Neoplasms; Receptors, Androgen; Thionucleotides; Up-Regulation | 2002 |
Cell motility as a chemotherapeutic target.
Topics: Animals; Antibodies; Antineoplastic Agents, Phytogenic; Cell Division; Cell Movement; Cytoskeleton; Male; Paclitaxel; Prostatic Neoplasms; Rats; Suramin; Vinblastine; Vincristine | 1991 |
87 trial(s) available for paclitaxel and Prostatic Neoplasms
| Article | Year |
|---|---|
Long-term oncological outcomes of a phase II trial of neoadjuvant chemohormonal therapy followed by radical prostatectomy for patients with clinically localised, high-risk prostate cancer.
Topics: Antineoplastic Agents; Carboplatin; Disease-Free Survival; Estramustine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Prostatectomy; Prostatic Neoplasms; Treatment Outcome | 2015 |
A Phase 3 Trial of 2 Years of Androgen Suppression and Radiation Therapy With or Without Adjuvant Chemotherapy for High-Risk Prostate Cancer: Final Results of Radiation Therapy Oncology Group Phase 3 Randomized Trial NRG Oncology RTOG 9902.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease Progression; Early Termination of Clinical Trials; Estramustine; Etoposide; Humans; Male; Middle Aged; Neoplasm Grading; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Time Factors | 2015 |
Phase I/II study of biweekly paclitaxel and radiation in androgen-ablated locally advanced prostate cancer.
Topics: Aged; Antineoplastic Agents, Phytogenic; Combined Modality Therapy; Disease-Free Survival; Drug Administration Schedule; Humans; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prostatic Neoplasms; Radiotherapy, Conformal; Treatment Outcome | 2008 |
Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel.
Topics: Adult; Aged; Albumins; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma; Cross-Over Studies; Fallopian Tube Neoplasms; Female; Humans; Male; Middle Aged; Ovarian Neoplasms; Paclitaxel; Prostatic Neoplasms; Solvents | 2008 |
Phase I study of bortezomib with weekly paclitaxel in patients with advanced solid tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Breast Neoplasms; Female; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Ovarian Neoplasms; Paclitaxel; Prostatic Neoplasms; Pyrazines; Treatment Outcome | 2008 |
Multicenter phase 2 study of neoadjuvant paclitaxel, estramustine phosphate, and carboplatin plus androgen deprivation before radiation therapy in patients with unfavorable-risk localized prostate cancer: results of Cancer and Leukemia Group B 99811.
Topics: Aged; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Disease-Free Survival; Drug Administration Schedule; Estramustine; Feasibility Studies; Humans; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms | 2008 |
Phase III multi-institutional trial of adjuvant chemotherapy with paclitaxel, estramustine, and oral etoposide combined with long-term androgen suppression therapy and radiotherapy versus long-term androgen suppression plus radiotherapy alone for high-ris
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Drug Administration Schedule; Estramustine; Etoposide; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Paclitaxel; Prostatic Neoplasms; Thromboembolism | 2009 |
Bone-targeted therapy: phase II study of strontium-89 in combination with alternating weekly chemohormonal therapies for patients with advanced androgen-independent prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Combined Modality Therapy; Doxorubicin; Estramustine; Humans; Ketoconazole; Male; Middle Aged; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Strontium Radioisotopes; Survival Rate; Treatment Outcome | 2008 |
Phase II trial of neoadjuvant nab-paclitaxel in high risk patients with prostate cancer undergoing radical prostatectomy.
Topics: Adenocarcinoma; Aged; Albumins; Humans; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Prostatectomy; Prostatic Neoplasms; Risk Factors | 2009 |
Phase II study of paclitaxel and vinorelbine (Pacl-Vin) in hormone-refractory metastatic prostate cancer: double tubulin targeting.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Cohort Studies; Drug Administration Schedule; Drug Delivery Systems; Drug Therapy, Combination; Humans; Male; Middle Aged; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Tubulin; Vinblastine; Vinorelbine | 2010 |
Pilot trial of adjuvant paclitaxel plus androgen deprivation for patients with high-risk prostate cancer after radical prostatectomy: results on toxicity, side effects and quality-of-life.
Topics: Aged; Androgen Antagonists; Combined Modality Therapy; Humans; Male; Middle Aged; Paclitaxel; Pilot Projects; Prostate; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Risk; Urinary Incontinence | 2010 |
A phase II study of paclitaxel poliglumex in combination with transdermal estradiol for the treatment of metastatic castration-resistant prostate cancer after docetaxel chemotherapy.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dose-Response Relationship, Drug; Estradiol; Humans; Male; Middle Aged; Neoplasm Metastasis; Orchiectomy; Paclitaxel; Polyglutamic Acid; Prostatic Neoplasms; Taxoids | 2010 |
A modular Phase I study of lenalidomide and paclitaxel in metastatic castration-resistant prostate cancer following prior taxane therapy.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Combined Modality Therapy; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Lenalidomide; Male; Middle Aged; Nausea; Neutropenia; Orchiectomy; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Analysis; Taxoids; Thalidomide; Treatment Outcome; Vomiting | 2010 |
A randomized phase II trial of mitoxantrone, estramustine and vinorelbine or bcl-2 modulation with 13-cis retinoic acid, interferon and paclitaxel in patients with metastatic castrate-resistant prostate cancer: ECOG 3899.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Estramustine; Humans; Interferons; Isotretinoin; Male; Middle Aged; Mitoxantrone; Neoplasm Metastasis; Paclitaxel; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Quality of Life; Survival Rate; Teratogens; Treatment Outcome; Vinblastine; Vinorelbine | 2010 |
Long-term follow-up of a prospective trial of trimodality therapy of weekly paclitaxel, radiation, and androgen deprivation in high-risk prostate cancer with or without prior prostatectomy.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Phytogenic; Chemoradiotherapy; Diarrhea; Drug Administration Schedule; Humans; Leukopenia; Male; Middle Aged; Neoplasm Grading; Paclitaxel; Prospective Studies; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Radiotherapy Dosage; Survival Analysis; Urination Disorders | 2012 |
Phase II evaluation of early oral estramustine, oral etoposide, and intravenous paclitaxel combined with hormonal therapy in patients with high-risk metastatic prostate adenocarcinoma: Southwest Oncology Group S0032.
Topics: Adenocarcinoma; Administration, Oral; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Estramustine; Etoposide; Humans; Injections, Intravenous; Male; Middle Aged; Paclitaxel; Prostatic Neoplasms; Risk Factors | 2011 |
Paclitaxel in combination with carboplatin as salvage treatment in patients with castration-resistant prostate cancer: a Hellenic oncology research group multicenter phase II study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Fatigue; Humans; Kaplan-Meier Estimate; Leukopenia; Male; Middle Aged; Nausea; Orchiectomy; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Salvage Therapy; Treatment Outcome | 2012 |
Phase I trial of oral estramustine and 3-hr infusional paclitaxel for the treatment of hormone refractory prostate cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Estramustine; Humans; Infusions, Intravenous; Male; Middle Aged; Paclitaxel; Prostatic Neoplasms; Survival Analysis | 2002 |
Combination chemotherapy with paclitaxel, estramustine and carboplatin for hormone refractory prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Estramustine; Humans; Male; Middle Aged; Multivariate Analysis; Paclitaxel; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms | 2002 |
An active regimen of weekly paclitaxel and estramustine in metastatic androgen-independent prostate cancer.
Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Estramustine; Humans; Infusions, Intravenous; Male; Middle Aged; Paclitaxel; Prostatic Neoplasms; Survival Analysis | 2002 |
Pharmacokinetics of high-dose oral calcitriol: results from a phase 1 trial of calcitriol and paclitaxel.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Calcitriol; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prostatic Neoplasms; Radioimmunoassay | 2002 |
Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Calcitriol; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Humans; Male; Middle Aged; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Rate; Taxoids | 2003 |
Estimating survival benefit in castrate metastatic prostate cancer: decision making in proceeding to a definitive phase III trial.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Trials, Phase III as Topic; Cohort Studies; Decision Support Techniques; Estramustine; Humans; Male; Paclitaxel; Probability; Prostatic Neoplasms; Research Design; Retrospective Studies; Survival Analysis; Treatment Outcome | 2003 |
Randomized, multicenter, phase II trial of two multicomponent regimens in androgen-independent prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Resistance, Neoplasm; Estramustine; Etoposide; Humans; Ketoconazole; Male; Middle Aged; Neoplasms, Hormone-Dependent; Paclitaxel; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Survival Rate; Treatment Outcome | 2003 |
Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/locallyadvanced prostate cancer.
Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Docetaxel; Estramustine; Feasibility Studies; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Testosterone; Treatment Outcome | 2003 |
Weekly low-dose docetaxel in advanced hormone-resistant prostate cancer patients previously exposed to chemotherapy.
Topics: Aged; Antineoplastic Agents, Phytogenic; Docetaxel; Drug Administration Schedule; Humans; Infusions, Intravenous; Male; Middle Aged; Paclitaxel; Palliative Care; Prostatic Neoplasms; Quality of Life; Taxoids; Treatment Outcome | 2003 |
A phase I trial of weekly paclitaxel, 13- cis-retinoic acid, and interferon alpha in patients with prostate cancer and other advanced malignancies.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Down-Regulation; Female; Humans; Interferon-alpha; Isotretinoin; Leukocytes, Mononuclear; Male; Middle Aged; Neoplasms; Paclitaxel; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Treatment Outcome | 2003 |
Dose escalation study of intravenous estramustine phosphate in combination with Paclitaxel and Carboplatin in patients with advanced prostate cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Estramustine; Humans; Male; Middle Aged; Paclitaxel; Prostatic Neoplasms; Treatment Outcome | 2003 |
Phase II trial of paclitaxel, estramustine, etoposide, and carboplatin in the treatment of patients with hormone-refractory prostate carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease Progression; Estramustine; Etoposide; Humans; Male; Middle Aged; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Rats; Survival Rate; Treatment Outcome | 2003 |
Weekly paclitaxel plus estramustine combination therapy in hormone-refractory prostate cancer: a pilot study.
Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Drug Administration Schedule; Estramustine; Humans; Infusions, Intravenous; Lymphatic Metastasis; Male; Middle Aged; Paclitaxel; Pain; Pilot Projects; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Treatment Outcome | 2003 |
Intermittent chemotherapy in metastatic androgen-independent prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Calcitriol; Dexamethasone; Disease-Free Survival; Docetaxel; Humans; Lymphatic Metastasis; Male; Middle Aged; Paclitaxel; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Rate; Taxoids | 2003 |
Clinical experience with intravenous estramustine phosphate, paclitaxel, and carboplatin in patients with castrate, metastatic prostate adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Disease-Free Survival; Drug Administration Schedule; Estramustine; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Treatment Outcome | 2003 |
Docetaxel and ketoconazole in advanced hormone-refractory prostate carcinoma: a phase I and pharmacokinetic study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Administration Schedule; Humans; Ketoconazole; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Prostatic Neoplasms; Taxoids; Treatment Outcome | 2003 |
Weekly paclitaxel, estramustine phosphate, and oral etoposide in the treatment of hormone-refractory prostate carcinoma: results of a Minnie Pearl Cancer Research Network phase II trial.
Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Estramustine; Etoposide; Fatigue; Humans; Infusions, Intravenous; Male; Middle Aged; Neutropenia; Paclitaxel; Prostatic Neoplasms; Sepsis; Survival Analysis; Treatment Outcome | 2003 |
Multicenter Phase II study of estramustine phosphate plus weekly paclitaxel in patients with androgen-independent prostate carcinoma.
Topics: Aged; Aged, 80 and over; Androgens; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Drug Administration Schedule; Estramustine; Humans; Infusions, Intravenous; Male; Middle Aged; Paclitaxel; Prostatic Neoplasms; Survival Analysis; Treatment Outcome | 2004 |
Increased endothelial uptake of paclitaxel as a potential mechanism for its antiangiogenic effects: potentiation by Cox-2 inhibition.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Collagen; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Drug Combinations; Endothelial Cells; Enzyme-Linked Immunosorbent Assay; Humans; In Vitro Techniques; Isoenzymes; Laminin; Lung; Male; Melanoma; Membrane Proteins; Neovascularization, Pathologic; Paclitaxel; Prostaglandin-Endoperoxide Synthases; Prostatic Neoplasms; Proteoglycans; Pyrazoles; Skin; Skin Neoplasms; Sulfonamides; Time Factors; Tumor Cells, Cultured; Umbilical Veins | 2005 |
Phase II randomized trial of weekly paclitaxel with or without estramustine phosphate in progressive, metastatic, hormone-refractory prostate cancer.
Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Estramustine; Humans; Logistic Models; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Paclitaxel; Probability; Prognosis; Prostatic Neoplasms; Reference Values; Risk Assessment; Survival Analysis; Treatment Outcome | 2004 |
Weekly paclitaxel and epirubicin in the treatment of symptomatic hormone-refractory advanced prostate carcinoma: report of a phase II trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Epirubicin; Humans; Male; Paclitaxel; Prostatic Neoplasms; Treatment Outcome | 2005 |
Pharmacokinetics of liquid calcitriol formulation in advanced solid tumor patients: comparison with caplet formulation.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biological Availability; Calcitriol; Calcium Channel Agonists; Capsules; Dexamethasone; Diarrhea; Humans; Male; Paclitaxel; Pharmaceutical Solutions; Prostatic Neoplasms | 2005 |
High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human
Topics: Adult; Aged; Aged, 80 and over; Animals; Antibodies, Monoclonal; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Breast Neoplasms; Cathepsins; Combined Modality Therapy; Cyclosporine; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Female; Heterocyclic Compounds, 1-Ring; Humans; Indium Radioisotopes; Male; Mice; Middle Aged; Neutropenia; Paclitaxel; Prostatic Neoplasms; Radioimmunotherapy; Soft Tissue Neoplasms; Treatment Outcome; Yttrium Radioisotopes | 2005 |
Monthly paclitaxel and carboplatin with oral estramustine phosphate in patients with hormone-refractory prostate cancer.
Topics: Administration, Oral; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Administration Schedule; Estramustine; Humans; Infusions, Intravenous; Male; Middle Aged; Paclitaxel; Prostatic Neoplasms; Survival Rate | 2005 |
Randomized Phase II study comparing paclitaxel and carboplatin versus mitoxantrone in patients with hormone-refractory prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Humans; Male; Middle Aged; Mitoxantrone; Paclitaxel; Prospective Studies; Prostatic Neoplasms; Treatment Failure | 2006 |
A phase I study of paclitaxel/doxorubicin/ thalidomide in patients with androgen- independent prostate cancer.
Topics: Aged; Androgens; Angiogenesis Inhibitors; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Doxorubicin; Humans; Immunologic Factors; Male; Middle Aged; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Thalidomide; Treatment Outcome | 2006 |
A phase II study of weekly paclitaxel/estramustine/carboplatin in hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Estramustine; Humans; Male; Middle Aged; Neoplasms, Hormone-Dependent; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Survival Rate; Treatment Outcome | 2006 |
Thalidomide/estramustine/paclitaxel in metastatic androgen-independent prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Disease Progression; Estramustine; Humans; Male; Middle Aged; Neoplasms, Hormone-Dependent; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Rate; Taxoids; Thalidomide; Time Factors; Treatment Outcome | 2006 |
Activity of weekly paclitaxel in advanced hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Combined Modality Therapy; Drug Administration Schedule; Humans; Male; Middle Aged; Paclitaxel; Prostatic Neoplasms; Treatment Outcome | 2007 |
Diethylstilbestrol and docetaxel: a Phase II study of tubulin active agents in patients with metastatic, androgen-independent prostate cancer.
Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Diethylstilbestrol; Drug Administration Schedule; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Treatment Outcome; Tubulin Modulators; Venous Thrombosis | 2007 |
Phase II evaluation of oral estramustine, oral etoposide, and intravenous paclitaxel in patients with hormone-sensitive prostate adenocarcinoma.
Topics: Adenocarcinoma; Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Disease Progression; Estramustine; Etoposide; Feasibility Studies; Humans; Injections, Intravenous; Male; Middle Aged; Neoplasms, Hormone-Dependent; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Rate; Treatment Outcome | 2007 |
Adaptive therapy for androgen-independent prostate cancer: a randomized selection trial of four regimens.
Topics: Aged; Algorithms; Androgens; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Confidence Intervals; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Estramustine; Etoposide; Humans; Ketoconazole; Logistic Models; Male; Middle Aged; Paclitaxel; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Research Design; Survival Analysis; Treatment Outcome; Vinblastine; Vincristine | 2007 |
Pilot trial of adjuvant paclitaxel plus estramustine in resected high-risk prostate cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Estramustine; Feasibility Studies; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Pilot Projects; Prostatectomy; Prostatic Neoplasms; Risk Factors | 2008 |
Paclitaxel plus estramustine in metastatic hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Drug Administration Schedule; Drug Resistance, Neoplasm; Estramustine; Fatigue; Hematologic Diseases; Hormones; Humans; Male; Nausea; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Treatment Outcome | 1995 |
Phase I study of paclitaxel and estramustine: preliminary activity in hormone-refractory prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Estramustine; Female; Humans; Male; Neoplasms; Neoplasms, Hormone-Dependent; Paclitaxel; Prostatic Neoplasms | 1995 |
Taxol in advanced, hormone-refractory carcinoma of the prostate. A phase II trial of the Eastern Cooperative Oncology Group.
Topics: Aged; Death, Sudden, Cardiac; Drug Resistance; Estrogens; Gonadotropin-Releasing Hormone; Humans; Leukopenia; Male; Middle Aged; Myocardial Infarction; Paclitaxel; Prostatic Neoplasms; Survival Rate | 1993 |
Phase I trial of dose-escalated paclitaxel and carboplatin in combination with ifosfamide and filgrastim: preliminary results.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Ifosfamide; Immunoblastic Lymphadenopathy; Lung Neoplasms; Male; Mesothelioma; Paclitaxel; Prostatic Neoplasms; Recombinant Proteins | 1997 |
Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Administration Schedule; Estramustine; Humans; Infusions, Intravenous; Male; Middle Aged; Paclitaxel; Prostatic Neoplasms; Survival Analysis; Treatment Outcome | 1997 |
Paclitaxel, estramustine, and etoposide in the treatment of hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Administration, Oral; Alopecia; Animals; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; DNA Replication; DNA, Neoplasm; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Estramustine; Etoposide; Follow-Up Studies; Humans; Infusions, Intravenous; Male; Microtubules; Nuclear Matrix; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Rats; Remission Induction; Tumor Cells, Cultured | 1997 |
Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer.
Topics: Aged; Aged, 80 and over; Androgens; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dose-Response Relationship, Drug; Estramustine; Gastrointestinal Diseases; Hematologic Diseases; Humans; Male; Middle Aged; Paclitaxel; Pain; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Analysis; Taxoids | 1999 |
Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Estramustine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prognosis; Prostatic Neoplasms; Survival Rate; Taxoids; Treatment Outcome | 1999 |
Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Drug Resistance, Neoplasm; Estramustine; Etoposide; Humans; Male; Middle Aged; Paclitaxel; Prostatic Neoplasms; Quality of Life; Soft Tissue Neoplasms; Survival Rate; Treatment Outcome | 1999 |
Phase I clinical and pharmacologic study of 13-cis-retinoic acid, interferon alfa, and paclitaxel in patients with prostate cancer and other advanced malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Female; Humans; In Vitro Techniques; Interferon-alpha; Isotretinoin; Leukocytes, Mononuclear; Liver; Male; Microsomes; Middle Aged; Paclitaxel; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured | 1999 |
Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results.
Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Docetaxel; Humans; Male; Middle Aged; Neoplasms, Hormone-Dependent; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids | 1999 |
A phase II trial of docetaxel (Taxotere) in hormone-refractory prostate cancer: correlation of antitumor effect to phosphorylation of Bcl-2.
Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Docetaxel; Gene Expression; Humans; Male; Middle Aged; Neoplasms, Hormone-Dependent; Paclitaxel; Phosphorylation; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Taxoids | 1999 |
Phase I/II studies of docetaxel (Taxotere) combined with estramustine in men with hormone-refractory prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Estramustine; Humans; Male; Neoplasms, Hormone-Dependent; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Analysis; Taxoids | 1999 |
A phase II study of docetaxel (Taxotere), estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: preliminary results of cancer and leukemia group B Trial 9780.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Estramustine; Humans; Hydrocortisone; Male; Middle Aged; Neoplasms, Hormone-Dependent; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Analysis; Taxoids | 1999 |
Preliminary evaluation of a short course of estramustine phosphate and docetaxel (Taxotere) in the treatment of hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Docetaxel; Estramustine; Humans; Male; Middle Aged; Neoplasms, Hormone-Dependent; Paclitaxel; Prostatic Neoplasms; Taxoids | 1999 |
Dexamethasone does not significantly contribute to the response rate of docetaxel and estramustine in androgen independent prostate cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Dexamethasone; Docetaxel; Drug Administration Schedule; Estramustine; Humans; Male; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids | 2000 |
Reversion of primary hyperfibrinogenolysis in patients with hormone-refractory prostate cancer using docetaxel.
Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Docetaxel; Drug Resistance, Neoplasm; Fibrinogen; Fibrinolysis; Hemorrhage; Humans; Male; Neoplasm Metastasis; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Urokinase-Type Plasminogen Activator | 2000 |
Weekly 1-hour infusion of paclitaxel. Clinical feasibility and efficacy in patients with hormone-refractory prostate carcinoma.
Topics: Aged; Androgens; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Drug Administration Schedule; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms, Hormone-Dependent; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Analysis | 2000 |
Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Dose-Response Relationship, Drug; Estramustine; Humans; Male; Middle Aged; Neoplasms, Hormone-Dependent; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Rate | 2001 |
Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Estramustine; Humans; Hydrocortisone; Male; Paclitaxel; Prostatic Neoplasms; Survival Rate; Taxoids | 2001 |
A Phase I/II study of weekly paclitaxel and 3 days of high dose oral estramustine in patients with hormone-refractory prostate carcinoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Dose-Response Relationship, Drug; Estramustine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Prostatic Neoplasms; Treatment Outcome | 2001 |
The impact of docetaxel, estramustine, and low dose hydrocortisone on the quality of life of men with hormone refractory prostate cancer and their partners: a feasibility study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anxiety; Docetaxel; Drug Resistance, Neoplasm; Emotions; Estramustine; Feasibility Studies; Female; Health Status; Humans; Hydrocortisone; Infusions, Intravenous; Male; Mental Health; Middle Aged; Paclitaxel; Pain; Prostatic Neoplasms; Quality of Life; Sexual Behavior; Spouses; Taxoids | 2001 |
Phase I trial of weekly paclitaxel plus oral estramustine phosphate in patients with hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Anaphylaxis; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Edema; Estramustine; Gonadotropin-Releasing Hormone; Humans; Infusions, Intravenous; Male; Middle Aged; Nausea; Paclitaxel; Prostatic Neoplasms; Thrombophlebitis; Treatment Outcome | 2001 |
Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Docetaxel; Drug Administration Schedule; Humans; Male; Middle Aged; Paclitaxel; Palliative Care; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Analysis; Taxoids | 2001 |
Weekly docetaxel and estramustine in patients with hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Administration Schedule; Estramustine; Humans; Male; Middle Aged; Paclitaxel; Prostatic Neoplasms; Survival Analysis; Taxoids | 2001 |
Docetaxel followed by hormone therapy after failure of definitive treatments for clinically localized/locally advanced prostate cancer: preliminary results.
Topics: Adenocarcinoma; Aged; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Docetaxel; Finasteride; Goserelin; Humans; Leuprolide; Male; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Paclitaxel; Pilot Projects; Prostate-Specific Antigen; Prostatic Neoplasms; Salvage Therapy; Taxoids; Tosyl Compounds | 2001 |
Docetaxel, estramustine, and short-term androgen withdrawal for patients with biochemical failure after definitive local therapy for prostate cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Estramustine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids | 2001 |
Neoadjuvant docetaxel followed by radical prostatectomy in patients with high-risk localized prostate cancer: a preliminary report.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents, Phytogenic; Docetaxel; Humans; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Pilot Projects; Prostatectomy; Prostatic Neoplasms; Taxoids | 2001 |
Preliminary observations of single-agent docetaxel as neoadjuvant therapy for locally advanced prostate cancer.
Topics: Aged; Antineoplastic Agents, Phytogenic; Docetaxel; Humans; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Prostatectomy; Prostatic Neoplasms; Taxoids | 2001 |
Weekly high-dose calcitriol and docetaxel in advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Calcitriol; Docetaxel; Drug Administration Schedule; Humans; Male; Middle Aged; Paclitaxel; Prostatic Neoplasms; Taxoids; Tumor Cells, Cultured | 2001 |
Docetaxel and exisulind in hormone-refractory prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Docetaxel; Humans; Male; Middle Aged; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Sulindac; Survival Analysis; Taxoids | 2001 |
A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer.
Topics: Adenocarcinoma; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Docetaxel; Humans; Male; Middle Aged; Paclitaxel; Prostatic Neoplasms; Taxoids; Thalidomide | 2001 |
Preliminary phase I results of G3139 (bcl-2 antisense oligonucleotide) therapy in combination with docetaxel in hormone-refractory prostate cancer.
Topics: Aged; Antineoplastic Agents; Docetaxel; Genes, bcl-2; Humans; Male; Middle Aged; Oligonucleotides, Antisense; Paclitaxel; Prostatic Neoplasms; Taxoids; Thionucleotides | 2001 |
Docetaxel, estramustine, plus trastuzumab in patients with metastatic androgen-independent prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Estramustine; Genes, erbB-2; Humans; Male; Middle Aged; Paclitaxel; Prostatic Neoplasms; Taxoids; Trastuzumab | 2001 |
Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer.
Topics: Aged; Aged, 80 and over; Analgesics; Antineoplastic Agents, Phytogenic; Disease Progression; Docetaxel; Drug Administration Schedule; Humans; Infusions, Intravenous; Male; Middle Aged; Paclitaxel; Pain; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids | 2001 |
HER-2 profiling and targeting in prostate carcinoma.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Disease Progression; Gene Expression Regulation, Neoplastic; Humans; Infusions, Intravenous; Male; Middle Aged; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2002 |
Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma.
Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Estramustine; Humans; Infusions, Intravenous; Male; Middle Aged; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Treatment Outcome | 2002 |
406 other study(ies) available for paclitaxel and Prostatic Neoplasms
| Article | Year |
|---|---|
Evaluation of the potential cancer chemotherapeutic efficacy of natural product isolates employing in vivo hollow fiber tests.
Topics: Animals; Biological Factors; Colonic Neoplasms; Diosgenin; Disease Models, Animal; Diterpenes; Drug Screening Assays, Antitumor; Female; Heterocyclic Compounds, 3-Ring; HL-60 Cells; Humans; Inhibitory Concentration 50; KB Cells; Leukemia P388; Male; Melanoma; Mice; Molecular Structure; Naphthoquinones; Ovarian Neoplasms; Paclitaxel; Polymers; Prostatic Neoplasms; Triterpenes; Tumor Cells, Cultured | 2002 |
Discovery of 2-arylthiazolidine-4-carboxylic acid amides as a new class of cytotoxic agents for prostate cancer.
Topics: Amides; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Drug Screening Assays, Antitumor; Humans; Inhibitory Concentration 50; Male; Prostatic Neoplasms; Receptors, Lysophosphatidic Acid; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship; Thiazoles | 2005 |
Modulating paclitaxel bioavailability for targeting prostate cancer.
Topics: Buffers; Cell Line, Tumor; Cell Proliferation; Culture Media, Serum-Free; Humans; Male; Molecular Structure; Paclitaxel; Prodrugs; Prostatic Neoplasms; Solutions; Structure-Activity Relationship | 2007 |
Synthesis and biological analysis of prostate-specific membrane antigen-targeted anticancer prodrugs.
Topics: Antigens, Surface; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Drug Screening Assays, Antitumor; Glutamate Carboxypeptidase II; Glutarates; Humans; Ligands; Male; Molecular Targeted Therapy; Prodrugs; Prostatic Neoplasms; Structure-Activity Relationship; Urea | 2010 |
Glionitrin B, a cancer invasion inhibitory diketopiperazine produced by microbial coculture.
Topics: Antineoplastic Agents; Aspergillus fumigatus; Diketopiperazines; Drug Screening Assays, Antitumor; Humans; Male; Molecular Structure; Prostatic Neoplasms; Sphingomonas | 2011 |
Total synthesis and bioactivity of the marine alkaloid pityriacitrin and some of its derivatives.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Humans; Indole Alkaloids; Malassezia; Male; Prostatic Neoplasms | 2011 |
Discovery of novel 2-aryl-4-benzoyl-imidazole (ABI-III) analogues targeting tubulin polymerization as antiproliferative agents.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Humans; Imidazoles; Male; Melanoma; Models, Molecular; Paclitaxel; Prostatic Neoplasms; Structure-Activity Relationship; Tubulin Modulators | 2012 |
New adamantane phenylalkylamines with σ-receptor binding affinity and anticancer activity, associated with putative antagonism of neuropathic pain.
Topics: Adamantane; Animals; Antineoplastic Agents; Apoptosis; Caspase 3; Cell Cycle; Cell Proliferation; Female; Humans; Male; Mice; Mice, SCID; Molecular Structure; Neuralgia; Ovarian Neoplasms; Pancreatic Neoplasms; Piperidines; Prostatic Neoplasms; Protein Binding; Receptors, sigma; Structure-Activity Relationship; Tumor Cells, Cultured | 2012 |
The pterocarpanquinone LQB-118 inhibits tumor cell proliferation by downregulation of c-Myc and cyclins D1 and B1 mRNA and upregulation of p21 cell cycle inhibitor expression.
Topics: Apoptosis; Cell Cycle; Cell Proliferation; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p21; Down-Regulation; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Male; Naphthoquinones; Prostatic Neoplasms; Proto-Oncogene Proteins c-myc; Pterocarpans; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured | 2014 |
Texas Native Plants Yield Compounds with Cytotoxic Activities against Prostate Cancer Cells.
Topics: Antineoplastic Agents; Cell Cycle; Chalcones; Drug Screening Assays, Antitumor; Humans; Male; Molecular Structure; Nuclear Magnetic Resonance, Biomolecular; Prostatic Neoplasms; Sesquiterpenes; Sesquiterpenes, Germacrane; Texas; Tubulin; Tubulin Modulators | 2016 |
Unique Polybrominated Hydrocarbons from the Australian Endemic Red Alga Ptilonia australasica.
Topics: Antineoplastic Agents; Australia; Cell Cycle; Drug Screening Assays, Antitumor; G1 Phase; Humans; Hydrocarbons, Brominated; Inhibitory Concentration 50; Male; Molecular Structure; Nuclear Magnetic Resonance, Biomolecular; Prostatic Neoplasms; Rhodophyta | 2016 |
Lignans from the Australian Endemic Plant Austrobaileya scandens.
Topics: Antineoplastic Agents, Phytogenic; Australia; Drug Screening Assays, Antitumor; Humans; Inhibitory Concentration 50; Lignans; Magnoliopsida; Male; Molecular Structure; Prostatic Neoplasms; S Phase | 2016 |
Heterocyclic-Fused Pyrimidines as Novel Tubulin Polymerization Inhibitors Targeting the Colchicine Binding Site: Structural Basis and Antitumor Efficacy.
Topics: Animals; Apoptosis; Binding Sites; Colchicine; Crystallography, X-Ray; Drug Design; Drug Resistance, Multiple; Heterografts; Humans; Male; Melanoma; Polymerization; Prostatic Neoplasms; Pyrimidines; Tubulin | 2018 |
Structural Modification of the 3,4,5-Trimethoxyphenyl Moiety in the Tubulin Inhibitor VERU-111 Leads to Improved Antiproliferative Activities.
Topics: Animals; Cell Proliferation; Chalcones; Humans; Male; Melanoma; Mice; Mice, Nude; Models, Molecular; Molecular Structure; Prostatic Neoplasms; Protein Conformation; Tubulin; Tubulin Modulators; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2018 |
5'-Chloro-2,2'-dihydroxychalcone and related flavanoids as treatments for prostate cancer.
Topics: Androgen Receptor Antagonists; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Chalcones; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Flavonoids; Humans; Male; Mice; Mice, SCID; Molecular Structure; Neoplasms, Experimental; Prostatic Neoplasms; Receptors, Androgen; Structure-Activity Relationship | 2018 |
Caspase-Dependent Apoptosis in Prostate Cancer Cells and Zebrafish by Corchorusoside C from Streptocaulon juventas.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apocynaceae; Apoptosis; Caspases; Cell Line, Tumor; Humans; I-kappa B Kinase; Male; Molecular Structure; Poly (ADP-Ribose) Polymerase-1; Prostate; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Pyrans; Vietnam; Zebrafish | 2019 |
Synthesis and biological evaluation of PSMA-targeting paclitaxel conjugates.
Topics: Animals; Drug Delivery Systems; Humans; Male; Mice; Paclitaxel; Prostatic Neoplasms | 2019 |
Installation of Pargyline, a LSD1 Inhibitor, in the HDAC Inhibitory Template Culminated in the Identification of a Tractable Antiprostate Cancer Agent.
Topics: Antineoplastic Agents; Histone Deacetylase Inhibitors; Histone Demethylases; Humans; Male; Pargyline; Prostatic Neoplasms | 2021 |
Possibility of paclitaxel to induce the stemness-related characteristics of prostate cancer cells.
Topics: Humans; Male; Paclitaxel; Prostatic Neoplasms | 2021 |
In Vivo Antitumor and Antimetastatic Efficacy of a Polyacetal-Based Paclitaxel Conjugate for Prostate Cancer Therapy.
Topics: Acetals; Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Drug Carriers; Humans; Male; Mice; Mice, Inbred BALB C; Paclitaxel; Polymers; Prostatic Neoplasms | 2022 |
Synergistic Interaction of CPP2 Coupled with Thiazole Derivates Combined with Clotrimazole and Antineoplastic Drugs in Prostate and Colon Cancer Cell Lines.
Topics: Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cell-Penetrating Peptides; Clotrimazole; Colonic Neoplasms; Drug Synergism; Fluorouracil; Humans; Male; Paclitaxel; Prostatic Neoplasms; Thiazoles | 2021 |
Lovastatin enhances chemosensitivity of paclitaxel-resistant prostate cancer cells through inhibition of CYP2C8.
Topics: Cell Line, Tumor; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP2C8 Inhibitors; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Lovastatin; Male; Models, Biological; Paclitaxel; Prognosis; Prostatic Neoplasms | 2022 |
Exosomes are secreted at similar densities by M21 and PC3 human cancer cells and show paclitaxel solubility.
Topics: Cell Line, Tumor; Drug Carriers; Extracellular Vesicles; Humans; Male; Melanoma; Microscopy, Electron, Transmission; Paclitaxel; Prostatic Neoplasms; Solubility | 2022 |
Qi Ling decreases paclitaxel resistance in the human prostate cancer by reversing tumor-associated macrophages function.
Topics: Animals; Humans; Interleukin-6; Male; Paclitaxel; Prostatic Neoplasms; Qi; Rats; Tumor-Associated Macrophages | 2022 |
TRPM2-AS promotes paclitaxel resistance in prostate cancer by regulating FOXK1 via sponging miR-497-5p.
Topics: Cell Line, Tumor; Drug Resistance, Neoplasm; Forkhead Transcription Factors; Humans; Male; MicroRNAs; Paclitaxel; Prostatic Neoplasms; RNA, Long Noncoding; TRPM Cation Channels | 2022 |
lncRNA-DANCR Promotes Taxol Resistance of Prostate Cancer Cells through Modulating the miR-33b-5p-LDHA Axis.
Topics: Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Glucose; Humans; Male; MicroRNAs; Paclitaxel; Prostatic Neoplasms; RNA, Long Noncoding | 2022 |
Curcumin Upregulates miR-148a to Increase the Chemosensitivity of CD44-Positive Prostate Cancer Stem Cells to Paclitaxel Through Targeting the MSK1/IRS1 axis.
Topics: Antioxidants; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bromides; Cell Line, Tumor; Curcumin; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Hyaluronan Receptors; Insulin Receptor Substrate Proteins; Male; MicroRNAs; Neoplastic Stem Cells; Paclitaxel; Prostate; Prostatic Neoplasms; Ribosomal Protein S6 Kinases, 90-kDa | 2022 |
Tripartite Motif-Containing Protein 11 Reverses Paclitaxel Resistance in Prostate Cancer Drug-Resistant Cells by Mediating Family with Sequence Similarity 46B Expression.
Topics: Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Humans; Male; Paclitaxel; Prostatic Neoplasms; Tripartite Motif Proteins; Ubiquitin-Protein Ligases | 2022 |
Paclitaxel Induces the Apoptosis of Prostate Cancer Cells via ROS-Mediated HIF-1α Expression.
Topics: Antineoplastic Agents; Apoptosis; Caspase 3; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Male; Paclitaxel; Prostatic Neoplasms; Reactive Oxygen Species | 2022 |
STEAP1 Knockdown Decreases the Sensitivity of Prostate Cancer Cells to Paclitaxel, Docetaxel and Cabazitaxel.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Cell Line, Tumor; Docetaxel; Humans; Male; Oxidoreductases; Paclitaxel; Prostate; Prostatic Neoplasms; Taxoids | 2023 |
Novel α-Trifluoromethyl Chalcone Exerts Antitumor Effects Against Prostate Cancer Cells.
Topics: Androgen Antagonists; Androgens; Cell Line, Tumor; Cell Proliferation; Chalcone; Chalcones; Humans; Male; Paclitaxel; Prostatic Neoplasms; Receptors, Androgen; Taxoids | 2023 |
Novel bioactive cationic cubosomes enhance the cytotoxic effect of paclitaxel against a paclitaxel resistant prostate cancer cell-line.
Topics: Antineoplastic Agents; Cell Line; Humans; Iodides; Male; Nanoparticles; Paclitaxel; Prostatic Neoplasms; Scattering, Small Angle; X-Ray Diffraction | 2023 |
Nanopore-related cellular death through cytoskeleton depolymerization by drug-induced ROS.
Topics: Cell Line, Tumor; Cytoskeleton; Humans; Male; Microscopy, Atomic Force; Nanopores; Paclitaxel; Prostatic Neoplasms; Reactive Oxygen Species | 2024 |
DANCR sponges miR-135a to regulate paclitaxel sensitivity in prostate cancer.
Topics: Antineoplastic Agents, Phytogenic; Binding Sites; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Knockdown Techniques; Humans; Male; MicroRNAs; Paclitaxel; PC-3 Cells; Prostatic Neoplasms; RNA, Long Noncoding; RNA, Small Interfering | 2019 |
Topological properties and in vitro identification of essential nodes of the Paclitaxel and Vincristine interactomes in PC-3 cells.
Topics: Apoptosis; Cell Line, Tumor; Humans; Male; Microtubules; Mitochondria; Paclitaxel; PC-3 Cells; Prostatic Neoplasms; Signal Transduction; Vincristine | 2019 |
Anisamide-functionalized pH-responsive amphiphilic chitosan-based paclitaxel micelles for sigma-1 receptor targeted prostate cancer treatment.
Topics: Animals; Chitosan; Delayed-Action Preparations; Drug Carriers; Gene Expression Regulation, Neoplastic; Hemolysis; Humans; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Male; Materials Testing; Mice; Micelles; Molecular Targeted Therapy; Paclitaxel; PC-3 Cells; Prostatic Neoplasms; Receptors, sigma; Sigma-1 Receptor; Xenograft Model Antitumor Assays | 2020 |
Aurora B Kinase Promotes CHIP-Dependent Degradation of HIF1α in Prostate Cancer Cells.
Topics: Apoptosis; Aurora Kinase B; Biomarkers, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Male; Paclitaxel; Phosphorylation; Prostatic Neoplasms; Proteolysis; Tumor Cells, Cultured; Ubiquitin-Protein Ligases; Ubiquitination | 2020 |
A pH-Responsive Charge-Reversal Drug Delivery System with Tumor-Specific Drug Release and ROS Generation for Cancer Therapy.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Delivery Systems; Drug Liberation; Humans; Hydrogen-Ion Concentration; Male; Mice; Mice, Inbred BALB C; Micelles; NAD(P)H Dehydrogenase (Quinone); Nanoparticles; NIH 3T3 Cells; Paclitaxel; Polymers; Prodrugs; Prostatic Neoplasms; Reactive Oxygen Species; Vitamin K 3 | 2020 |
Knockdown of lncRNA CCAT1 enhances sensitivity of paclitaxel in prostate cancer via regulating miR-24-3p and FSCN1.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Carrier Proteins; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Male; Microfilament Proteins; MicroRNAs; Paclitaxel; Prostatic Neoplasms; RNA, Long Noncoding; Signal Transduction; Up-Regulation | 2020 |
CD133 suppression increases the sensitivity of prostate cancer cells to paclitaxel.
Topics: AC133 Antigen; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Humans; Male; Neoplastic Stem Cells; Paclitaxel; Prostate; Prostatic Neoplasms; RNA, Small Interfering; Signal Transduction; TOR Serine-Threonine Kinases | 2020 |
Synthesis of PLGA/chitosan/zeolites and PLGA/chitosan/metal organic frameworks nanofibers for targeted delivery of Paclitaxel toward prostate cancer cells death.
Topics: Antineoplastic Agents; Cell Death; Cell Line, Tumor; Cell Survival; Chitosan; Drug Carriers; Drug Delivery Systems; Humans; Male; Metal-Organic Frameworks; Microscopy, Electron, Scanning; Nanofibers; Nanoparticles; Paclitaxel; Polylactic Acid-Polyglycolic Acid Copolymer; Prostatic Neoplasms; Spectroscopy, Fourier Transform Infrared; X-Ray Diffraction; Zeolites | 2020 |
Multifunctional nanobubbles carrying indocyanine green and paclitaxel for molecular imaging and the treatment of prostate cancer.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Drug Delivery Systems; Humans; Indocyanine Green; Male; Mice, Nude; Molecular Imaging; Nanoparticles; Paclitaxel; PC-3 Cells; Photoacoustic Techniques; Prostatic Neoplasms; Theranostic Nanomedicine; Ultrasonography | 2020 |
Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; DNA Repair-Deficiency Disorders; Docetaxel; Drug Therapy; Humans; Male; Middle Aged; Paclitaxel; Platinum Compounds; Prostatic Neoplasms; Retrospective Studies | 2020 |
LncRNA AFAP1-AS1 modulates the sensitivity of paclitaxel-resistant prostate cancer cells to paclitaxel via miR-195-5p/FKBP1A axis.
Topics: Animals; Antineoplastic Agents, Phytogenic; Heterografts; Humans; Male; Mice; Mice, Nude; MicroRNAs; Paclitaxel; PC-3 Cells; Prostatic Neoplasms; RNA, Long Noncoding; Signal Transduction; Tacrolimus Binding Proteins; Transfection | 2020 |
Toxicity profile of taxanes in Tunisian cancer patients: A retrospective study of 90 cases.
Topics: Adult; Aged; Alopecia; Antineoplastic Agents; Breast Neoplasms; Cisplatin; Digestive System Diseases; Docetaxel; Fatigue; Female; Fluorouracil; Hematologic Diseases; Humans; Male; Middle Aged; Nail Diseases; Nervous System Diseases; Ovarian Neoplasms; Paclitaxel; Prostatic Neoplasms; Retrospective Studies; Stomach Neoplasms; Taxoids; Tunisia | 2021 |
Sequential Release of Pooled siRNAs and Paclitaxel by Aptamer-Functionalized Shell-Core Nanoparticles to Overcome Paclitaxel Resistance of Prostate Cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Drug Carriers; Drug Delivery Systems; Drug Resistance, Neoplasm; Humans; Male; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Paclitaxel; Prostatic Neoplasms; RNA, Small Interfering; RNAi Therapeutics | 2021 |
Propofol enhanced the cell sensitivity to paclitaxel (PTX) in prostatic cancer (PC) through modulation of HOTAIR.
Topics: Apoptosis; Cell Line, Tumor; Cell Survival; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Male; Paclitaxel; Propofol; Prostatic Neoplasms; RNA, Long Noncoding | 2021 |
GDI2 is a target of paclitaxel that affects tumorigenesis of prostate cancer via the p75NTR signaling pathway.
Topics: Apoptosis; Carcinogenesis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Disease Progression; Drug Evaluation, Preclinical; Gene Expression Regulation, Neoplastic; Guanine Nucleotide Dissociation Inhibitors; Humans; Male; Nerve Tissue Proteins; Paclitaxel; Prostatic Neoplasms; Receptors, Nerve Growth Factor; Signal Transduction; Up-Regulation | 2021 |
Norcantharidin combined with paclitaxel induces endoplasmic reticulum stress mediated apoptotic effect in prostate cancer cells by targeting SIRT7 expression.
Topics: Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Endoplasmic Reticulum Stress; Humans; Male; Paclitaxel; Prostatic Neoplasms; Sirtuins | 2021 |
Mechanotransduction-Induced Reversible Phenotypic Switching in Prostate Cancer Cells.
Topics: Cell Line, Tumor; Humans; Male; Mechanotransduction, Cellular; Paclitaxel; Phenotype; Prostatic Neoplasms; Signal Transduction | 2017 |
Down-regulation of E-cadherin enhances prostate cancer chemoresistance via Notch signaling.
Topics: Animals; Antigens, CD; Cadherins; Cell Line, Tumor; Cell Movement; Down-Regulation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Paclitaxel; Prostatic Neoplasms; Receptors, Notch; Signal Transduction; Xenograft Model Antitumor Assays | 2017 |
Inhibiting G protein βγ signaling blocks prostate cancer progression and enhances the efficacy of paclitaxel.
Topics: Animals; Antineoplastic Agents; Carcinogenesis; Cell Growth Processes; Cell Line, Tumor; Cell Movement; Drug Resistance, Neoplasm; GTP-Binding Protein alpha Subunits; GTP-Binding Protein beta Subunits; GTP-Binding Protein gamma Subunits; Humans; Male; Mice; Mice, Nude; Neoplastic Stem Cells; Paclitaxel; Prostatic Neoplasms; Signal Transduction; Xenograft Model Antitumor Assays | 2017 |
Human cancer-associated fibroblasts enhance glutathione levels and antagonize drug-induced prostate cancer cell death.
Topics: Antineoplastic Agents; Cancer-Associated Fibroblasts; Cell Death; Cell Line, Tumor; Cell Survival; Coculture Techniques; Culture Media, Conditioned; DNA Damage; Doxorubicin; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glutathione; Humans; Male; Paclitaxel; Primary Cell Culture; Prostatic Neoplasms; Reactive Oxygen Species; Signal Transduction; Tumor Microenvironment; Tumor Suppressor Protein p53 | 2017 |
Intercellular transmission of the unfolded protein response promotes survival and drug resistance in cancer cells.
Topics: Activating Transcription Factor 4; Animals; Antineoplastic Agents; Bortezomib; Cell Survival; Drug Resistance; eIF-2 Kinase; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Heat-Shock Proteins; Humans; Male; Mice; Mice, Inbred C57BL; Paclitaxel; Prostatic Neoplasms; Transcription Factor CHOP; Tubulin Modulators; Tumor Cells, Cultured; Unfolded Protein Response; Wnt Proteins | 2017 |
Morin promotes prostate cancer cells chemosensitivity to paclitaxel through miR-155/GATA3 axis.
Topics: 3' Untranslated Regions; Animals; Apoptosis; Cell Line, Tumor; Cell Survival; Cluster Analysis; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Flavonoids; GATA3 Transcription Factor; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Male; Mice; MicroRNAs; Paclitaxel; Prostatic Neoplasms; RNA Interference; Xenograft Model Antitumor Assays | 2017 |
Paclitaxel-loaded and A10-3.2 aptamer-targeted poly(lactide-
Topics: Animals; Antigens, Surface; Antineoplastic Agents, Phytogenic; Aptamers, Nucleotide; Cell Line, Tumor; Drug Delivery Systems; Drug Liberation; Glutamate Carboxypeptidase II; Humans; Lactic Acid; Male; Mice; Mice, Nude; Nanostructures; Paclitaxel; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Prostatic Neoplasms; Ultrasonography | 2017 |
Double-receptor-targeting multifunctional iron oxide nanoparticles drug delivery system for the treatment and imaging of prostate cancer.
Topics: Animals; Cell Death; Cell Line, Tumor; Cell Survival; Computer Simulation; Drug Delivery Systems; Drug Liberation; Endocytosis; Ferric Compounds; Humans; Hydrodynamics; Hydrogen-Ion Concentration; Iron; Magnetic Resonance Imaging; Male; Nanoparticles; Paclitaxel; Particle Size; Peptides; Prostatic Neoplasms; Surface Properties | 2017 |
MiR-199a suppresses prostate cancer paclitaxel resistance by targeting YES1.
Topics: Animals; Antineoplastic Agents, Phytogenic; Case-Control Studies; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Humans; Male; Mice; Mice, Nude; MicroRNAs; Neoplasm Transplantation; Paclitaxel; Prostatic Neoplasms; Proto-Oncogene Proteins c-yes; Real-Time Polymerase Chain Reaction | 2018 |
Bioresponsive albumin-conjugated paclitaxel prodrugs for cancer therapy.
Topics: Absorption, Physiological; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, Tumor; Drug Delivery Systems; Drug Liberation; Female; Glutathione; Humans; Injections, Intravenous; Male; Mice, Inbred BALB C; Optical Imaging; Oxidation-Reduction; Paclitaxel; Prodrugs; Prostatic Neoplasms; Reactive Oxygen Species; Serum Albumin, Bovine; Serum Albumin, Human; Tissue Distribution; Tumor Microenvironment; Whole Body Imaging; Xenograft Model Antitumor Assays | 2018 |
Prostate-Specific Membrane Antigen Targeted Therapy of Prostate Cancer Using a DUPA-Paclitaxel Conjugate.
Topics: Animals; Antigens, Surface; Cell Line, Tumor; Drug Delivery Systems; Drug Liberation; Glutamate Carboxypeptidase II; Glutarates; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Paclitaxel; Prostate; Prostatic Neoplasms; Urea; Xenograft Model Antitumor Assays | 2018 |
[Anti-prostate cancer effect of roemerine: An experimental study].
Topics: Alkaloids; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease Models, Animal; Drug Therapy, Combination; Drugs, Chinese Herbal; Male; Mice; Mice, Nude; Paclitaxel; Prostatic Neoplasms | 2017 |
Overexpression of PER3 reverses paclitaxel resistance of prostate cancer cells by inhibiting the Notch pathway.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Male; Middle Aged; Paclitaxel; Period Circadian Proteins; Prostatic Neoplasms; Receptor, Notch1; Signal Transduction; Up-Regulation | 2018 |
Biodegradable, Hydrogen Peroxide, and Glutathione Dual Responsive Nanoparticles for Potential Programmable Paclitaxel Release.
Topics: Animals; Antineoplastic Agents; Biodegradable Plastics; Cell Line, Tumor; CHO Cells; Cricetulus; Drug Carriers; Drug Liberation; Glutathione; Green Chemistry Technology; Humans; Hydrogen Peroxide; Male; Mice; Nanoparticles; Paclitaxel; Polymers; Prostatic Neoplasms; Sulfides; Xenograft Model Antitumor Assays | 2018 |
Zinc enhances chemosensitivity to paclitaxel in PC‑3 prostate cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Cell Proliferation; Drug Resistance, Neoplasm; Humans; Male; Mitochondria; Paclitaxel; Prostatic Neoplasms; Tumor Cells, Cultured; Zinc | 2018 |
PSMA Antibody-Conjugated Pentablock Copolymer Nanomicellar Formulation for Targeted Delivery to Prostate Cancer.
Topics: Antigens, Surface; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Drug Compounding; Drug Delivery Systems; Glutamate Carboxypeptidase II; Humans; Male; Micelles; Paclitaxel; Polymers; Prostatic Neoplasms; X-Ray Diffraction | 2018 |
Paclitaxel resistance and the role of miRNAs in prostate cancer cell lines.
Topics: Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Male; MicroRNAs; Paclitaxel; Prostatic Neoplasms | 2019 |
A stent film of paclitaxel presenting extreme accumulation of paclitaxel in tumor tissue and excellent antitumor efficacy after implantation beneath the subcutaneous tumor xenograft in mice.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Chemistry, Pharmaceutical; Drug Carriers; Drug Liberation; Drug-Eluting Stents; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Paclitaxel; Polyesters; Prostatic Neoplasms; Xenograft Model Antitumor Assays | 2018 |
MicroRNA-34a Attenuates Paclitaxel Resistance in Prostate Cancer Cells via Direct Suppression of JAG1/Notch1 Axis.
Topics: 3' Untranslated Regions; Animals; Antagomirs; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Female; Hepatocyte Nuclear Factor 1-alpha; Humans; Jagged-1 Protein; Kaplan-Meier Estimate; Male; Mice; Mice, Nude; MicroRNAs; Paclitaxel; Prostatic Neoplasms; Receptor, Notch1; Signal Transduction | 2018 |
Long non-coding RNA Linc00518 promotes paclitaxel resistance of the human prostate cancer by sequestering miR-216b-5p.
Topics: 3' Untranslated Regions; Base Sequence; Cell Line, Tumor; Drug Resistance, Neoplasm; GATA6 Transcription Factor; Gene Expression Regulation, Neoplastic; Humans; Male; MicroRNAs; Paclitaxel; Prognosis; Prostatic Neoplasms; RNA, Long Noncoding | 2019 |
Zinc promotes prostate cancer cell chemosensitivity to paclitaxel by inhibiting epithelial-mesenchymal transition and inducing apoptosis.
Topics: Adjuvants, Pharmaceutic; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, Tumor; Cell Survival; Epithelial-Mesenchymal Transition; Gene Expression Regulation, Neoplastic; Humans; Male; Nuclear Proteins; Paclitaxel; Prostate; Prostatic Neoplasms; Twist-Related Protein 1; Zinc | 2019 |
Anisamide-targeted PEGylated gold nanoparticles designed to target prostate cancer mediate: Enhanced systemic exposure of siRNA, tumour growth suppression and a synergistic therapeutic response in combination with paclitaxel in mice.
Topics: Animals; Antineoplastic Agents, Phytogenic; Benzamides; Cell Line, Tumor; Combined Modality Therapy; Gene Knockdown Techniques; Gene Transfer Techniques; Gold; Humans; Male; Metal Nanoparticles; Mice; Mice, Inbred BALB C; Mice, Nude; NF-kappa B; Paclitaxel; Polyethylene Glycols; Polyethyleneimine; Prostatic Neoplasms; RNA, Small Interfering; Treatment Outcome; Xenograft Model Antitumor Assays | 2019 |
MicroRNA‑302a upregulation mediates chemo‑resistance in prostate cancer cells.
Topics: Antagomirs; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; G2 Phase Cell Cycle Checkpoints; Histone Demethylases; Humans; M Phase Cell Cycle Checkpoints; Male; MicroRNAs; Neoplasm Proteins; Paclitaxel; Prostatic Neoplasms; Up-Regulation | 2019 |
Zinc cooperates with p53 to inhibit the activity of mitochondrial aconitase through reactive oxygen species accumulation.
Topics: Aconitate Hydratase; Animals; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Paclitaxel; PC-3 Cells; Prostatic Neoplasms; Reactive Oxygen Species; Tumor Suppressor Protein p53; Up-Regulation; Xenograft Model Antitumor Assays; Zinc | 2019 |
Gold-caged copolymer nanoparticles as multimodal synergistic photodynamic/photothermal/chemotherapy platform against lethality androgen-resistant prostate cancer.
Topics: Androgens; Animals; Antineoplastic Agents; Apoptosis; Calcium Channels; Cell Cycle Checkpoints; Cell Line, Tumor; Endocytosis; Gold; Humans; Hyperthermia, Induced; Infrared Rays; Inhibitory Concentration 50; Male; Metal Nanoparticles; Mice; Mice, Nude; Paclitaxel; Photochemotherapy; Phototherapy; Poloxamer; Polyethyleneimine; Polymers; Prostatic Neoplasms; Reactive Oxygen Species; TRPV Cation Channels; Up-Regulation; Xenograft Model Antitumor Assays | 2019 |
Molecular Engineering-Based Aptamer-Drug Conjugates with Accurate Tunability of Drug Ratios for Drug Combination Targeted Cancer Therapy.
Topics: Antineoplastic Agents; Aptamers, Nucleotide; Camptothecin; Dasatinib; Drug Carriers; Drug Delivery Systems; Humans; Male; Molecular Targeted Therapy; Paclitaxel; Prostatic Neoplasms; Stilbenes; Tumor Cells, Cultured | 2019 |
Impact of PLK-1 silencing on endothelial cells and cancer cells of diverse histological origin.
Topics: Antineoplastic Agents, Phytogenic; Base Sequence; Carcinoma, Non-Small-Cell Lung; Cell Cycle Checkpoints; Cell Cycle Proteins; Cell Line, Tumor; Cell Survival; Down-Regulation; Endothelial Cells; Humans; Lung Neoplasms; Male; Molecular Sequence Data; Molecular Targeted Therapy; Paclitaxel; Polo-Like Kinase 1; Prostatic Neoplasms; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Reference Values; RNA, Small Interfering; S Phase; Tumor Cells, Cultured; Tumor Microenvironment | 2013 |
[Advances and significance of paclitaxel in the therapy of prostate cancer].
Topics: Humans; Male; Paclitaxel; Prostatic Neoplasms | 2013 |
FTIR spectral signature of anticancer drug effects on PC-3 cancer cells: is there any influence of the cell cycle?
Topics: Antineoplastic Agents, Phytogenic; Cell Cycle; Cell Line, Tumor; Cluster Analysis; Flow Cytometry; Humans; Image Processing, Computer-Assisted; Male; Microscopy, Fluorescence; Microtubules; Mitosis; Paclitaxel; Principal Component Analysis; Prostatic Neoplasms; Spectroscopy, Fourier Transform Infrared; Spindle Apparatus | 2013 |
Impact of anti-PLK1 siRNA-containing F3-targeted liposomes on the viability of both cancer and endothelial cells.
Topics: Antineoplastic Agents, Phytogenic; Cell Cycle Proteins; Cell Death; Cell Line, Tumor; Cell Survival; Endothelial Cells; G2 Phase Cell Cycle Checkpoints; Gene Silencing; Humans; Inhibitory Concentration 50; Liposomes; Male; Mitosis; Paclitaxel; Polo-Like Kinase 1; Prostatic Neoplasms; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; RNA, Messenger; RNA, Small Interfering | 2013 |
Plk1-dependent microtubule dynamics promotes androgen receptor signaling in prostate cancer.
Topics: Cell Cycle Proteins; Cell Line, Tumor; Humans; Male; Microtubules; Paclitaxel; Phosphorylation; Polo-Like Kinase 1; Prostatic Neoplasms; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Receptors, Androgen; Signal Transduction | 2013 |
Development of innovative paclitaxel-loaded small PLGA nanoparticles: study of their antiproliferative activity and their molecular interactions on prostatic cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Proliferation; Cell Survival; Endocytosis; Humans; Lactic Acid; Male; Nanoparticles; Paclitaxel; Particle Size; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Prostatic Neoplasms; Surface Properties | 2013 |
[Successful treatment with docetaxel and prednisolone for paxlitaxel and carboplatin-resistant prostate cancer].
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Paclitaxel; Prednisolone; Prostatic Neoplasms; Taxoids | 2013 |
Caffeic acid phenethyl ester synergistically enhances docetaxel and paclitaxel cytotoxicity in prostate cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Caffeic Acids; Caspase 3; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Docetaxel; Drug Synergism; Estrogen Receptor alpha; Estrogen Receptor beta; Forkhead Box Protein O1; Forkhead Transcription Factors; Humans; Inhibitory Concentration 50; Male; Paclitaxel; Phenylethyl Alcohol; Prostatic Neoplasms; Taxoids | 2013 |
Alpha-tomatine synergises with paclitaxel to enhance apoptosis of androgen-independent human prostate cancer PC-3 cells in vitro and in vivo.
Topics: Androgens; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; bcl-2-Associated X Protein; bcl-Associated Death Protein; Cell Line, Tumor; Drug Synergism; Drug Therapy, Combination; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Paclitaxel; Phosphatidylinositol 3-Kinases; Phytotherapy; Plant Extracts; Prostate; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Solanum lycopersicum; Tomatine | 2013 |
Nanoparticulate paclitaxel demonstrates antitumor activity in PC3 and Ace-1 aggressive prostate cancer cell lines.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Caspase 3; Caspase 7; Cell Line, Tumor; Cell Survival; Dogs; Humans; Male; Nanoparticles; Paclitaxel; Prostatic Neoplasms | 2013 |
shRNA-mediated GSTP1 gene silencing enhances androgen-independent cell line DU145 chemosensitivity.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Fluorouracil; Gene Silencing; Glutathione S-Transferase pi; Humans; Male; Paclitaxel; Prostatic Neoplasms; RNA, Messenger; RNA, Small Interfering; Transfection | 2014 |
Induction of paclitaxel resistance by ERα mediated prohibitin mitochondrial-nuclear shuttling.
Topics: Active Transport, Cell Nucleus; Antineoplastic Agents; Cell Death; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Estrogens; Gene Expression Regulation, Neoplastic; Humans; Male; Mitochondria; Paclitaxel; Prohibitins; Prostatic Neoplasms; Repressor Proteins | 2013 |
Nanoparticles of star-like copolymer mannitol-functionalized poly(lactide)-vitamin E TPGS for delivery of paclitaxel to prostate cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Humans; Male; Nanoparticles; Paclitaxel; Polyesters; Prostatic Neoplasms; Proton Magnetic Resonance Spectroscopy; Vitamin E | 2014 |
Design, synthesis and bioevaluation of an EphA2 receptor-based targeted delivery system.
Topics: Amino Acid Sequence; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Drug Carriers; Drug Design; Female; Humans; Male; Mice; Mice, Inbred BALB C; Paclitaxel; Peptides; Prostatic Neoplasms; Receptor, EphA2; Transplantation, Heterologous | 2014 |
Direct comparison of two albumin-based paclitaxel-loaded nanoparticle formulations: is the crosslinked version more advantageous?
Topics: Albumin-Bound Paclitaxel; Albumins; Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Chemistry, Pharmaceutical; Cross-Linking Reagents; Drug Carriers; Drug Stability; Injections, Intravenous; Male; Mice; Nanoparticles; Nanotechnology; Paclitaxel; Permeability; Prostatic Neoplasms; Rats, Wistar; Solubility; Technology, Pharmaceutical; Tissue Distribution | 2014 |
Targeting ribosomal S6 kinases/Y-box binding protein-1 signaling improves cellular sensitivity to taxane in prostate cancer.
Topics: Antineoplastic Agents, Phytogenic; Bridged-Ring Compounds; Cell Line, Tumor; Drug Delivery Systems; Drug Resistance, Neoplasm; Gene Knockdown Techniques; Humans; Male; Paclitaxel; Prostatic Neoplasms; Ribosomal Protein S6 Kinases; Signal Transduction; Taxoids; Y-Box-Binding Protein 1 | 2014 |
The role of the SHH gene in prostate cancer cell resistance to paclitaxel.
Topics: Antineoplastic Agents, Phytogenic; ATP-Binding Cassette Transporters; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Hedgehog Proteins; Humans; Male; Paclitaxel; Prostatic Neoplasms; Transfection; Treatment Failure; Up-Regulation | 2014 |
Fat composition changes in bone marrow during chemotherapy and radiation therapy.
Topics: Adipose Tissue; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Blood Cell Count; Bone Marrow; Bone Marrow Cells; Capecitabine; Cervical Vertebrae; Cetuximab; Chemoradiotherapy; Cisplatin; Deoxycytidine; Endometrial Neoplasms; Female; Fluorouracil; Humans; Lumbar Vertebrae; Magnetic Resonance Imaging; Male; Middle Aged; Mitomycin; Paclitaxel; Prospective Studies; Prostatic Neoplasms; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated; Rectal Neoplasms; Spine; Thoracic Vertebrae; Uterine Cervical Neoplasms | 2014 |
Down-modulation of Bcl-2 sensitizes PTEN-mutated prostate cancer cells to starvation and taxanes.
Topics: Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Down-Regulation; Humans; Male; Mutation; Paclitaxel; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; PTEN Phosphohydrolase | 2014 |
Prostate cancer cell response to paclitaxel is affected by abnormally expressed securin PTTG1.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, Tumor; Down-Regulation; Gene Silencing; Humans; Male; Mitosis; Myeloid Cell Leukemia Sequence 1 Protein; Paclitaxel; Prostatic Neoplasms; RNA, Small Interfering; Securin; Transfection | 2014 |
Src inhibition potentiates antitumoral effect of paclitaxel by blocking tumor-induced angiogenesis.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Cell Movement; Cell Proliferation; Fluorescent Antibody Technique; Focal Adhesion Kinase 1; Humans; Immunoenzyme Techniques; Male; Mice; Neovascularization, Pathologic; Paclitaxel; Prostatic Neoplasms; Protein Kinase Inhibitors; src-Family Kinases; Tumor Cells, Cultured; Vascular Endothelial Growth Factor Receptor-2 | 2014 |
In vitro synergistic efficacy of conjugated linoleic acid, oleic acid, safflower oil and taxol cytotoxicity on PC3 cells.
Topics: Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Drug Synergism; Humans; Linoleic Acids, Conjugated; Male; Oleic Acid; Paclitaxel; Prostatic Neoplasms; Safflower Oil | 2015 |
Multifunctional nanoparticles for prostate cancer therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Survival; Delayed-Action Preparations; Diffusion; Drug Compounding; Drug Stability; Humans; Male; Nanocapsules; Neoplastic Stem Cells; Paclitaxel; Particle Size; Prostatic Neoplasms; Treatment Outcome; Veratrum Alkaloids | 2015 |
Sox2 is involved in paclitaxel resistance of the prostate cancer cell line PC-3 via the PI3K/Akt pathway.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Cyclin E; Drug Resistance, Neoplasm; G1 Phase; Humans; Inhibitor of Apoptosis Proteins; Male; Paclitaxel; Phosphatidylinositol 3-Kinases; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; S Phase; Signal Transduction; SOXB1 Transcription Factors; Survivin | 2014 |
Knockdown of clusterin expression increases the in vitro sensitivity of human prostate cancer cells to paclitaxel.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Clusterin; Down-Regulation; Gene Deletion; Gene Expression Regulation, Neoplastic; Humans; Male; Paclitaxel; Prostatic Neoplasms; RNA, Messenger; RNA, Small Interfering | 2014 |
PSMA-mediated endosome escape-accelerating polymeric micelles for targeted therapy of prostate cancer and the real time tracing of their intracellular trafficking.
Topics: Animals; Antigens, Surface; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Drug Carriers; Endosomes; Glutamate Carboxypeptidase II; Humans; Hydrogen-Ion Concentration; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Micelles; Paclitaxel; Polyamines; Polyesters; Polymers; Prostatic Neoplasms; Transplantation, Heterologous | 2015 |
Protein kinase A type II-α regulatory subunit regulates the response of prostate cancer cells to taxane treatment.
Topics: Bridged-Ring Compounds; Cell Line, Tumor; Cyclic AMP-Dependent Protein Kinases; Docetaxel; Humans; Male; Paclitaxel; Prostatic Neoplasms; Protein Kinase Inhibitors; Taxoids | 2014 |
Regulation of T-type calcium channel expression by sodium butyrate in prostate cancer cells.
Topics: Butyric Acid; Calcium Channels, T-Type; Cell Differentiation; Cell Line; Cell Line, Tumor; Cell Proliferation; Cell Survival; Histone Deacetylase Inhibitors; Humans; Male; Paclitaxel; Prostatic Neoplasms; Thapsigargin | 2015 |
MTDH/AEG-1-based DNA vaccine suppresses metastasis and enhances chemosensitivity to paclitaxel in pelvic lymph node metastasis.
Topics: Administration, Oral; Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Drug Resistance, Neoplasm; Lymphatic Metastasis; Male; Membrane Proteins; Mice; Mice, Inbred C57BL; Paclitaxel; Pelvic Neoplasms; Prostatic Neoplasms; RNA-Binding Proteins; Survival Rate; Vaccines, DNA | 2015 |
Combining paclitaxel with ABT-263 has a synergistic effect on paclitaxel resistant prostate cancer cells.
Topics: Aniline Compounds; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Caspases; Cell Cycle Checkpoints; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression; Gene Knockdown Techniques; Humans; Male; Mitosis; Paclitaxel; Prostatic Neoplasms; Signal Transduction; Sulfonamides; Tumor Cells, Cultured | 2015 |
Core-Cross-Linking Accelerates Antitumor Activities of Paclitaxel-Conjugate Micelles to Prostate Multicellular Tumor Spheroids: A Comparison of 2D and 3D Models.
Topics: Cell Culture Techniques; Drug Delivery Systems; Humans; Male; Micelles; Nanoparticles; Paclitaxel; Polyethylene Glycols; Prostatic Neoplasms; Spheroids, Cellular | 2015 |
An Atomic Force Microscope Study Revealed Two Mechanisms in the Effect of Anticancer Drugs on Rate-Dependent Young's Modulus of Human Prostate Cancer Cells.
Topics: Amino Acids; Celecoxib; Cell Line, Tumor; Cytoskeleton; Disulfiram; Elastic Modulus; Fluorescent Antibody Technique; Heterocyclic Compounds, 3-Ring; Humans; Male; Microscopy, Atomic Force; Models, Theoretical; Paclitaxel; Prostatic Neoplasms | 2015 |
Early Reporting of Apoptosis by Real-time Imaging of Cancer Cells Labeled with Green Fluorescent Protein in the Nucleus and Red Fluorescent Protein in the Cytoplasm.
Topics: Apoptosis; Cell Line, Tumor; Cell Tracking; Cytoplasm; DNA Fragmentation; Green Fluorescent Proteins; Humans; Luminescent Proteins; Male; Microscopy, Fluorescence; Molecular Imaging; Paclitaxel; Prostatic Neoplasms; Red Fluorescent Protein | 2015 |
Enhanced antitumor efficacy by cyclic RGDyK-conjugated and paclitaxel-loaded pH-responsive polymeric micelles.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Delayed-Action Preparations; Diffusion; Drug Synergism; Hydrogen-Ion Concentration; Integrin alphaVbeta3; Male; Mice; Micelles; Nanocapsules; Paclitaxel; Peptides, Cyclic; Polymers; Prostatic Neoplasms; Treatment Outcome | 2015 |
Redox-Sensitive PEG-Polypeptide Nanoporous Particles for Survivin Silencing in Prostate Cancer Cells.
Topics: Cell Line, Tumor; Cell Survival; Humans; Inhibitor of Apoptosis Proteins; Male; Nanoparticles; Paclitaxel; Polyethylene Glycols; Polylysine; Prostatic Neoplasms; RNA, Small Interfering; Survivin | 2015 |
BRCA 1/2 gene mutation and gastrointestinal stromal tumours: a potential association.
Topics: Aged; Antineoplastic Agents, Alkylating; Breast Neoplasms, Male; Cyclophosphamide; Doxorubicin; Fatal Outcome; Gastrointestinal Stromal Tumors; Genes, BRCA2; Genetic Predisposition to Disease; Genotype; Germ-Line Mutation; Humans; Male; Mutation; Neoadjuvant Therapy; Paclitaxel; Predictive Value of Tests; Prostatic Neoplasms | 2015 |
Dietary flavonoid fisetin binds to β-tubulin and disrupts microtubule dynamics in prostate cancer cells.
Topics: Acetylation; Animals; Binding Sites; Cell Cycle Proteins; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Flavonoids; Flavonols; Male; Microtubule-Associated Proteins; Microtubules; Molecular Docking Simulation; Neoplasm Invasiveness; Nuclear Proteins; Paclitaxel; Prostatic Neoplasms; Protein Binding; Protein Conformation; Protein Processing, Post-Translational; Protein Stability; Signal Transduction; Surface Plasmon Resonance; Time Factors; Tubulin; Tubulin Modulators | 2015 |
A paclitaxel-loaded recombinant polypeptide nanoparticle outperforms Abraxane in multiple murine cancer models.
Topics: Albumin-Bound Paclitaxel; Animals; Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Survival; Drug Delivery Systems; Female; Gene Expression Regulation, Neoplastic; Humans; In Vitro Techniques; Male; Mice; Microscopy, Confocal; Microscopy, Fluorescence; Nanoconjugates; Nanoparticles; Neoplasm Transplantation; Paclitaxel; Peptides; Prostatic Neoplasms; Recombinant Proteins; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2015 |
Integrative transcriptomics-based identification of cryptic drivers of taxol-resistance genes in ovarian carcinoma cells: Analysis of the androgen receptor.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Inhibitory Concentration 50; Male; Oligonucleotide Array Sequence Analysis; Oligonucleotides; Ovarian Neoplasms; Paclitaxel; Phenotype; Polymerase Chain Reaction; Prostatic Neoplasms; Receptors, Androgen; RNA Interference; Transcription Factors; Transcriptome; Up-Regulation | 2015 |
Microvesicle- and exosome-mediated drug delivery enhances the cytotoxicity of Paclitaxel in autologous prostate cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Survival; Cell-Derived Microparticles; Chemistry, Pharmaceutical; Dose-Response Relationship, Drug; Drug Carriers; Endocytosis; Exosomes; Humans; Male; Nanoparticles; Paclitaxel; Phenotype; Prostatic Neoplasms; Time Factors | 2015 |
Anti-Proliferative Effects of Hesa-A on Human Cancer Cells with Different Metastatic Potential.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Female; Humans; Inhibitory Concentration 50; Lung Neoplasms; Male; Neoplasms; Ovarian Neoplasms; Paclitaxel; Plant Preparations; Prostatic Neoplasms | 2015 |
Downregulation of cytokeratin 18 is associated with paclitaxel‑resistance and tumor aggressiveness in prostate cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Humans; Keratin-18; Male; Mice; Neoplasm Transplantation; Paclitaxel; Prognosis; Prostatic Neoplasms; Survival Analysis | 2016 |
Inhibition of bone loss with surface-modulated, drug-loaded nanoparticles in an intraosseous model of prostate cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Bone Marrow; Bone Neoplasms; Bone Resorption; Cell Line, Tumor; Humans; Male; Mice, Nude; Nanoparticles; Paclitaxel; Prostatic Neoplasms; Surface Properties; Tibia; Tissue Distribution; X-Ray Microtomography | 2016 |
Combination therapy induces unfolded protein response and cytoskeletal rearrangement leading to mitochondrial apoptosis in prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; beta Catenin; Caspases; Cell Cycle Checkpoints; Cell Death; Cell Line, Tumor; Cytoskeleton; Enzyme Activation; G1 Phase; G2 Phase; HSP70 Heat-Shock Proteins; Humans; Interferon-gamma; Interleukin-8; Male; Matrix Metalloproteinases; Membrane Potential, Mitochondrial; Mitochondria; Neoplastic Stem Cells; Paclitaxel; Peptides, Cyclic; Phosphorylation; Prostatic Neoplasms; Reactive Oxygen Species; Thapsigargin; Transforming Growth Factor beta; Unfolded Protein Response; X-Rays | 2016 |
Skp2 is associated with paclitaxel resistance in prostate cancer cells.
Topics: Antineoplastic Agents; Cadherins; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p27; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Male; Paclitaxel; Prostatic Neoplasms; S-Phase Kinase-Associated Proteins; Up-Regulation | 2016 |
Loss of PKCδ Induces Prostate Cancer Resistance to Paclitaxel through Activation of Wnt/β-Catenin Pathway and Mcl-1 Accumulation.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Aurora Kinase A; beta Catenin; Cell Cycle Checkpoints; Cell Line, Tumor; Chromones; Drug Resistance, Neoplasm; Gene Expression; Gene Silencing; Humans; Male; Mitosis; Models, Biological; Morpholines; Myeloid Cell Leukemia Sequence 1 Protein; Paclitaxel; Prostatic Neoplasms; Protein Kinase C-delta; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Wnt Signaling Pathway | 2016 |
Acoustic Cluster Therapy (ACT) enhances the therapeutic efficacy of paclitaxel and Abraxane® for treatment of human prostate adenocarcinoma in mice.
Topics: Albumin-Bound Paclitaxel; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Drug Delivery Systems; Drug Liberation; Humans; Male; Mice; Paclitaxel; Prostatic Neoplasms; Ultrasonic Waves | 2016 |
Combination therapy of paclitaxel and cyclopamine polymer-drug conjugates to treat advanced prostate cancer.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Delivery Systems; Humans; Male; Mice; Mice, Nude; Micelles; Nanoconjugates; Paclitaxel; Polymers; Prostatic Neoplasms; Veratrum Alkaloids | 2017 |
Naringenin-Induced Apoptotic Cell Death in Prostate Cancer Cells Is Mediated via the PI3K/AKT and MAPK Signaling Pathways.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Flavanones; Humans; Male; MAP Kinase Signaling System; Membrane Potential, Mitochondrial; Paclitaxel; Phosphatidylinositol 3-Kinases; Phosphorylation; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Reactive Oxygen Species | 2017 |
Stabilization of Paclitaxel-Conjugated Micelles by Cross-Linking with Cystamine Compromises the Antitumor Effects against Two- and Three-Dimensional Tumor Cellular Models.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Cystamine; Drug Carriers; Humans; Male; Micelles; Models, Theoretical; Paclitaxel; Polymers; Prostatic Neoplasms | 2016 |
Selection and antitumor activity of anti-Bcl-2 DNAzymes.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; DNA, Catalytic; Female; Humans; Kinetics; Male; Mice; Mice, Inbred BALB C; Oligonucleotides; Paclitaxel; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2 | 2016 |
Red Maca (Lepidium meyenii) did not affect cell viability despite increased androgen receptor and prostate-specific antigen gene expression in the human prostate cancer cell line LNCaP.
Topics: 2-Methoxyestradiol; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Drug Synergism; Estradiol; Gene Expression; Humans; Kallikreins; Lepidium; Male; Paclitaxel; Plant Extracts; Prostate-Specific Antigen; Prostatic Neoplasms; Real-Time Polymerase Chain Reaction; Receptors, Androgen; RNA, Messenger | 2016 |
Mechanism of paclitaxel resistance in a human prostate cancer cell line, PC3-PR, and its sensitization by cabazitaxel.
Topics: Acetylation; Anilides; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Drug Resistance, Neoplasm; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Male; Paclitaxel; Prostatic Neoplasms; Protein Stability; Taxoids; Tubulin; Tubulin Modulators; Vorinostat | 2016 |
Thermoresponsive Delivery of Paclitaxel by β-Cyclodextrin-Based Poly(N-isopropylacrylamide) Star Polymer via Inclusion Complexation.
Topics: Acrylamides; Animals; Antineoplastic Agents, Phytogenic; beta-Cyclodextrins; Cell Survival; Drug Delivery Systems; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Inclusion Bodies; Male; Nanoparticles; Paclitaxel; Polymers; Prostatic Neoplasms; Rats; Temperature; Tumor Cells, Cultured | 2016 |
Basic helix-loop-helix transcription factor DEC2 functions as an anti-apoptotic factor during paclitaxel-induced apoptosis in human prostate cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Basic Helix-Loop-Helix Transcription Factors; Biomarkers; Cell Line, Tumor; Cell Survival; Gene Expression; Gene Knockdown Techniques; Humans; Male; Paclitaxel; Prostatic Neoplasms; RNA Interference; RNA, Small Interfering; Tumor Suppressor Proteins | 2016 |
Application of sequential factorial design and orthogonal array composite design (OACD) to study combination of 5 prostate cancer drugs.
Topics: Antineoplastic Combined Chemotherapy Protocols; Artemisinins; Cell Line, Tumor; Cisplatin; Docetaxel; Doxorubicin; Drug Interactions; Humans; Male; Models, Statistical; Paclitaxel; Prostatic Neoplasms; Regression Analysis; Taxoids | 2017 |
Effects of Eg5 knockdown on human prostate cancer xenograft growth and chemosensitivity.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Down-Regulation; Drug Therapy, Combination; Humans; Kinesins; Male; Oligonucleotides; Oligonucleotides, Antisense; Paclitaxel; Prostatic Neoplasms; RNA, Messenger; Tubulin Modulators; Xenograft Model Antitumor Assays | 2008 |
The effect of tyrosine kinase inhibitors, tyrphostins: AG1024 and SU1498, on autocrine growth of prostate cancer cells (DU145).
Topics: Antineoplastic Agents; Apoptosis; Autocrine Communication; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cinnamates; Culture Media, Conditioned; Dose-Response Relationship, Drug; Humans; Male; Paclitaxel; Prostatic Neoplasms; Protein Kinase Inhibitors; Tyrphostins | 2008 |
Activation of the mitochondria-driven pathway of apoptosis in human PC-3 prostate cancer cells by a novel hydrophilic paclitaxel derivative, 7-xylosyl-10-deacetylpaclitaxel.
Topics: Annexin A5; Antineoplastic Agents, Phytogenic; Apoptosis; bcl-X Protein; BH3 Interacting Domain Death Agonist Protein; Caspase 10; Cell Cycle; Cell Line, Tumor; Cell Proliferation; DNA Fragmentation; fas Receptor; Humans; Male; Mitochondria; NF-kappa B; Paclitaxel; Prostatic Neoplasms; Taxus | 2008 |
Mitochondrial DNA depletion reduces PARP-1 levels and promotes progression of the neoplastic phenotype in prostate carcinoma.
Topics: Androgens; Apoptosis; Carcinogens; Cell Line, Tumor; Cell Migration Assays; Cell Movement; Cell Transformation, Neoplastic; DNA, Mitochondrial; Drug Resistance, Neoplasm; Ethidium; Humans; Male; Membrane Potential, Mitochondrial; Neoplasm Invasiveness; Neoplasms, Hormone-Dependent; Paclitaxel; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Prostatic Neoplasms | 2008 |
Intratumoral delivery of paclitaxel for treatment of orthotopic prostate cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Drug Delivery Systems; Male; Models, Animal; Neoplasms, Experimental; Ointments; Paclitaxel; Prostatic Neoplasms; Rats; Tumor Burden; Weight Loss | 2009 |
Multigene targeting of signal transduction pathways for the treatment of breast and prostate tumors: comparison between combination therapies employing bispecific oligonucleotides with either Rapamycin or Paclitaxel.
Topics: Androgen Receptor Antagonists; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis Regulatory Proteins; Breast Neoplasms; Cell Line, Tumor; Combined Modality Therapy; ErbB Receptors; Female; Gene Targeting; Humans; Male; Oligonucleotides, Antisense; Paclitaxel; Prostatic Neoplasms; Receptors, Androgen; Signal Transduction; Sirolimus; Transforming Growth Factor alpha | 2009 |
GLI2 knockdown using an antisense oligonucleotide induces apoptosis and chemosensitizes cells to paclitaxel in androgen-independent prostate cancer.
Topics: Androgens; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Base Sequence; Cell Line, Tumor; Disease Progression; Dose-Response Relationship, Drug; Humans; Kruppel-Like Transcription Factors; Male; Membrane Proteins; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Hormone-Dependent; Nuclear Proteins; Oligonucleotides, Antisense; Paclitaxel; Prostatic Neoplasms; Saccharomyces cerevisiae Proteins; Zinc Finger Protein Gli2 | 2008 |
Acid ceramidase upregulation in prostate cancer cells confers resistance to radiation: AC inhibition, a potential radiosensitizer.
Topics: Acid Ceramidase; Animals; Cell Line, Tumor; Ceramides; Enzyme Activation; Enzyme Inhibitors; Humans; Male; Mice; Mice, Nude; Myristates; Paclitaxel; Phosphotransferases (Alcohol Group Acceptor); Propanolamines; Prostatic Neoplasms; Radiation-Sensitizing Agents; RNA, Small Interfering; Sensitivity and Specificity; Sphingosine; Up-Regulation; Xenograft Model Antitumor Assays | 2009 |
[Influence of SNCG transfection on the effectiveness of anti-tumor drugs in PC-3 cell lines].
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cisplatin; Drug Screening Assays, Antitumor; gamma-Synuclein; Humans; Male; Neoplasm Proteins; Paclitaxel; Prostatic Neoplasms; Transfection | 2008 |
Synergy of 5-aza-2'-deoxycytidine (DAC) and paclitaxel in both androgen-dependent and -independent prostate cancer cell lines.
Topics: Androgens; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Azacitidine; Caspases; Cell Cycle; Cell Division; Cell Line, Tumor; Decitabine; Flow Cytometry; Humans; Male; Mitochondria; Oxidoreductases; Paclitaxel; Prostatic Neoplasms; Tetrazolium Salts; Up-Regulation | 2009 |
Chemotherapeutic sensitization by endoplasmic reticulum stress: increasing the efficacy of taxane against prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Death; Cell Line, Tumor; Docetaxel; Endoplasmic Reticulum; Endoplasmic Reticulum Chaperone BiP; Enzyme-Linked Immunosorbent Assay; Formazans; Heat-Shock Proteins; Humans; Male; Molecular Chaperones; Organoselenium Compounds; Paclitaxel; Prostatic Neoplasms; RNA, Small Interfering; Taxoids; Tetrazolium Salts; Thapsigargin; Time Factors; Transcription Factor CHOP; Transfection | 2009 |
Bone marrow CFU-GM and human tumor xenograft efficacy of three tubulin binding agents.
Topics: Animals; Antineoplastic Agents, Phytogenic; Body Weight; Bone Marrow Cells; Breast Neoplasms; Disease Progression; Female; Humans; Lymphoma; Male; Mice; Mice, Inbred BALB C; Multiple Myeloma; Oligopeptides; Paclitaxel; Prostatic Neoplasms; Tubulin; Tumor Stem Cell Assay; Vincristine; Xenograft Model Antitumor Assays | 2009 |
Programmed cell death protein 4 down-regulates Y-box binding protein-1 expression via a direct interaction with Twist1 to suppress cancer cell growth.
Topics: Apoptosis Regulatory Proteins; Cell Growth Processes; Cell Line, Tumor; Cisplatin; Down-Regulation; Glioma; Humans; Male; Nuclear Proteins; Paclitaxel; Prostatic Neoplasms; RNA-Binding Proteins; Transcription, Genetic; Transfection; Twist-Related Protein 1; Y-Box-Binding Protein 1 | 2009 |
A novel triterpenoid isolated from the root bark of Ailanthus excelsa Roxb (Tree of Heaven), AECHL-1 as a potential anti-cancer agent.
Topics: Ailanthus; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Cell Cycle Proteins; Cell Line; Cell Line, Tumor; Cell Proliferation; Cisplatin; Drug Screening Assays, Antitumor; Female; Humans; Male; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Mice, Nude; Molecular Structure; Neoplasm Transplantation; Paclitaxel; Plants, Medicinal; Prostatic Neoplasms; Transplantation, Heterologous; Triterpenes; Tumor Suppressor Proteins | 2009 |
Paclitaxel, estramustine and carboplatin combination chemotherapy after initial docetaxel-based chemotherapy in castration-resistant prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Drug Resistance, Neoplasm; Estramustine; Humans; Male; Middle Aged; Paclitaxel; Prostatic Neoplasms; Taxoids; Time Factors; Treatment Outcome | 2009 |
[Synergic effects of the combination of VEGF-targeted shRNA and taxol on human prostate cancer DU145 both in vitro and in vivo].
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Movement; Cell Proliferation; Genetic Vectors; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Paclitaxel; Plasmids; Prostatic Neoplasms; RNA Interference; RNA, Small Interfering; Transfection; Tubulin Modulators; Tumor Burden; Vascular Endothelial Growth Factor A; Vincristine | 2009 |
Enhanced cytotoxicity of a polymer-drug conjugate with triple payload of paclitaxel.
Topics: Acrylamides; Adenocarcinoma; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dendrimers; Drug Delivery Systems; Male; Mice; Paclitaxel; Prodrugs; Prostatic Neoplasms | 2009 |
Treatment of prostate and breast tumors employing mono- and bi-specific antisense oligonucleotides targeting apoptosis inhibitory proteins clusterin and bcl-2.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Clusterin; Drug Delivery Systems; Drug Screening Assays, Antitumor; Female; Humans; Male; Neoplasm Proteins; Oligonucleotides, Antisense; Paclitaxel; Phosphorothioate Oligonucleotides; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; RNA, Neoplasm; Sirolimus; Substrate Specificity | 2010 |
Paclitaxel encapsulated in cationic liposomes: a new option for neovascular targeting for the treatment of prostate cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Liposomes; Male; Paclitaxel; Prostatic Neoplasms; Rats | 2009 |
Receptor mediated uptake of paclitaxel from a synthetic high density lipoprotein nanocarrier.
Topics: Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Drug Carriers; Drug Delivery Systems; Humans; Lipoproteins, HDL; Male; Nanoparticles; Paclitaxel; Prostatic Neoplasms; Scavenger Receptors, Class B | 2010 |
[The mTOR inhibitor enhances chemosensitivity of androgen-independent prostate cancer cell line].
Topics: Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Drug Therapy, Combination; Humans; Male; Paclitaxel; Prostatic Neoplasms; Protein Kinase Inhibitors; Sirolimus | 2009 |
CTEN/tensin 4 expression induces sensitivity to paclitaxel in prostate cancer.
Topics: Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Male; Microfilament Proteins; Paclitaxel; Predictive Value of Tests; Prostatic Neoplasms; Tensins | 2010 |
Bcl-2 modulation to activate apoptosis in prostate cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biphenyl Compounds; Cisplatin; Drug Synergism; Humans; Immunohistochemistry; Male; Mice; Mice, Inbred C57BL; Mice, Nude; Myeloid Cell Leukemia Sequence 1 Protein; Nitrophenols; Paclitaxel; Piperazines; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Sulfonamides; Tumor Suppressor Protein p53 | 2009 |
Pharmacologic inhibition of Pim kinases alters prostate cancer cell growth and resensitizes chemoresistant cells to taxanes.
Topics: Apoptosis; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Caspases; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Male; Paclitaxel; Prostatic Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-pim-1; Recombinant Proteins; Taxoids | 2009 |
Inhibition of the androgen receptor as a novel mechanism of taxol chemotherapy in prostate cancer.
Topics: Androgen Receptor Antagonists; Androgens; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Chromatin Immunoprecipitation; Chromones; Docetaxel; Enzyme Inhibitors; Forkhead Box Protein O1; Forkhead Transcription Factors; Humans; Immunoblotting; Immunoenzyme Techniques; Luciferases; Male; Mice; Mice, Inbred NOD; Mice, SCID; Morpholines; Orchiectomy; Paclitaxel; Phosphoinositide-3 Kinase Inhibitors; Prostate-Specific Antigen; Prostatic Neoplasms; PTEN Phosphohydrolase; Receptors, Androgen; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Taxoids | 2009 |
Design, synthesis, characterization, and biological evaluation of triazine dendrimers bearing paclitaxel using ester and ester/disulfide linkages.
Topics: Acylation; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Cross-Linking Reagents; Dendrimers; Disulfides; Drug Delivery Systems; Drug Design; Esters; Half-Life; Humans; Inhibitory Concentration 50; Male; Paclitaxel; Prostatic Neoplasms; Triazines | 2009 |
miR-21: an oncomir on strike in prostate cancer.
Topics: Cell Line, Tumor; Cisplatin; Drug Screening Assays, Antitumor; Gamma Rays; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Male; MicroRNAs; Paclitaxel; Prostate; Prostatic Neoplasms; PTEN Phosphohydrolase; Radiation Tolerance | 2010 |
The formulation of aptamer-coated paclitaxel-polylactide nanoconjugates and their targeting to cancer cells.
Topics: Animals; Antineoplastic Agents, Phytogenic; Biocompatible Materials; Cell Line, Tumor; Drug Carriers; Drug Delivery Systems; Humans; Male; Molecular Structure; Nanoparticles; Paclitaxel; Polyesters; Prostatic Neoplasms | 2010 |
Combination chemotherapy with weekly paclitaxel or docetaxel, carboplatin, and estramustine for hormone-refractory prostate cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease Progression; Docetaxel; Drug Administration Schedule; Estramustine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasms, Hormone-Dependent; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids | 2010 |
Improved tumor-targeting drug delivery and therapeutic efficacy by cationic liposome modified with truncated bFGF peptide.
Topics: Animals; Antineoplastic Agents; Cations; Cell Line, Tumor; Doxorubicin; Drug Carriers; Female; Fibroblast Growth Factor 2; Flow Cytometry; In Situ Nick-End Labeling; Injections, Intravenous; Liposomes; Male; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Microscopy, Atomic Force; Neoplasm Transplantation; Paclitaxel; Particle Size; Prostatic Neoplasms; Protein Binding; Receptors, Fibroblast Growth Factor; Surface Properties | 2010 |
MiR-148a attenuates paclitaxel resistance of hormone-refractory, drug-resistant prostate cancer PC3 cells by regulating MSK1 expression.
Topics: Animals; Base Sequence; Cell Line, Tumor; Drug Resistance, Neoplasm; Epithelial Cells; Hormones; Humans; Male; MicroRNAs; Molecular Sequence Data; Neoplasm Invasiveness; Paclitaxel; Prostatic Neoplasms; Ribosomal Protein S6 Kinases; Ribosomal Protein S6 Kinases, 90-kDa; Sequence Homology, Amino Acid | 2010 |
Biological assessment of triazine dendrimer: toxicological profiles, solution behavior, biodistribution, drug release and efficacy in a PEGylated, paclitaxel construct.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line; Cell Line, Tumor; Chromatography, Gel; Chromatography, High Pressure Liquid; Colonic Neoplasms; Dendrimers; Fractionation, Field Flow; Hep G2 Cells; Humans; Male; Mice; Mice, SCID; Models, Chemical; Molecular Weight; Paclitaxel; Polyethylene Glycols; Prostatic Neoplasms; Rats; Swine; Triazines; Xenograft Model Antitumor Assays | 2010 |
Magnetic-nanoparticle-modified paclitaxel for targeted therapy for prostate cancer.
Topics: Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Drug Carriers; Drug Delivery Systems; Humans; Magnetics; Male; Molecular Structure; Nanoparticles; Paclitaxel; Prostatic Neoplasms | 2010 |
[Study of sequence-dependent in vitro effects of zoledronic acid and paclitaxel upon DU145 prostate cancer cells].
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Diphosphonates; Humans; Imidazoles; Male; Paclitaxel; Prostatic Neoplasms; Zoledronic Acid | 2010 |
MiR-34a attenuates paclitaxel-resistance of hormone-refractory prostate cancer PC3 cells through direct and indirect mechanisms.
Topics: 3' Untranslated Regions; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Daunorubicin; DNA Primers; Drug Resistance, Neoplasm; Etoposide; Humans; Male; MicroRNAs; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Sirtuin 1; Tumor Suppressor Protein p53 | 2010 |
Fluorescent, superparamagnetic nanospheres for drug storage, targeting, and imaging: a multifunctional nanocarrier system for cancer diagnosis and treatment.
Topics: Animals; Cell Line, Tumor; Cell Transformation, Neoplastic; Drug Carriers; Fluorescent Dyes; Humans; Lactic Acid; Magnetite Nanoparticles; Male; Mice; Molecular Imaging; Nanomedicine; Paclitaxel; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Prostatic Neoplasms; Quantum Dots | 2010 |
[Primary urothelial carcinoma with sarcomatous transformation of the prostate].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Combined Modality Therapy; Cystectomy; Deoxycytidine; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Invasiveness; Paclitaxel; Prostatectomy; Prostatic Neoplasms; Radiotherapy, Adjuvant; Sarcoma; Treatment Outcome; Urethral Neoplasms | 2010 |
Hyperpolarized 13C spectroscopic imaging informs on hypoxia-inducible factor-1 and myc activity downstream of platelet-derived growth factor receptor.
Topics: Animals; Benzamides; Capillary Permeability; Carbon Isotopes; Humans; Hypoxia-Inducible Factor 1; Imatinib Mesylate; L-Lactate Dehydrogenase; Lactic Acid; Magnetic Resonance Spectroscopy; Male; Mice; Mice, Nude; Neovascularization, Pathologic; Paclitaxel; Piperazines; Prostatic Neoplasms; Proto-Oncogene Proteins c-myc; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Signal Transduction; Vascular Endothelial Growth Factor A | 2010 |
Development of a novel prodrug of paclitaxel that is cleaved by prostate-specific antigen: an in vitro and in vivo evaluation study.
Topics: Animals; Antineoplastic Agents, Phytogenic; Chromatography, High Pressure Liquid; Drug Evaluation; Humans; Luminescence; Male; Maximum Tolerated Dose; Mice; Mice, SCID; Neoplasm Transplantation; Paclitaxel; Prodrugs; Prostate-Specific Antigen; Prostatic Neoplasms; Tumor Cells, Cultured | 2010 |
Preparation, characterization, and in vitro targeted delivery of folate-decorated paclitaxel-loaded bovine serum albumin nanoparticles.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cattle; Cell Line, Tumor; Chemistry, Pharmaceutical; Drug Carriers; Drug Compounding; Drug Delivery Systems; Drug Stability; Folic Acid; Humans; In Vitro Techniques; Male; Microscopy, Confocal; Microscopy, Electron, Scanning; Nanoparticles; Paclitaxel; Particle Size; Prostatic Neoplasms; Serum Albumin, Bovine; Solubility; Surface Properties | 2010 |
Chemotherapy for hormone-refractory prostate cancer: a physician's dilemma.
Topics: Drug Delivery Systems; Humans; Male; Paclitaxel; Prostatic Neoplasms; Tubulin; Vinblastine | 2010 |
In vitro and in vivo anticancer action of Saquinavir-NO, a novel nitric oxide-derivative of the protease inhibitor saquinavir, on hormone resistant prostate cancer cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cisplatin; Doxorubicin; Drug Resistance, Neoplasm; Drug Synergism; Humans; Male; Mice; Mice, Nude; Paclitaxel; Prostatic Neoplasms; Protease Inhibitors; Saquinavir; Transplantation, Heterologous; Tumor Suppressor Protein p53 | 2011 |
Involvement of mitochondrial permeability transition pore opening in 7-xylosyl-10-deacetylpaclitaxel-induced apoptosis.
Topics: Adenosine Triphosphate; Antineoplastic Agents, Phytogenic; Apoptosis; bcl-2-Associated X Protein; Calcium; Cell Line, Tumor; Cyclosporine; Cytosol; Drug Evaluation, Preclinical; Humans; Hydrogen Peroxide; Male; Membrane Potential, Mitochondrial; Mitochondria; Mitochondrial Membrane Transport Proteins; Mitochondrial Permeability Transition Pore; Paclitaxel; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2 | 2011 |
Low-dose paclitaxel enhances the anti-tumor efficacy of GM-CSF surface-modified whole-tumor-cell vaccine in mouse model of prostate cancer.
Topics: Animals; Antigens, Neoplasm; Antineoplastic Agents, Phytogenic; Cancer Vaccines; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Combined Modality Therapy; Dendritic Cells; Disease Models, Animal; Flow Cytometry; Granulocyte-Macrophage Colony-Stimulating Factor; Lymphocytes, Tumor-Infiltrating; Male; Mice; Mice, Inbred C57BL; Paclitaxel; Prostatic Neoplasms; T-Lymphocytes; Tumor Cells, Cultured | 2011 |
TMPRSS2/ERG fusion gene expression alters chemo- and radio-responsiveness in cell culture models of androgen independent prostate cancer.
Topics: Adenocarcinoma; Androgens; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Chemoradiotherapy; DNA Repair; Gene Expression Regulation, Neoplastic; Humans; Male; Oncogene Proteins, Fusion; Paclitaxel; Phenotype; Prostatic Neoplasms; Serine Endopeptidases; Trans-Activators; Transcriptional Regulator ERG | 2011 |
Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinoma, Ductal, Breast; Cell Line, Tumor; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Female; Humans; Injections, Intraperitoneal; Lung Neoplasms; Male; Metformin; Mice; Mice, Nude; Neoplasms; Paclitaxel; Prostatic Neoplasms; Xenograft Model Antitumor Assays | 2011 |
Resistance to paclitaxel increases the sensitivity to other microenvironmental stresses in prostate cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Combined Modality Therapy; Drug Resistance, Neoplasm; Hot Temperature; Humans; Hyperthermia, Induced; Male; Paclitaxel; Prostatic Neoplasms; Stress, Physiological | 2011 |
Increased accumulation of paclitaxel and doxorubicin in proliferating capillary cells and prostate cancer cells following ultrasound exposure.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Proliferation; Doxorubicin; Humans; Male; Mannitol; Paclitaxel; Prostatic Neoplasms; Rhodamines; Scintillation Counting; Spectrometry, Fluorescence; Transducers; Tumor Cells, Cultured; Ultrasonography; Umbilical Cord | 2011 |
123I-MIP-1072, a small-molecule inhibitor of prostate-specific membrane antigen, is effective at monitoring tumor response to taxane therapy.
Topics: Animals; Antigens, Surface; Antineoplastic Agents; Cell Count; Cell Line, Tumor; Cell Proliferation; Glutamate Carboxypeptidase II; Glutamates; Humans; Iodine Radioisotopes; Male; Mice; Paclitaxel; Prostatic Neoplasms; Treatment Outcome; Tumor Burden; Urea; Xenograft Model Antitumor Assays | 2011 |
Clusterin is a critical downstream mediator of stress-induced YB-1 transactivation in prostate cancer.
Topics: Apoptosis; Benzoquinones; Bridged-Ring Compounds; Cell Line, Tumor; Cell Proliferation; Clusterin; Drug Resistance, Neoplasm; Endoplasmic Reticulum Stress; Gene Expression Regulation, Neoplastic; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Leupeptins; Male; Paclitaxel; Promoter Regions, Genetic; Prostatic Neoplasms; Protein Binding; RNA, Small Interfering; Taxoids; Transcriptional Activation; Y-Box-Binding Protein 1 | 2011 |
Paclitaxel induces apoptosis through activation of nuclear protein kinase C-δ and subsequent activation of Golgi associated Cdk1 in human hormone refractory prostate cancer.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; CDC2 Protein Kinase; Golgi Apparatus; Humans; Male; Paclitaxel; Prostatic Neoplasms; Protein Kinase C-delta; Tumor Cells, Cultured | 2011 |
ETS1 promotes chemoresistance and invasion of paclitaxel-resistant, hormone-refractory PC3 prostate cancer cells by up-regulating MDR1 and MMP9 expression.
Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Male; Matrix Metalloproteinase 9; Matrix Metalloproteinase Inhibitors; Neoplasm Invasiveness; Paclitaxel; Prostatic Neoplasms; Proto-Oncogene Protein c-ets-1; Up-Regulation | 2012 |
Cooperative dual-activity targeted nanomedicine for specific and effective prostate cancer therapy.
Topics: Animals; Antibodies, Neoplasm; Antineoplastic Agents; Cell Line, Tumor; Contrast Media; Drug Carriers; Humans; Magnetic Resonance Imaging; Magnets; Male; Mice; Molecular Targeted Therapy; Nanomedicine; Paclitaxel; Polyethylene Glycols; Prostate-Specific Antigen; Prostatic Neoplasms; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Antitumor activity and molecular dynamics simulations of paclitaxel-laden triazine dendrimers.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Dendrimers; Humans; Male; Mice; Mice, Nude; Mice, SCID; Molecular Dynamics Simulation; Paclitaxel; Prostatic Neoplasms; Triazines; Xenograft Model Antitumor Assays | 2012 |
Pim-1 knockdown potentiates paclitaxel-induced apoptosis in human hormone-refractory prostate cancers through inhibition of NHEJ DNA repair.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; DNA End-Joining Repair; DNA Helicases; DNA-Binding Proteins; Drug Resistance, Neoplasm; Gene Knockdown Techniques; Histones; Humans; Ku Autoantigen; Male; Microtubules; Paclitaxel; Prostatic Neoplasms; Proto-Oncogene Proteins c-pim-1 | 2012 |
Hyaluronan oligomers-HPMA copolymer conjugates for targeting paclitaxel to CD44-overexpressing ovarian carcinoma.
Topics: Cell Line, Tumor; Cell Survival; Drug Delivery Systems; Female; Humans; Hyaluronan Receptors; Hyaluronic Acid; Male; Oligosaccharides; Ovarian Neoplasms; Paclitaxel; Polymers; Prostatic Neoplasms; Tumor Cells, Cultured | 2012 |
[Support of hematological homeostasis during chemotherapy with taxanes].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Caproates; Docetaxel; Female; Fever; Follow-Up Studies; Homeostasis; Humans; Imidazoles; Lung Neoplasms; Male; Middle Aged; Neoplasms; Neutropenia; Ovarian Neoplasms; Paclitaxel; Prostatic Neoplasms; Protective Agents; Severity of Illness Index; Stomach Neoplasms; Taxoids; Tongue Neoplasms | 2011 |
Targeted antivascular therapy with the apolipoprotein(a) kringle V, rhLK8, inhibits the growth and metastasis of human prostate cancer in an orthotopic nude mouse model.
Topics: Angiogenesis Inhibitors; Animals; Apolipoproteins A; Disease Models, Animal; Humans; Kringles; Male; Mice; Mice, Nude; Neoplasm Metastasis; Paclitaxel; Peptide Fragments; Prostatic Neoplasms; Recombinant Proteins; Xenograft Model Antitumor Assays | 2012 |
Telomere and microtubule targeting in treatment-sensitive and treatment-resistant human prostate cancer cells.
Topics: Cell Line, Tumor; Docetaxel; Drug Delivery Systems; Drug Resistance, Neoplasm; Humans; Male; Microtubules; Paclitaxel; Prostatic Neoplasms; Taxoids; Telomere; Treatment Outcome | 2012 |
GRP78 regulates clusterin stability, retrotranslocation and mitochondrial localization under ER stress in prostate cancer.
Topics: Apoptosis; Cell Line, Tumor; Clusterin; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Heat-Shock Proteins; Humans; Leupeptins; Male; Membrane Potential, Mitochondrial; Mitochondria; Mitochondrial Membranes; Paclitaxel; Prostatic Neoplasms; Protein Transport; RNA Interference; RNA, Messenger; RNA, Small Interfering; Thapsigargin; Up-Regulation | 2013 |
Aberrant expression of the neuronal-specific protein DCDC2 promotes malignant phenotypes and is associated with prostate cancer progression.
Topics: Binding Sites; Cell Movement; Disease Progression; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Male; Microtubule-Associated Proteins; Microtubules; Paclitaxel; Promoter Regions, Genetic; Prostatic Neoplasms; Reference Values; Transcription Factors; Tubulin Modulators | 2013 |
Chemoresistance in prostate cancer cells is regulated by miRNAs and Hedgehog pathway.
Topics: Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Cycle; Cell Differentiation; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genes, Neoplasm; Hedgehog Proteins; Humans; Male; MicroRNAs; Models, Biological; Paclitaxel; Prostatic Neoplasms; Real-Time Polymerase Chain Reaction; Reproducibility of Results; Side-Population Cells; Signal Transduction; Veratrum Alkaloids | 2012 |
Adenoviral neutral endopeptidase gene delivery in combination with paclitaxel for the treatment of prostate cancer.
Topics: Adenoviridae; Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Gene Transfer Techniques; Humans; Male; Mice; Neprilysin; Paclitaxel; Prostatic Neoplasms; Signal Transduction; Xenograft Model Antitumor Assays | 2012 |
Paclitaxel-loaded iron platinum stealth immunomicelles are potent MRI imaging agents that prevent prostate cancer growth in a PSMA-dependent manner.
Topics: Animals; Antibodies; Antigens, Surface; Antineoplastic Agents, Phytogenic; Cell Growth Processes; Cell Line, Tumor; Contrast Media; Glutamate Carboxypeptidase II; Humans; Immunoconjugates; Iron; Magnetic Resonance Imaging; Magnetite Nanoparticles; Male; Mice; Mice, Nude; Micelles; Paclitaxel; Particle Size; Platinum; Prostatic Neoplasms; Xenograft Model Antitumor Assays | 2012 |
Characterization of the low pH/low nutrient-resistant LNCaP cell subline LNCaP-F10.
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Calcium-Calmodulin-Dependent Protein Kinases; Cell Line, Tumor; Cell Proliferation; Death-Associated Protein Kinases; DNA Fragmentation; Docetaxel; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Hydrogen-Ion Concentration; Inhibitor of Apoptosis Proteins; Male; Mice; Mice, Nude; Neoplasm Transplantation; Paclitaxel; Poly(ADP-ribose) Polymerases; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Survivin; Taxoids; Transplantation, Heterologous | 2012 |
PEG-derivatized embelin as a nanomicellar carrier for delivery of paclitaxel to breast and prostate cancers.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzoquinones; Breast Neoplasms; Cell Line, Tumor; Female; Male; Mice; Mice, Inbred BALB C; Micelles; Nanocapsules; Paclitaxel; Polyethylene Glycols; Prostatic Neoplasms; Treatment Outcome | 2013 |
Acquisition of paclitaxel resistance is associated with a more aggressive and invasive phenotype in prostate cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Movement; Cell Nucleus; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Humans; Inhibitory Concentration 50; Keratin-18; Keratin-19; Keratin-8; Male; Mice; Neoplasm Invasiveness; Paclitaxel; Prostatic Neoplasms; Xenograft Model Antitumor Assays | 2013 |
Sensitivity and mechanisms of taxol-resistant prostate adenocarcinoma cells to Vernonia amygdalina extract.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Cell Culture Techniques; Cell Line, Tumor; Cell Proliferation; DNA, Neoplasm; Drug Resistance, Neoplasm; Humans; Male; Paclitaxel; Plant Extracts; Plant Leaves; Prostatic Neoplasms; Vernonia | 2013 |
Cellular bases of the antitumor activity of the novel taxane IDN 5109 (BAY59-8862) on hormone-refractory prostate cancer.
Topics: Antineoplastic Agents; bcl-X Protein; Blotting, Western; Bridged-Ring Compounds; CDC2 Protein Kinase; Cell Cycle; Cell Death; Cell Division; Cell Nucleus; Cell Separation; Dose-Response Relationship, Drug; Down-Regulation; Endothelial Growth Factors; Fibroblast Growth Factor 2; Flow Cytometry; Humans; In Situ Nick-End Labeling; Inhibitory Concentration 50; Intercellular Signaling Peptides and Proteins; Lymphokines; Male; Maturation-Promoting Factor; Mitosis; Neoplasm Transplantation; Neovascularization, Pathologic; Paclitaxel; Phosphorylation; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-raf; Subcellular Fractions; Taxoids; Time Factors; Tubulin; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2002 |
Editorial: the coming revolution in the treatment of prostate cancer patients.
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Estramustine; Forecasting; Humans; Male; Neoadjuvant Therapy; Paclitaxel; Prostatic Neoplasms; Taxoids; Vinblastine | 2002 |
Survival of docetaxel-resistant prostate cancer cells in vitro depends on phenotype alterations and continuity of drug exposure.
Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; bcl-X Protein; Cell Division; Cell Survival; Clone Cells; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Giant Cells; Humans; Kinetics; Male; Paclitaxel; Phenotype; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Taxoids; Tubulin; Tumor Cells, Cultured | 2002 |
Prompt resolution of acute disseminated intravascular coagulation with docetaxel and cisplatin in hormone refractory prostate cancer.
Topics: Acute Disease; Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Disseminated Intravascular Coagulation; Docetaxel; Humans; Male; Paclitaxel; Platelet Count; Prostatic Neoplasms; Taxoids; Treatment Outcome | 2002 |
Antibody to vascular endothelial growth factor slows growth of an androgen-independent xenograft model of prostate cancer.
Topics: Androgens; Animals; Antibodies, Monoclonal; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Disease Models, Animal; Drug Therapy, Combination; Endothelial Growth Factors; Humans; Immunoenzyme Techniques; In Situ Nick-End Labeling; Intercellular Signaling Peptides and Proteins; Lymphokines; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms, Hormone-Dependent; Neovascularization, Pathologic; Paclitaxel; Prostatic Neoplasms; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2002 |
New study expands look at effects of high-dose vitamin D with docetaxel for advanced prostate cancer patients.
Topics: Docetaxel; Humans; Male; Multicenter Studies as Topic; Paclitaxel; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids; Vitamin D | 2002 |
Inhibition of growth and metastasis of orthotopic human prostate cancer in athymic mice by combination therapy with pegylated interferon-alpha-2b and docetaxel.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cadherins; Cell Division; Docetaxel; Dose-Response Relationship, Drug; Drug Synergism; Fibroblast Growth Factor 2; Humans; Immunohistochemistry; Interferon alpha-2; Interferon-alpha; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Mice; Mice, Nude; Neoplasm Metastasis; Paclitaxel; Polyethylene Glycols; Prostatic Neoplasms; Random Allocation; Recombinant Proteins; Taxoids; Xenograft Model Antitumor Assays | 2002 |
Effects of the herbal extract PC-SPES on microtubule dynamics and paclitaxel-mediated prostate tumor growth inhibition.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Division; Drugs, Chinese Herbal; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Mice, Nude; Microtubules; Oligonucleotide Array Sequence Analysis; Paclitaxel; Phytotherapy; Plant Extracts; Prostatic Neoplasms; Transplantation, Heterologous; Tubulin; Tumor Cells, Cultured | 2002 |
Zinc inhibits nuclear factor-kappa B activation and sensitizes prostate cancer cells to cytotoxic agents.
Topics: Active Transport, Cell Nucleus; Amino Acid Chloromethyl Ketones; Apoptosis; Blotting, Western; Caspase Inhibitors; Enzyme Inhibitors; Flow Cytometry; Humans; Immunoblotting; Immunohistochemistry; JNK Mitogen-Activated Protein Kinases; Male; Mitogen-Activated Protein Kinases; NF-kappa B; Paclitaxel; Prostatic Neoplasms; Proteins; Time Factors; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha; Zinc | 2002 |
Editorial: States and state transitions are all that really matter.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Estramustine; Humans; Male; Mitoxantrone; Paclitaxel; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms | 2002 |
Studies with CWR22 xenografts in nude mice suggest that ZD1839 may have a role in the treatment of both androgen-dependent and androgen-independent human prostate cancer.
Topics: Anilides; Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Carboplatin; Disease Models, Animal; ErbB Receptors; Female; Gefitinib; Humans; Male; Mice; Mice, Nude; Neoplasms, Hormone-Dependent; Nitriles; Paclitaxel; Prostatic Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Receptors, Androgen; Testosterone; Tosyl Compounds; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2002 |
Regulation of Bcl-2 during androgen-unresponsive progression of prostate cancer.
Topics: Androgens; Apoptosis; bcl-2-Associated X Protein; bcl-X Protein; Butyrates; Disease Progression; Humans; Male; Microscopy, Confocal; Oxidative Stress; Paclitaxel; Prostatic Neoplasms; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured | 2002 |
Experimental therapy of human prostate cancer by inhibiting MDM2 expression with novel mixed-backbone antisense oligonucleotides: in vitro and in vivo activities and mechanisms.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Combined Modality Therapy; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Fluorouracil; Genetic Therapy; Humans; In Vitro Techniques; Irinotecan; Male; Mice; Mice, Nude; Nuclear Proteins; Oligonucleotides, Antisense; Paclitaxel; Prostatic Neoplasms; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-mdm2; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2003 |
Rho kinase and matrix metalloproteinase inhibitors cooperate to inhibit angiogenesis and growth of human prostate cancer xenotransplants.
Topics: Amides; Animals; Aorta, Thoracic; Cell Division; Cell Line; Drug Synergism; Enzyme Inhibitors; Humans; Hydroxamic Acids; In Vitro Techniques; Intracellular Signaling Peptides and Proteins; Male; Matrix Metalloproteinase Inhibitors; Matrix Metalloproteinases; Mice; Mice, SCID; Microscopy, Fluorescence; Myosin-Light-Chain Phosphatase; Neoplasm Transplantation; Neovascularization, Pathologic; Paclitaxel; Phosphoprotein Phosphatases; Phosphorylation; Prostatic Neoplasms; Protein Serine-Threonine Kinases; Pyridines; Rabbits; rho-Associated Kinases; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2003 |
Chemosensitization of human prostate cancer using antisense agents targeting the type 1 insulin-like growth factor receptor.
Topics: Antineoplastic Agents; Apoptosis; Cisplatin; Down-Regulation; Humans; Male; Mitoxantrone; Oligonucleotides, Antisense; Paclitaxel; Prostatic Neoplasms; Receptor, IGF Type 1; Transfection; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2003 |
The X-linked inhibitor of apoptosis protein inhibits taxol-induced apoptosis in LNCaP cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Caspase 3; Caspases; Cell Division; Cell Line, Tumor; Enzyme Precursors; Gene Expression; Humans; Male; Paclitaxel; Prostatic Neoplasms; Proteins; Transfection; X-Linked Inhibitor of Apoptosis Protein | 2003 |
Increased frequency of venous thromboembolism with the combination of docetaxel and thalidomide in patients with metastatic androgen-independent prostate cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Middle Aged; Paclitaxel; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Retrospective Studies; Taxoids; Thalidomide; Venous Thrombosis | 2003 |
Blockade of epidermal growth factor receptor signaling in tumor cells and tumor-associated endothelial cells for therapy of androgen-independent human prostate cancer growing in the bone of nude mice.
Topics: Administration, Oral; Animals; Antineoplastic Agents, Phytogenic; Blotting, Western; Bone and Bones; Bone Neoplasms; Dose-Response Relationship, Drug; Endothelial Growth Factors; Endothelium, Vascular; ErbB Receptors; Fibroblast Growth Factor 2; Immunohistochemistry; In Situ Nick-End Labeling; Intercellular Signaling Peptides and Proteins; Interleukin-8; Lymphokines; Male; Mice; Mice, Nude; Microscopy, Fluorescence; Neoplasm Metastasis; Neoplasm Transplantation; Paclitaxel; Phosphorylation; Platelet Endothelial Cell Adhesion Molecule-1; Proliferating Cell Nuclear Antigen; Prostatic Neoplasms; Pyrimidines; Pyrroles; Signal Transduction; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2003 |
Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Blotting, Western; Bone Neoplasms; Cell Division; Disease Models, Animal; Enzyme Inhibitors; Fluorescent Antibody Technique; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Immunohistochemistry; In Situ Nick-End Labeling; Male; Mice; Mice, Nude; Microcirculation; Neoplasms, Experimental; Paclitaxel; Phosphorylation; Piperazines; Platelet-Derived Growth Factor; Prostatic Neoplasms; Protein-Tyrosine Kinases; Pyrimidines; Radiographic Image Enhancement; Receptors, Platelet-Derived Growth Factor; Signal Transduction; Tumor Cells, Cultured | 2003 |
Inhibition of PC-3 prostate cancer cell growth in vitro using both antisense oligonucleotides and taxol.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; ErbB Receptors; Gene Expression Regulation, Neoplastic; Humans; Male; Oligonucleotides, Antisense; Paclitaxel; Phosphatidylethanolamines; Prostatic Neoplasms; RNA, Neoplasm; Transforming Growth Factor alpha; Tumor Cells, Cultured | 2003 |
Activity of docetaxel with or without estramustine phosphate versus mitoxantrone in androgen dependent and independent human prostate cancer xenografts.
Topics: Androgens; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Estramustine; Humans; Male; Mice; Mice, Nude; Middle Aged; Mitoxantrone; Neoplasm Transplantation; Paclitaxel; Prostatic Neoplasms; Taxoids | 2003 |
Adenocarcinoma cells exposed in vitro to Navelbine or Taxol increase Ep-CAM expression through a novel mechanism.
Topics: Adenocarcinoma; Animals; Antigens, Neoplasm; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Cell Adhesion Molecules; Cell Survival; Chromium; Colonic Neoplasms; Epithelial Cell Adhesion Molecule; Female; G2 Phase; Humans; In Vitro Techniques; Lutetium; Male; Mice; Mice, Nude; Mitosis; Paclitaxel; Prostatic Neoplasms; Tumor Cells, Cultured; Vinblastine; Vinorelbine | 2003 |
The effects of 2-substituted oestrogen sulphamates on the growth of prostate and ovarian cancer cells.
Topics: 2-Methoxyestradiol; Apoptosis; Cell Division; Cell Separation; Estradiol; Estrone; Female; Flow Cytometry; G1 Phase; G2 Phase; Humans; Hydroxyestrones; Immunoblotting; Inhibitory Concentration 50; Male; Mitosis; Models, Chemical; Ovarian Neoplasms; Paclitaxel; Phosphorylation; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Time Factors; Tumor Cells, Cultured | 2003 |
Calcitriol and alopecia--is it the hair apparent?
Topics: Alopecia; Antineoplastic Combined Chemotherapy Protocols; Calcitriol; Docetaxel; Humans; Male; Neoplasm Metastasis; Paclitaxel; Prostatic Neoplasms; Taxoids | 2003 |
Adenovirus-mediated inhibition of NF-kappaB confers chemo-sensitization and apoptosis in prostate cancer cells.
Topics: Adenoviridae; Antineoplastic Agents, Phytogenic; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Division; Chloramphenicol O-Acetyltransferase; Drug Resistance, Neoplasm; Electrophoretic Mobility Shift Assay; Gene Expression Regulation, Neoplastic; Genes, Dominant; Humans; I-kappa B Proteins; Male; Neoplasms, Hormone-Dependent; NF-kappa B; Paclitaxel; Prostatic Neoplasms; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 2003 |
Blockage of the lacrimal drainage apparatus as a side effect of docetaxel therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Squamous Cell; Dacryocystorhinostomy; Docetaxel; Drainage; Esophageal Neoplasms; Female; Humans; Intubation; Lacrimal Duct Obstruction; Lung Neoplasms; Male; Middle Aged; Nasolacrimal Duct; Ovarian Neoplasms; Paclitaxel; Prostatic Neoplasms; Taxoids; Texas | 2003 |
Challenging problems in advanced malignancy: Case 2. Disseminated intravascular coagulation in metastatic hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Hormonal; Bone Neoplasms; Disseminated Intravascular Coagulation; Fatal Outcome; Humans; Male; Paclitaxel; Prostatic Neoplasms | 2003 |
ERK inhibitor PD98059 enhances docetaxel-induced apoptosis of androgen-independent human prostate cancer cells.
Topics: Apoptosis; bcl-X Protein; Butadienes; Docetaxel; Drug Synergism; Enzyme Inhibitors; Flavonoids; Humans; Male; Mitogen-Activated Protein Kinases; Neoplasms, Hormone-Dependent; Nitriles; Paclitaxel; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Taxoids; Tumor Cells, Cultured; Vinblastine; Vinorelbine | 2003 |
Weekly administration of docetaxel for symptomatic metastatic hormone-refractory prostate carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Docetaxel; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Taxoids | 2003 |
Unique induction of p21(WAF1/CIP1)expression by vinorelbine in androgen-independent prostate cancer cells.
Topics: Androgen Antagonists; Animals; Antineoplastic Agents, Phytogenic; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Drug Interactions; Drug Resistance, Neoplasm; Drug Therapy, Combination; Enzyme Inhibitors; Gene Deletion; Gene Expression Regulation, Neoplastic; Male; Paclitaxel; Prostatic Neoplasms; Tumor Cells, Cultured; Vinblastine; Vinorelbine | 2003 |
Combination chemotherapy for hormone-refractory prostate carcinoma: progress and pitfalls.
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Drug Resistance, Neoplasm; Estramustine; Etoposide; Humans; Male; Paclitaxel; Prostatic Neoplasms; Treatment Outcome | 2003 |
Paclitaxel and Cisplatin-induced neurotoxicity: a protective role of acetyl-L-carnitine.
Topics: Acetylcarnitine; Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Cisplatin; Colonic Neoplasms; Female; Ganglia, Spinal; HeLa Cells; Humans; Lung Neoplasms; Male; Models, Animal; Neurotoxins; Ovarian Neoplasms; Paclitaxel; Prostatic Neoplasms; Rats; Rats, Wistar | 2003 |
Identification of a novel function of TWIST, a bHLH protein, in the development of acquired taxol resistance in human cancer cells.
Topics: Drug Resistance, Neoplasm; Female; Gene Amplification; Gene Expression Regulation, Neoplastic; Helix-Loop-Helix Motifs; Humans; Inhibitory Concentration 50; Male; Nasopharyngeal Neoplasms; Nuclear Proteins; Ovarian Neoplasms; Paclitaxel; Prostatic Neoplasms; Transcription Factors; Tumor Cells, Cultured; Twist-Related Protein 1; Urinary Bladder Neoplasms; Vincristine | 2004 |
Anti-tumor effect of combination therapy with intratumoral controlled-release paclitaxel (PACLIMER microspheres) and radiation.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Combined Modality Therapy; Delayed-Action Preparations; Humans; Male; Mice; Mice, Nude; Microspheres; Neoplasm Transplantation; Paclitaxel; Prostatic Neoplasms; Radiation-Sensitizing Agents | 2004 |
The cytoskeleton differentially localizes the early growth response gene-1 protein in cancer and benign cells of the prostate.
Topics: Active Transport, Cell Nucleus; Adenocarcinoma; Cell Cycle; Cell Line; Cell Line, Tumor; Cell Nucleus; Cytoskeleton; DNA-Binding Proteins; Early Growth Response Protein 1; Humans; Immediate-Early Proteins; Immunohistochemistry; Male; Microtubules; Nocodazole; Paclitaxel; Prostate; Prostatic Neoplasms; Transcription Factors | 2004 |
Phosphorylation of FADD is critical for sensitivity to anticancer drug-induced apoptosis.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents, Phytogenic; Apoptosis; Carrier Proteins; Fas-Associated Death Domain Protein; Humans; JNK Mitogen-Activated Protein Kinases; Male; MAP Kinase Kinase 7; MAP Kinase Kinase Kinase 1; MAP Kinase Kinase Kinases; Mitogen-Activated Protein Kinase 8; Mitogen-Activated Protein Kinase Kinases; Mitogen-Activated Protein Kinases; Paclitaxel; Phosphorylation; Prostatic Neoplasms | 2004 |
Enhanced therapeutic effects of doxorubicin and paclitaxel in combination with liposome-entrapped ends-modified raf antisense oligonucleotide against human prostate, lung and breast tumor models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubicin; Female; Humans; Liposomes; Lung Neoplasms; Male; Mice; Mice, Nude; Oligonucleotides, Antisense; Paclitaxel; Prostatic Neoplasms; Proto-Oncogene Proteins c-raf; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2004 |
[Potentiation of focal ultrasound treatment of prostate adenocarcinoma by concomitant chemotherapy with estramustine phosphate and paclitaxel].
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Combined Modality Therapy; Disease Models, Animal; Estramustine; Male; Paclitaxel; Prostatic Neoplasms; Rats; Ultrasonic Therapy | 2004 |
Quantification of disseminated tumor cells in the bloodstream of patients with hormone-refractory prostate carcinoma undergoing cytotoxic chemotherapy.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Estramustine; Humans; Immunomagnetic Separation; Keratins; Leukocyte Common Antigens; Male; Middle Aged; Mitoxantrone; Neoplasms, Hormone-Dependent; Neoplastic Cells, Circulating; Paclitaxel; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Tumor Cells, Cultured | 2004 |
Antiangiogenic effect of metronomic paclitaxel treatment in prostate cancer and non-tumor tissue in the same animals: a quantitative study.
Topics: Angiogenesis Inhibitors; Animals; Body Weight; Male; Necrosis; Neovascularization, Pathologic; Paclitaxel; Prostatic Neoplasms; Rats; Vascular Endothelial Growth Factor A | 2004 |
A new screening system for proliferation-independent anti-cancer agents.
Topics: Antineoplastic Agents; Apoptosis; Cell Differentiation; Cell Survival; Drug Evaluation, Preclinical; Humans; Immunoenzyme Techniques; Ki-67 Antigen; Male; Neurosecretory Systems; Paclitaxel; Prostatic Neoplasms; Resting Phase, Cell Cycle; Thapsigargin; Tumor Cells, Cultured; Vinblastine | 2004 |
Simultaneous blockade of platelet-derived growth factor-receptor and epidermal growth factor-receptor signaling and systemic administration of paclitaxel as therapy for human prostate cancer metastasis in bone of nude mice.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Bone Neoplasms; Cell Division; Enzyme Inhibitors; ErbB Receptors; Humans; Imatinib Mesylate; In Situ Nick-End Labeling; Male; Mice; Mice, Nude; Paclitaxel; Phosphorylation; Piperazines; Platelet Endothelial Cell Adhesion Molecule-1; Prostatic Neoplasms; Pyrimidines; Pyrroles; Receptors, Platelet-Derived Growth Factor; Substrate Specificity; Xenograft Model Antitumor Assays | 2004 |
Caffeic acid phenethyl ester-induced PC-3 cell apoptosis is caspase-dependent and mediated through the loss of inhibitors of apoptosis proteins.
Topics: Apoptosis; Blotting, Western; Caffeic Acids; Caspase Inhibitors; Cell Line, Tumor; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Humans; Male; NF-kappa B; Paclitaxel; Phenylethyl Alcohol; Prostatic Neoplasms; Tumor Necrosis Factor-alpha | 2004 |
Role of c-myc protein in hormone refractory prostate carcinoma: cellular response to paclitaxel.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Caspases; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Enzyme Activation; Gene Expression; Hormones; Humans; Male; Paclitaxel; Phosphorylation; Prostatic Neoplasms; Proto-Oncogene Mas; Proto-Oncogene Proteins c-myc; Signal Transduction; Tumor Cells, Cultured | 2004 |
Efficacy of transferrin-conjugated paclitaxel-loaded nanoparticles in a murine model of prostate cancer.
Topics: Animals; Biocompatible Materials; Disease Models, Animal; Drug Delivery Systems; Male; Mice; Mice, Nude; Nanotechnology; Paclitaxel; Pharmaceutical Vehicles; Polyethylene Glycols; Prostatic Neoplasms; Survival Analysis; Transferrin | 2004 |
Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer.
Topics: Androgens; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Division; Disease Progression; Dose-Response Relationship, Drug; Heat-Shock Proteins; Humans; Male; Mice; Mice, Nude; Neoplasms, Hormone-Dependent; Oligonucleotides, Antisense; Paclitaxel; Prostatic Neoplasms; RNA, Small Interfering | 2004 |
Inhibition of Wnt signaling downregulates Akt activity and induces chemosensitivity in PTEN-mutated prostate cancer cells.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents, Phytogenic; Apoptosis; beta Catenin; Carrier Proteins; Cell Line, Tumor; Cytoskeletal Proteins; Down-Regulation; Drug Resistance, Neoplasm; Gene Expression; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Male; Mutation; Paclitaxel; Phosphoric Monoester Hydrolases; Prostatic Neoplasms; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Repressor Proteins; Signal Transduction; Trans-Activators; Transfection; Tumor Suppressor Proteins | 2005 |
[Synergistic effects of paclitaxel and gemcitabine on androgen-independent prostate cancer].
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Gemcitabine; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms | 2004 |
Blockade of paclitaxel-induced thymidine phosphorylase expression can accelerate apoptosis in human prostate cancer cells.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Apoptosis; Caspase 3; Caspase 8; Caspases; Enzyme Induction; Humans; Immunohistochemistry; Male; Middle Aged; Paclitaxel; Poly(ADP-ribose) Polymerases; Prostate-Specific Antigen; Prostatic Neoplasms; Thymidine Phosphorylase | 2004 |
[The synergistic effects of paclitaxel and gemcitabine on prostate cancer cell line PC-3].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, Tumor; Deoxycytidine; Dose-Response Relationship, Drug; Down-Regulation; Drug Synergism; Flow Cytometry; Gemcitabine; Humans; Male; Paclitaxel; Prostatic Neoplasms | 2004 |
Phosphatidylinositol 3'-kinase activation leads to multidrug resistance protein-1 expression and subsequent chemoresistance in advanced prostate cancer cells.
Topics: Base Sequence; Cell Line, Tumor; Cell Survival; DNA Primers; Doxorubicin; Drug Resistance, Neoplasm; Enzyme Activation; Humans; Male; Paclitaxel; Phosphatidylinositol 3-Kinases; Prostatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; RNA, Small Interfering; Signal Transduction | 2004 |
Noninvasive in vivo whole body luminescent analysis of luciferase labelled orthotopic prostate tumours.
Topics: Animals; Antineoplastic Agents, Phytogenic; Firefly Luciferin; Luciferases; Luminescent Agents; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Paclitaxel; Prostatic Neoplasms; Tumor Cells, Cultured | 2004 |
Evaluation of the fibroblast growth factor system as a potential target for therapy in human prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Disease-Free Survival; Drug Synergism; Drug Therapy, Combination; Fibroblast Growth Factors; Humans; Immunohistochemistry; Male; Middle Aged; Paclitaxel; Prostatic Hyperplasia; Prostatic Neoplasms; Recombinant Fusion Proteins; Tumor Cells, Cultured | 2005 |
Different effect of paclitaxel on primary tumor mass, tumor cell contents, and metastases for four experimental human prostate tumors expressing luciferase.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Gene Expression Regulation, Enzymologic; Humans; Luciferases; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Metastasis; Paclitaxel; Prostatic Neoplasms; Transfection; Treatment Outcome; Xenograft Model Antitumor Assays | 2005 |
In vitro assessment of cytotoxic agent combinations for hormone-refractory prostate cancer treatment.
Topics: Alkaloids; Antineoplastic Combined Chemotherapy Protocols; Benzophenanthridines; Carboplatin; Drug Antagonism; Drug Synergism; Humans; In Vitro Techniques; Isotretinoin; Male; Mitoxantrone; Neoplasms, Hormone-Dependent; Paclitaxel; Phenanthridines; Prostatic Neoplasms; Treatment Outcome; Tumor Cells, Cultured | 2005 |
Adenovirus-mediated inhibition of survivin expression sensitizes human prostate cancer cells to paclitaxel in vitro and in vivo.
Topics: Adenoviridae; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Caspases; Cell Line, Tumor; Drug Resistance, Neoplasm; Genetic Therapy; Humans; In Vitro Techniques; Inhibitor of Apoptosis Proteins; Male; Mice; Mice, Nude; Microtubule-Associated Proteins; Neoplasm Proteins; Paclitaxel; Prostatic Neoplasms; Survivin; Up-Regulation | 2005 |
Docetaxel-based chemotherapy as second-line treatment for paclitaxel-based chemotherapy-resistant hormone-refractory prostate cancer: a pilot study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Docetaxel; Hormones; Humans; Male; Middle Aged; Paclitaxel; Pilot Projects; Prostatic Neoplasms; Taxoids; Treatment Failure | 2005 |
Methylseleninic acid potentiates apoptosis induced by chemotherapeutic drugs in androgen-independent prostate cancer cells.
Topics: Androgens; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Caspases; Drug Therapy, Combination; Enzyme Activation; Etoposide; Humans; JNK Mitogen-Activated Protein Kinases; Male; Organoselenium Compounds; p38 Mitogen-Activated Protein Kinases; Paclitaxel; Phosphorylation; Poly(ADP-ribose) Polymerases; Prostatic Neoplasms; Tumor Cells, Cultured | 2005 |
Synergistic inhibitory effect of high-intensity focused ultrasound combined with chemotherapy on Dunning adenocarcinoma.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Estramustine; Male; Paclitaxel; Prostatic Neoplasms; Rats; Ultrasound, High-Intensity Focused, Transrectal | 2005 |
Efficacy of an intratumoral controlled release formulation of clusterin antisense oligonucleotide complexed with chitosan containing paclitaxel or docetaxel in prostate cancer xenograft models.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Chemistry, Pharmaceutical; Chitosan; Clusterin; Delayed-Action Preparations; Docetaxel; Drug Therapy, Combination; Glycoproteins; Humans; Injections, Intralesional; Male; Mice; Mice, Inbred BALB C; Molecular Chaperones; Neoplasm Transplantation; Ointments; Oligonucleotides, Antisense; Paclitaxel; Prostatic Neoplasms; Taxoids; Transplantation, Heterologous; Xenograft Model Antitumor Assays | 2005 |
Modulation of bone microenvironment with zoledronate enhances the therapeutic effects of STI571 and paclitaxel against experimental bone metastasis of human prostate cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Bone and Bones; Bone Neoplasms; Cell Line, Tumor; Diphosphonates; Dose-Response Relationship, Drug; Drug Synergism; Humans; Imatinib Mesylate; Imidazoles; Immunohistochemistry; Male; Mice; Mice, Nude; Osteoclasts; Paclitaxel; Piperazines; Prostatic Neoplasms; Pyrimidines; Zoledronic Acid | 2005 |
Growth of LNCaP cells in monoculture and coculture with osteoblasts and response to tNOX inhibitors.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antioxidants; Bone Neoplasms; Capsaicin; Catechin; Cell Survival; Cisplatin; Humans; Isoflavones; Male; Osteoblasts; Paclitaxel; Plant Extracts; Prostatic Neoplasms; Tumor Cells, Cultured | 2005 |
Paclitaxel suppresses the growth of primary prostate tumours (RM-1) and metastases in the lung in C57BL/6 mice.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Division; Cell Proliferation; G2 Phase; Lung Neoplasms; Male; Mice; Mice, Inbred C57BL; Paclitaxel; Prostatic Neoplasms | 2006 |
Patupilone (epothilone B, EPO906) inhibits growth and metastasis of experimental prostate tumors in vivo.
Topics: Animals; Antineoplastic Agents; Body Weight; Cell Line, Tumor; Epothilones; Humans; Lymphatic Metastasis; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Paclitaxel; Prostatic Neoplasms; Xenograft Model Antitumor Assays | 2005 |
Dual inhibition of the epidermal growth factor and vascular endothelial growth factor phosphorylation for antivascular therapy of human prostate cancer in the prostate of nude mice.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Capillary Permeability; Cell Growth Processes; Cell Line, Tumor; ErbB Receptors; Humans; In Situ Nick-End Labeling; Male; Mice; Mice, Nude; Microscopy, Fluorescence; Neovascularization, Pathologic; Paclitaxel; Phosphorylation; Platelet Endothelial Cell Adhesion Molecule-1; Prostatic Neoplasms; Protein Kinase Inhibitors; Purines; Receptors, Vascular Endothelial Growth Factor; Xenograft Model Antitumor Assays | 2005 |
Up-regulation of TWIST in prostate cancer and its implication as a therapeutic target.
Topics: Adenocarcinoma; Apoptosis; Cell Line, Tumor; Epithelial Cells; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Male; Mesoderm; Neoplasm Invasiveness; Nuclear Proteins; Paclitaxel; Prostatic Neoplasms; Transcription Factors; Transfection; Twist-Related Protein 1; Up-Regulation | 2005 |
Inhibitory effects of 12-O-tetradecanoylphorbol-13-acetate alone or in combination with all-trans retinoic acid on the growth of cultured human pancreas cancer cells and pancreas tumor xenografts in immunodeficient mice.
Topics: Animals; Apoptosis; Body Weight; Cell Cycle; Cell Proliferation; Humans; Immunohistochemistry; Male; Mice; Neoplasm Transplantation; Paclitaxel; Pancreatic Neoplasms; Phosphorylation; Prostatic Neoplasms; Protein Kinase C; Retinoblastoma Protein; Sulindac; Tetradecanoylphorbol Acetate; Transplantation, Heterologous; Tretinoin; Tumor Cells, Cultured | 2005 |
Timing is everything: preclinical evidence supporting simultaneous rather than sequential chemohormonal therapy for prostate cancer.
Topics: Androgens; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line; Cell Survival; Combined Modality Therapy; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Oligonucleotide Array Sequence Analysis; Orchiectomy; Paclitaxel; Prostatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Analysis; Time Factors; Xenograft Model Antitumor Assays | 2005 |
Endothelin-1 inhibits apoptosis in prostate cancer.
Topics: Annexin A5; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; bcl-Associated Death Protein; Carrier Proteins; Cell Line, Tumor; Cell Survival; DNA Methylation; Dose-Response Relationship, Drug; Endothelin-1; Flow Cytometry; Humans; Immunoblotting; Male; Membrane Proteins; Paclitaxel; Phosphatidylinositol 3-Kinases; Phosphorylation; Promoter Regions, Genetic; Prostatic Neoplasms; Protein Binding; Proto-Oncogene Proteins c-bcl-2; Receptors, Endothelin | 2005 |
Combined low-dose imatinib mesylate and paclitaxel lack synergy in an experimental model of extra-osseous hormone-refractory prostate cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Tumor; Drug Administration Schedule; Drug Synergism; Fluorescent Antibody Technique; Imatinib Mesylate; Male; Mice; Mice, SCID; Models, Animal; Neoplasm Transplantation; Neovascularization, Pathologic; Paclitaxel; Piperazines; Prostatic Neoplasms; Pyrimidines; Random Allocation; Receptors, Platelet-Derived Growth Factor; Treatment Failure | 2005 |
Expression of the inhibitors of apoptosis proteins in cisplatin-resistant prostate cancer cells.
Topics: Apoptosis; Baculoviral IAP Repeat-Containing 3 Protein; Bisbenzimidazole; Cell Line, Tumor; Cell Proliferation; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Fluorouracil; Humans; Immunoblotting; Inhibitor of Apoptosis Proteins; Male; Microtubule-Associated Proteins; Neoplasm Proteins; Neuronal Apoptosis-Inhibitory Protein; Paclitaxel; Phenotype; Prostatic Neoplasms; Survivin; Taxoids; Tetrazolium Salts; Time Factors; Ubiquitin-Protein Ligases; X-Linked Inhibitor of Apoptosis Protein | 2005 |
Does paclitaxel (Taxol) given after (111)In-labeled monoclonal antibodies increase tumor-cumulated activity in epithelial cancers?
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Combined Modality Therapy; Female; Heterocyclic Compounds, 1-Ring; Humans; Immunoglobulin G; Indium Radioisotopes; Male; Mammary Neoplasms, Experimental; Mice; Neoplasm Transplantation; Neoplasms, Glandular and Epithelial; Paclitaxel; Prostatic Neoplasms; Radioimmunotherapy; Time Factors | 2005 |
Enhancement of the therapeutic index: from nonmyeloablative and myeloablative toward pretargeted radioimmunotherapy for metastatic prostate cancer.
Topics: Antibodies, Monoclonal; Antigens; Antigens, Neoplasm; Bone Marrow; Cathepsins; Combined Modality Therapy; Electrophoresis, Polyacrylamide Gel; Epitopes; Glycoproteins; Humans; Immunohistochemistry; Male; Maleimides; Maximum Tolerated Dose; Models, Chemical; Mucin-1; Mucins; Neoplasm Metastasis; Paclitaxel; Peptide Library; Peptides; Polyethylene Glycols; Prostatic Neoplasms; Protein Binding; Radioimmunotherapy; Radiometry; Yttrium Radioisotopes | 2005 |
A selective retinoid X receptor agonist bexarotene (LGD1069, Targretin) prevents and overcomes multidrug resistance in advanced prostate cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bexarotene; Cell Line, Tumor; Cell Proliferation; Cisplatin; Doxorubicin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Humans; Inhibitory Concentration 50; Male; Mice; Mice, Nude; Paclitaxel; Prostatic Neoplasms; Retinoid X Receptors; Reverse Transcriptase Polymerase Chain Reaction; RNA, Neoplasm; Tetrahydronaphthalenes | 2006 |
A novel antisense oligonucleotide inhibiting several antiapoptotic Bcl-2 family members induces apoptosis and enhances chemosensitivity in androgen-independent human prostate cancer PC3 cells.
Topics: Androgens; Antineoplastic Agents; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; bcl-Associated Death Protein; bcl-X Protein; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Down-Regulation; Gene Expression Regulation, Neoplastic; Humans; Inhibitor of Apoptosis Proteins; Inhibitory Concentration 50; Male; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Metastasis; Neoplasm Proteins; Oligonucleotide Array Sequence Analysis; Oligonucleotides; Oligonucleotides, Antisense; Paclitaxel; Prostate; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2005 |
Inactivation of Id-1 in prostate cancer cells: A potential therapeutic target in inducing chemosensitization to taxol through activation of JNK pathway.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Cell Survival; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Activation; Gene Expression Profiling; Humans; Inhibitor of Differentiation Protein 1; Male; MAP Kinase Kinase 4; Paclitaxel; Prostatic Neoplasms; RNA Interference; Tumor Cells, Cultured; Up-Regulation | 2006 |
Positive inter-regulation between beta-catenin/T cell factor-4 signaling and endothelin-1 signaling potentiates proliferation and survival of prostate cancer cells.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; beta Catenin; Cell Proliferation; Endothelin A Receptor Antagonists; Endothelin-1; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Paclitaxel; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Promoter Regions, Genetic; Prostatic Neoplasms; Signal Transduction; TCF Transcription Factors; Thymidine; Transcription Factor 7-Like 2 Protein; Transcription, Genetic; Tumor Cells, Cultured | 2006 |
Tumor lysis syndrome in a patient with metastatic, androgen independent prostate cancer.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Bone Marrow Neoplasms; Bone Neoplasms; Hematuria; Humans; Hydronephrosis; Liver Neoplasms; Male; Middle Aged; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Renal Dialysis; Renal Insufficiency; Tumor Lysis Syndrome | 2005 |
2-Methoxyestradiol and paclitaxel have similar effects on the cell cycle and induction of apoptosis in prostate cancer cells.
Topics: 2-Methoxyestradiol; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Cycle; Cyclin B1; Cyclin-Dependent Kinases; Estradiol; Humans; Male; Paclitaxel; Prostatic Neoplasms; Tubulin Modulators; Tumor Cells, Cultured | 2006 |
[Prostate cancer with penile metastasis: a case report].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Carboplatin; Combined Modality Therapy; Estramustine; Humans; Male; Orchiectomy; Paclitaxel; Penile Neoplasms; Prostate-Specific Antigen; Prostatic Neoplasms | 2005 |
Alisol B acetate, a triterpene from Alismatis rhizoma, induces Bax nuclear translocation and apoptosis in human hormone-resistant prostate cancer PC-3 cells.
Topics: Alismataceae; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; bcl-2-Associated X Protein; Blotting, Western; Caspases; Cell Nucleus; Cholestenones; Curcumin; Drug Resistance, Neoplasm; Flow Cytometry; Humans; Male; Membrane Potentials; Mitochondria; Neoplasms, Hormone-Dependent; Nitric Oxide Synthase; Paclitaxel; Prostatic Neoplasms; Protein Transport; Proto-Oncogene Proteins c-bcl-2; Triterpenes; Tumor Cells, Cultured | 2006 |
Epidermal growth factor receptor inhibitor (PD168393) potentiates cytotoxic effects of paclitaxel against androgen-independent prostate cancer cells.
Topics: Adenocarcinoma; Androgens; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Drug Combinations; Drug Screening Assays, Antitumor; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Male; Paclitaxel; Prostatic Neoplasms; Quinazolines | 2006 |
Circulating chromogranin a and hormone refractory prostate cancer chemotherapy.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Agents; Biomarkers, Tumor; Carboplatin; Chromogranin A; Chromogranins; Humans; Male; Middle Aged; Mitoxantrone; Paclitaxel; Prostatic Neoplasms; Treatment Failure | 2006 |
Rh2 synergistically enhances paclitaxel or mitoxantrone in prostate cancer models.
Topics: Animals; Antineoplastic Agents; Drug Synergism; Drugs, Chinese Herbal; Ginsenosides; Humans; Male; Mice; Mice, Nude; Mitoxantrone; Paclitaxel; Prostatic Neoplasms; Tumor Cells, Cultured | 2006 |
Induction of apoptosis and enhancement of chemosensitivity in human prostate cancer LNCaP cells using bispecific antisense oligonucleotide targeting Bcl-2 and Bcl-xL genes.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-X Protein; Blotting, Western; Clusterin; Docetaxel; Flow Cytometry; Genes, bcl-2; Humans; Male; Mitoxantrone; Oligonucleotides, Antisense; Paclitaxel; Prostatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Taxoids; Tumor Cells, Cultured | 2006 |
Activation of membrane androgen receptors potentiates the antiproliferative effects of paclitaxel on human prostate cancer cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Membrane; Cell Membrane Permeability; Cell Proliferation; Cytoskeleton; Dose-Response Relationship, Drug; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Paclitaxel; Prostatic Neoplasms; Receptors, Androgen; Serum Albumin, Bovine; Testosterone; Tumor Cells, Cultured | 2006 |
Effects of 12-O-tetradecanoylphorbol-13-acetate (TPA) in combination with paclitaxel (Taxol) on prostate Cancer LNCaP cells cultured in vitro or grown as xenograft tumors in immunodeficient mice.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Culture Techniques; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Drug Screening Assays, Antitumor; Humans; Injections, Intraperitoneal; JNK Mitogen-Activated Protein Kinases; Male; Mice; Mice, Nude; Mice, SCID; Paclitaxel; Phosphorylation; Prostatic Neoplasms; Structure-Activity Relationship; Tetradecanoylphorbol Acetate; Treatment Outcome; Xenograft Model Antitumor Assays | 2006 |
Targeting platelet-derived growth factor receptor on endothelial cells of multidrug-resistant prostate cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Blotting, Western; Bone Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Endothelial Cells; Fluorescent Antibody Technique; Humans; Imatinib Mesylate; Immunohistochemistry; In Situ Nick-End Labeling; Lymphatic Metastasis; Male; Mice; Mice, Nude; Microcirculation; Neoplasm Transplantation; Neovascularization, Pathologic; Paclitaxel; Phosphorylation; Piperazines; Prostatic Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Random Allocation; Receptors, Platelet-Derived Growth Factor; Reverse Transcriptase Polymerase Chain Reaction; Tibia; Tumor Cells, Cultured | 2006 |
Response to second-line chemotherapy in patients with hormone refractory prostate cancer receiving two sequences of mitoxantrone and taxanes.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Mitoxantrone; Paclitaxel; Prostatic Neoplasms; Retrospective Studies; Taxoids | 2006 |
Evaluation of Calvert's formula for dosage adjustment of carboplatin in Japanese patients with hormone refractory prostate cancer.
Topics: Aged; Antineoplastic Agents; Carboplatin; Creatinine; Dose-Response Relationship, Drug; Humans; Male; Metabolic Clearance Rate; Middle Aged; Models, Theoretical; Paclitaxel; Prostatic Neoplasms | 2006 |
Combinational antitumor effect of siRNA against midkine and paclitaxel on growth of human prostate cancer xenografts.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Proliferation; Combined Modality Therapy; Cytokines; Gene Expression Regulation, Neoplastic; Genetic Therapy; Humans; Male; Mice; Mice, Nude; Midkine; Paclitaxel; Prostatic Neoplasms; RNA, Small Interfering; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2006 |
Antivascular therapy of cancer metastasis.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Disease Progression; Growth Substances; Humans; Imatinib Mesylate; Male; Mice; Mice, Nude; Neoplasm Metastasis; Neoplasms; Paclitaxel; Piperazines; Platelet-Derived Growth Factor; Prostatic Neoplasms; Pyrimidines; Receptors, Growth Factor; Receptors, Platelet-Derived Growth Factor | 2006 |
Tissue inhibitor of metalloproteinase-3 induces apoptosis in prostate cancer cells and confers increased sensitivity to paclitaxel.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Caspases; Drug Synergism; Humans; Immunohistochemistry; Male; Mitochondria; Neoplasm Proteins; Paclitaxel; Prostatic Neoplasms; Tissue Inhibitor of Metalloproteinase-3; Tumor Cells, Cultured | 2006 |
Therapy of multidrug resistant human prostate tumors in the prostate of nude mice by simultaneous targeting of the epidermal growth factor receptor and vascular endothelial growth factor receptor on tumor-associated endothelial cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Endothelial Cells; ErbB Receptors; Humans; In Situ Nick-End Labeling; Lymphatic Metastasis; Male; Mice; Mice, Nude; Paclitaxel; Phosphorylation; Prostatic Neoplasms; Purines; Receptors, Vascular Endothelial Growth Factor; Xenograft Model Antitumor Assays | 2006 |
Bispecific antisense oligonucleotides with multiple binding sites for the treatment of prostate tumors and their applicability to combination therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Binding Sites; Cell Line, Tumor; Cell Proliferation; Cyclophosphamide; Diethylstilbestrol; ErbB Receptors; Humans; Male; Oligonucleotides, Antisense; Paclitaxel; Prostatic Neoplasms; Transforming Growth Factor alpha | 2006 |
Therapeutic interactions between stathmin inhibition and chemotherapeutic agents in prostate cancer.
Topics: Adenoviridae; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Combined Modality Therapy; Doxorubicin; Etoposide; Fluorouracil; Humans; Male; Paclitaxel; Prostatic Neoplasms; RNA, Catalytic; Stathmin | 2006 |
Anti-HER2 cationic immunoemulsion as a potential targeted drug delivery system for the treatment of prostate cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Complement Activation; Drug Delivery Systems; Emulsions; Humans; Immunoconjugates; Male; Mice; Paclitaxel; Palmitates; Prostatic Neoplasms; Receptor, ErbB-2; Trastuzumab | 2007 |
Evidence of a novel antiapoptotic factor: role of inhibitor of differentiation or DNA binding (Id-1) in anticancer drug-induced apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Carcinoma, Hepatocellular; Catechin; Cell Line, Tumor; Cell Survival; Cisplatin; Down-Regulation; Doxorubicin; Etoposide; Female; HeLa Cells; Humans; Inhibitor of Differentiation Protein 1; Liver Neoplasms; Male; Mechlorethamine; Methotrexate; Mitomycin; Nasopharyngeal Neoplasms; Paclitaxel; Prostatic Neoplasms; Vincristine | 2007 |
Preferential chemosensitization of PTEN-mutated prostate cells by silencing the Akt kinase.
Topics: Antineoplastic Agents, Phytogenic; Cell Line; Cell Line, Tumor; Gene Expression; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Male; Mutation; Oncogene Protein v-akt; Paclitaxel; Prostate; Prostatic Neoplasms; PTEN Phosphohydrolase; RNA, Small Interfering; Signal Transduction; Tubulin Modulators | 2007 |
Effect of paclitaxel on intracellular localization of c-Myc and P-c-Myc in prostate carcinoma cell lines.
Topics: Active Transport, Cell Nucleus; Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma; Cell Line, Tumor; Humans; Intracellular Fluid; Male; Paclitaxel; Phosphorylation; Prostatic Neoplasms; Proto-Oncogene Mas; Proto-Oncogene Proteins c-myc | 2007 |
[A case report of paclitaxel combined with carboplatin for poorly differentiated prostate cancer with renal failure].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Humans; Male; Paclitaxel; Prostatic Neoplasms; Renal Dialysis; Renal Insufficiency | 2007 |
The establishment of two paclitaxel-resistant prostate cancer cell lines and the mechanisms of paclitaxel resistance with two cell lines.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line; Drug Resistance, Neoplasm; Humans; Male; Paclitaxel; Prostatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; RNA, Small Interfering; Transfection | 2007 |
[Study on the relationship between Aurora A expression in cancer cell and treatment efficacy of taxol for prostate cancer].
Topics: Antineoplastic Agents; Aurora Kinases; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Gene Expression Regulation, Neoplastic; Humans; Male; Paclitaxel; Prostatic Neoplasms; Protein Serine-Threonine Kinases; Up-Regulation | 2007 |
Expression of LIM kinase 1 is associated with reversible G1/S phase arrest, chromosomal instability and prostate cancer.
Topics: Antineoplastic Agents, Phytogenic; Cell Cycle; Chromosomal Instability; Fluorescent Antibody Technique; G1 Phase; Humans; Immunoblotting; Immunohistochemistry; Lim Kinases; Male; Paclitaxel; Precancerous Conditions; Prostatic Neoplasms; Protein Kinases; S Phase; Tissue Array Analysis | 2007 |
Evaluation of the antiproliferative effects of Essiac on in vitro and in vivo models of prostate cancer compared to paclitaxel.
Topics: Animals; Antineoplastic Agents, Phytogenic; Area Under Curve; Cell Cycle; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Flow Cytometry; Immunohistochemistry; Ki-67 Antigen; Male; Mice; Mice, Nude; Paclitaxel; Plant Extracts; Proliferating Cell Nuclear Antigen; Prostatic Neoplasms; Random Allocation; Transplantation, Heterologous | 2007 |
Docetaxel for prostate cancer.
Topics: Antineoplastic Agents, Phytogenic; Clinical Trials as Topic; Humans; Male; Paclitaxel; Prostatic Neoplasms | 2007 |
The preparation and characterization of anti-VEGFR2 conjugated, paclitaxel-loaded PLLA or PLGA microspheres for the systemic targeting of human prostate tumors.
Topics: Animals; Antibodies, Blocking; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Drug Compounding; Drug Delivery Systems; Endothelial Cells; Fluorescein-5-isothiocyanate; Humans; Immunoglobulin G; Lactic Acid; Male; Mice; Mice, Inbred BALB C; Microspheres; Neoplasm Transplantation; Paclitaxel; Particle Size; Pilot Projects; Polyesters; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Polymers; Prostatic Neoplasms; Vascular Endothelial Growth Factor Receptor-2 | 2008 |
Paclitaxel enhanced radiation sensitization for the suppression of human prostate cancer tumor growth via a p53 independent pathway.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Drug Screening Assays, Antitumor; Gene Expression Regulation, Neoplastic; Genes, p53; Humans; Male; Mice; Mice, SCID; Paclitaxel; Prostatic Neoplasms; Radiation-Sensitizing Agents; Transfection; Tumor Suppressor Protein p53; X-Ray Therapy | 2007 |
Identification of a novel inhibitor of differentiation-1 (ID-1) binding partner, caveolin-1, and its role in epithelial-mesenchymal transition and resistance to apoptosis in prostate cancer cells.
Topics: Apoptosis; Caveolin 1; Cell Movement; Drug Resistance, Neoplasm; Epithelium; Gene Expression Regulation, Neoplastic; Humans; Inhibitor of Differentiation Protein 1; Male; Mesoderm; Molecular Sequence Data; Neoplasm Invasiveness; Paclitaxel; Prostatic Neoplasms; Protein Binding; Two-Hybrid System Techniques | 2007 |
Distinct prognostic role of prostate-specific antigen doubling time and velocity at emergence of androgen independence in patients treated with chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Androgen Antagonists; Androgens; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Neoplasms, Hormone-Dependent; Paclitaxel; Prognosis; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Salvage Therapy; Survival Analysis; Taxoids; Time Factors | 2007 |
Zinc deficiency reduces paclitaxel efficacy in LNCaP prostate cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Cell Cycle; Humans; Immunoenzyme Techniques; Male; Neoplasms, Hormone-Dependent; Paclitaxel; Prostatic Neoplasms; Tumor Cells, Cultured; Zinc | 2007 |
Late coronary stent thrombosis complicating urologic surgery.
Topics: Aged; Clopidogrel; Coronary Stenosis; Drug-Eluting Stents; Fatal Outcome; Humans; Immunosuppressive Agents; Lymph Node Excision; Male; Paclitaxel; Platelet Aggregation Inhibitors; Prostatic Neoplasms; Thrombosis; Ticlopidine; Withholding Treatment | 2008 |
Possible roles of vinexinbeta in growth and paclitaxel sensitivity in human prostate cancer PC-3 cells.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Proliferation; Gene Silencing; Humans; Male; Muscle Proteins; Paclitaxel; Prostatic Neoplasms; RNA Interference | 2007 |
Development of an adenoviral vector with robust expression driven by p53.
Topics: Adenoviridae; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; DNA, Complementary; Dose-Response Relationship, Drug; Doxorubicin; Enhancer Elements, Genetic; Genes, p53; Genes, Reporter; Genetic Therapy; Genetic Vectors; Humans; Introns; Luciferases; Male; Paclitaxel; Promoter Regions, Genetic; Prostatic Neoplasms; Rabbits; Transduction, Genetic; Transfection; Transgenes | 2008 |
Quantitative image analysis of intra-tumoral bFGF level as a molecular marker of paclitaxel resistance.
Topics: Animals; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Enzyme-Linked Immunosorbent Assay; Female; Fibroblast Growth Factor 2; HT29 Cells; Humans; Image Processing, Computer-Assisted; Immunohistochemistry; Inhibitory Concentration 50; Male; Mice; Mice, SCID; Paclitaxel; Pancreatic Neoplasms; Pharyngeal Neoplasms; Prostatic Neoplasms; Sensitivity and Specificity; Statistics as Topic; Tissue Culture Techniques; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2008 |
Methylseleninic acid enhances taxane drug efficacy against human prostate cancer and down-regulates antiapoptotic proteins Bcl-XL and survivin.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-X Protein; Cell Line, Tumor; Docetaxel; Down-Regulation; Drug Synergism; Humans; Immunoblotting; Inhibitor of Apoptosis Proteins; Male; Mice; Microtubule-Associated Proteins; Neoplasm Proteins; Organoselenium Compounds; Paclitaxel; Prostatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Survivin; Taxoids; Xenograft Model Antitumor Assays | 2008 |
Endobronchial metastasis from prostate cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bronchial Neoplasms; Bronchoscopy; Carboplatin; Estramustine; Humans; Male; Middle Aged; Paclitaxel; Prostatic Neoplasms; Tomography, X-Ray Computed | 2008 |
Inactivation of ID-1 gene induces sensitivity of prostate cancer cells to chemotherapeutic drugs.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Colony-Forming Units Assay; Drug Resistance, Neoplasm; Enzyme Activation; Humans; Inhibitor of Differentiation Protein 1; JNK Mitogen-Activated Protein Kinases; Male; Neoplasms, Hormone-Dependent; Paclitaxel; Prostatic Neoplasms; RNA, Small Interfering; Tumor Cells, Cultured | 2008 |
Paclitaxel (taxol) inhibits protein isoprenylation and induces apoptosis in PC-3 human prostate cancer cells.
Topics: Apoptosis; Cell Survival; GTP-Binding Proteins; Humans; Male; Oncogene Protein p21(ras); Paclitaxel; Prostatic Neoplasms; Protein Prenylation; rap GTP-Binding Proteins; Tumor Cells, Cultured | 1995 |
Lack of radiosensitization after paclitaxel treatment of three human carcinoma cell lines.
Topics: Breast Neoplasms; Carcinoma; Cell Cycle; Cell Survival; Colonic Neoplasms; Dose-Response Relationship, Drug; Female; Flow Cytometry; G2 Phase; Humans; Male; Mitosis; Paclitaxel; Prostatic Neoplasms; Radiation Tolerance; Radiation-Sensitizing Agents; Radiotherapy Dosage; Tumor Cells, Cultured | 1995 |
Immunoassays of the metalloproteinase (MMP-2) and tissue inhibitor of metalloproteinase (TIMP 1 and 2) levels in noninvasive and metastatic PC-3 clones: effects of taxol.
Topics: Animals; Antibody Specificity; Blotting, Western; Bone Neoplasms; Cell Division; Clone Cells; Enzyme-Linked Immunosorbent Assay; Gelatinases; Glycoproteins; Humans; Immunoassay; Immunoblotting; Male; Matrix Metalloproteinase 2; Metalloendopeptidases; Mice; Mice, SCID; Neoplasm Invasiveness; Neoplasm Transplantation; Paclitaxel; Prostatic Neoplasms; Protein Biosynthesis; Proteins; Tissue Inhibitor of Metalloproteinase-2; Tissue Inhibitor of Metalloproteinases; Tumor Cells, Cultured | 1994 |
Estramustine: a novel radiation enhancer in human carcinoma cells.
Topics: Breast Neoplasms; Cell Cycle; Cell Survival; Colonic Neoplasms; Combined Modality Therapy; Estramustine; Female; Flow Cytometry; Glioma; HeLa Cells; Humans; Male; Microtubules; Neoplasms; Paclitaxel; Prostatic Neoplasms; Radiation-Sensitizing Agents; Tumor Cells, Cultured; Vinblastine | 1994 |
Taxol-induced apoptosis and phosphorylation of Bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathway.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Cell Line; Enzyme Activation; Female; HL-60 Cells; Humans; Male; Paclitaxel; Phosphorylation; Prostatic Neoplasms; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-raf; Signal Transduction; Tetradecanoylphorbol Acetate; Tumor Cells, Cultured | 1996 |
Taxol induces bcl-2 phosphorylation and death of prostate cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; bcl-2-Associated X Protein; Cell Survival; DNA, Neoplasm; Drug Screening Assays, Antitumor; Humans; Male; Microtubules; Neoplasm Proteins; Paclitaxel; Phosphorylation; Prostatic Neoplasms; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured | 1996 |
Effect of estramustine, etoposide, and taxol on prostate cancer cell growth in vitro and in vivo.
Topics: Animals; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Cell Division; Cell Survival; Cells, Cultured; Estramustine; Etoposide; Humans; Male; Paclitaxel; Prostatic Neoplasms; Rats | 1996 |
Taxol reduces circulating tumor cells to prevent bone metastases in SCID mice.
Topics: Animals; Bone Neoplasms; Cell Survival; Humans; Idoxuridine; Keratins; Male; Mice; Mice, SCID; Neoplasm Metastasis; Paclitaxel; Prostatic Neoplasms; Transplantation, Heterologous; Tubulin; Tumor Cells, Cultured | 1995 |
The Harry W. Fischer Lecture Session. Contrast Media: a meandering look.
Topics: Adenocarcinoma; Animals; Awards and Prizes; Contrast Media; Diagnostic Imaging; Dose-Response Relationship, Drug; Female; Humans; Lymphatic Metastasis; Male; Paclitaxel; Prostatic Neoplasms; Research; Structure-Activity Relationship | 1996 |
Bcl2 is the guardian of microtubule integrity.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Chronic Disease; Docetaxel; G2 Phase; Humans; Leukemia; Lymphoma, B-Cell; Male; Microtubules; Paclitaxel; Phosphorylation; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Taxoids; Tumor Cells, Cultured | 1997 |
Interaction of estramustine with tubulin isotypes.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Binding Sites; Brain; Cattle; Colchicine; Estramustine; Guanosine Diphosphate; Guanosine Triphosphate; Humans; In Vitro Techniques; Male; Microtubule Proteins; Mitosis; Paclitaxel; Prostatic Neoplasms; Tubulin; Vinca Alkaloids | 1997 |
Multidrug resistance in androgen-independent growing rat prostate carcinoma cells is mediated by P-glycoprotein.
Topics: Androgens; Animals; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Fluorescent Dyes; Genes, MDR; Male; Methotrexate; Neoplasms, Hormone-Dependent; Paclitaxel; Prostatic Neoplasms; Rats; Rhodamine 123; Rhodamines; Tumor Cells, Cultured; Verapamil; Vinblastine | 1997 |
Enhancement of paclitaxel activity against hormone-refractory prostate cancer cells in vitro and in vivo by quinacrine.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Synergism; Genes, ras; Humans; Lovastatin; Male; Mice; Neoplasm Transplantation; Paclitaxel; Prostatic Neoplasms; Quinacrine; Transplantation, Heterologous; Tumor Cells, Cultured | 1997 |
Effects of alendronate and taxol on PC-3 ML cell bone metastases in SCID mice.
Topics: Alendronate; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Humans; Lumbar Vertebrae; Male; Metalloendopeptidases; Mice; Mice, SCID; Neoplasm Metastasis; Neoplasm Transplantation; Neoplasms, Experimental; Paclitaxel; Prostatic Neoplasms; Survival Rate; Tumor Cells, Cultured | 1996 |
Treatment of human prostate tumors PC-3 and TSU-PR1 with standard and investigational agents in SCID mice.
Topics: Aged; Animals; Antineoplastic Agents; Depsipeptides; Drugs, Investigational; Female; Humans; Lactams; Lactones; Male; Mice; Mice, Nude; Mice, SCID; Middle Aged; Paclitaxel; Piperazines; Prostatic Neoplasms; Vinblastine | 1997 |
Cloning and sequencing of human betaIII-tubulin cDNA: induction of betaIII isotype in human prostate carcinoma cells by acute exposure to antimicrotubule agents.
Topics: Amino Acid Sequence; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Base Sequence; Cloning, Molecular; DNA, Complementary; Drug Resistance; Estramustine; Humans; Male; Microtubules; Molecular Sequence Data; Paclitaxel; Prostatic Neoplasms; Sequence Analysis, DNA; Tubulin; Tumor Cells, Cultured; Vinblastine | 1998 |
Altered beta-tubulin isotype expression in paclitaxel-resistant human prostate carcinoma cells.
Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Drug Resistance, Neoplasm; Humans; Male; Microtubules; Neoplasm Proteins; Paclitaxel; Prostatic Neoplasms; Tubulin; Tumor Cells, Cultured | 1998 |
Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate, and breast cancer.
Topics: Adenoviridae; Animals; Antineoplastic Agents, Phytogenic; Cell Cycle; Combined Modality Therapy; Disease Models, Animal; Drug Synergism; Female; Gene Transfer Techniques; Genes, p53; Genetic Therapy; Genetic Vectors; Head and Neck Neoplasms; Humans; Male; Mammary Neoplasms, Animal; Mice; Microtubules; Neoplasms; Ovarian Neoplasms; Paclitaxel; Prostatic Neoplasms; Transduction, Genetic; Treatment Outcome; Tumor Cells, Cultured | 1998 |
Involvement of microtubules in the regulation of Bcl2 phosphorylation and apoptosis through cyclic AMP-dependent protein kinase.
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Breast Neoplasms; Caspase 3; Caspases; Cyclic AMP-Dependent Protein Kinases; Cysteine Endopeptidases; DNA Damage; Enzyme Activation; Female; Humans; Male; Microtubules; Nocodazole; Paclitaxel; Phosphorylation; Prostatic Neoplasms; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Tumor Cells, Cultured; Vincristine | 1998 |
Paclitaxel, bropirimine and linomide: effect on growth inhibition in a murine prostate cancer model by different growth regulatory mechanisms.
Topics: Animals; Antineoplastic Agents; Cell Division; Cytosine; Hydroxyquinolines; Immunohistochemistry; Male; Mice; Models, Biological; Paclitaxel; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Rats; Rats, Inbred F344 | 1998 |
Androgen-dependent and -independent human prostate xenograft tumors as models for drug activity evaluation.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Doxorubicin; Drug Screening Assays, Antitumor; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Proteins; Neoplasm Transplantation; Neoplasms, Hormone-Dependent; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Transplantation, Heterologous; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 1998 |
Selective potentiation of gynecologic cancer cell growth in vitro by electromagnetic fields.
Topics: Cell Division; Cisplatin; Electromagnetic Fields; Endometrial Neoplasms; Female; Genital Neoplasms, Female; Humans; Male; Ovarian Neoplasms; Paclitaxel; Prostatic Neoplasms; Tumor Cells, Cultured | 1998 |
Taxol and estramustine-induced modulation of human prostate cancer cell apoptosis via alteration in bcl-xL and bak expression.
Topics: Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; bcl-X Protein; Estramustine; Gene Expression Regulation, Neoplastic; Glyceraldehyde-3-Phosphate Dehydrogenases; Humans; Kinetics; Male; Membrane Proteins; Paclitaxel; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Transcription, Genetic; Tumor Cells, Cultured | 1997 |
In vitro evaluation of synergism or antagonism with combinations of new cytotoxic agents.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Etoposide; Gemcitabine; Humans; Male; Paclitaxel; Prostatic Neoplasms; Sarcoma; Tumor Cells, Cultured; Vinblastine; Vinorelbine | 1998 |
Paclitaxel is more effective than thalidomide in inhibiting LNCaP tumor growth in a prostate cancer model.
Topics: Androgen Antagonists; Animals; Antineoplastic Agents, Phytogenic; Humans; Male; Mice; Mice, Nude; Paclitaxel; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Thalidomide; Tumor Cells, Cultured | 1998 |
A novel taxane with improved tolerability and therapeutic activity in a panel of human tumor xenografts.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Division; Cell Survival; Colonic Neoplasms; Drug Resistance, Multiple; Female; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Ovarian Neoplasms; Paclitaxel; Prostatic Neoplasms; Transplantation, Heterologous; Tumor Cells, Cultured; Uterine Cervical Neoplasms | 1999 |
Activation of Rb and decline in androgen receptor protein precede retinoic acid-induced apoptosis in androgen-dependent LNCaP cells and their androgen-independent derivative.
Topics: Antigens, Surface; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Carboxypeptidases; Cell Differentiation; Cell Division; Dihydrotestosterone; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Flow Cytometry; Gene Expression Regulation, Neoplastic; Glutamate Carboxypeptidase II; Growth Inhibitors; Humans; Keratins; Male; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Receptors, Androgen; Retinoblastoma Protein; Tretinoin; Tumor Cells, Cultured | 1999 |
Interaction between stromal cells and tumor cells induces chemoresistance and matrix metalloproteinase secretion.
Topics: Animals; Coculture Techniques; Collagenases; Drug Resistance, Neoplasm; Endothelium, Vascular; Epithelial Cells; Gelatinases; Humans; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Metalloendopeptidases; Microcirculation; Paclitaxel; Prostatic Neoplasms; Protease Inhibitors; Rats; Stromal Cells; Tetracyclines; Tumor Cells, Cultured | 1999 |
Chemotherapy combination shows efficacy in hormone-refractory prostate cancer.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Administration Routes; Estramustine; Follow-Up Studies; Humans; Hydrocortisone; Male; Paclitaxel; Prostatic Neoplasms; Taxoids; Treatment Outcome | 1999 |
Cytotoxicity and neurocytotoxicity of new marine anticancer agents evaluated using in vitro assays.
Topics: Animals; Antineoplastic Agents; Cell Division; Depsipeptides; Drug Screening Assays, Antitumor; Growth Inhibitors; Humans; Male; Nervous System Diseases; Oligopeptides; Paclitaxel; PC12 Cells; Peptides, Cyclic; Prostatic Neoplasms; Pyrans; Rats; Spiro Compounds; Tumor Cells, Cultured; Vinblastine; Vincristine; Vinorelbine | 1999 |
Signaling network of paclitaxel-induced apoptosis in the LNCaP prostate cancer cell line.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Caspases; Cell Cycle Proteins; Cyclin B; Cyclin B1; Dose-Response Relationship, Drug; HeLa Cells; Humans; Male; Paclitaxel; Prostatic Neoplasms; Tumor Cells, Cultured | 1999 |
Response of prostate cancer to anti-Her-2/neu antibody in androgen-dependent and -independent human xenograft models.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Female; Humans; Immunohistochemistry; Male; Mice; Mice, Nude; Paclitaxel; Prostatic Neoplasms; Receptor, ErbB-2; Transplantation, Heterologous; Trastuzumab | 1999 |
In vivo anti-tumor activity of a novel indolocarbazole compound, J-107088, on murine and human tumors transplanted into mice.
Topics: Animals; Antineoplastic Agents; Body Weight; Breast Neoplasms; Carbazoles; Cisplatin; Colonic Neoplasms; Doxorubicin; Drug Administration Schedule; Female; Glucosides; Humans; Indoles; Leukemia P388; Lung Neoplasms; Male; Mice; Mice, Inbred Strains; Mice, Nude; Neoplasms; Paclitaxel; Prostatic Neoplasms; Time Factors | 1999 |
Docetaxel (Taxotere) in hormone-refractory prostate cancer: a new addition to the physicians' toolbag.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Docetaxel; Humans; Male; Neoplasms, Hormone-Dependent; Paclitaxel; Prostatic Neoplasms; Taxoids | 1999 |
Docetaxel (Taxotere) and estramustine versus mitoxantrone and prednisone for hormone-refractory prostate cancer: scientific basis and design of Southwest Oncology Group Study 9916.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Docetaxel; Estramustine; Humans; Male; Mitoxantrone; Neoplasms, Hormone-Dependent; Paclitaxel; Prednisone; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids | 1999 |
Combination therapy with the farnesyl protein transferase inhibitor SCH66336 and SCH58500 (p53 adenovirus) in preclinical cancer models.
Topics: Adenocarcinoma; Adenoviruses, Human; Alkyl and Aryl Transferases; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Survival; Drug Synergism; Female; Genes, ras; Humans; Male; Mice; Mice, Nude; Mice, SCID; Mice, Transgenic; Ovarian Neoplasms; Paclitaxel; Pancreatic Neoplasms; Piperidines; Prostatic Neoplasms; Pyridines; Teratocarcinoma; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 1999 |
Targeting bcl-2 gene to delay androgen-independent progression and enhance chemosensitivity in prostate cancer using antisense bcl-2 oligodeoxynucleotides.
Topics: Androgens; Animals; Antineoplastic Agents, Phytogenic; Blotting, Northern; Blotting, Western; Disease Progression; DNA Primers; DNA, Neoplasm; Docetaxel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Gene Targeting; Genes, bcl-2; Male; Mice; Oligodeoxyribonucleotides, Antisense; Paclitaxel; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; Taxoids | 1999 |
Docetaxel (Taxotere): a new option for the treatment of hormone-refractory prostate cancer. Proceedings of a symposium. Chicago, Illinois, USA. April 23, 1999.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Docetaxel; Humans; Male; Neoplasms, Hormone-Dependent; Paclitaxel; Prostatic Neoplasms; Taxoids | 1999 |
Chemosensitization and delayed androgen-independent recurrence of prostate cancer with the use of antisense Bcl-2 oligodeoxynucleotides.
Topics: Androgens; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Male; Mammary Neoplasms, Experimental; Mice; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Oligonucleotides, Antisense; Paclitaxel; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm | 2000 |
Androgen and taxol cause cell type-specific alterations of centrosome and DNA organization in androgen-responsive LNCaP and androgen-independent DU145 prostate cancer cells.
Topics: Androgens; Antineoplastic Agents, Phytogenic; Cell Division; Centrosome; Dihydrotestosterone; DNA, Neoplasm; Humans; Male; Metribolone; Microscopy, Electron; Microscopy, Fluorescence; Neoplasms, Hormone-Dependent; Paclitaxel; Prostatic Neoplasms; Testosterone Congeners | 2000 |
Efficacy of microtubule-active drugs followed by ketoconazole in human metastatic prostate cancer cell lines.
Topics: Antineoplastic Agents; Drug Screening Assays, Antitumor; Humans; Ketoconazole; Male; Microtubules; Paclitaxel; Phosphorylation; Prostatic Neoplasms; Tumor Cells, Cultured; Vinblastine | 2000 |
Antisense suppression of proline-directed protein kinase FA enhances chemosensitivity in human prostate cancer cells.
Topics: Antineoplastic Agents; Carboplatin; Cell Survival; Cisplatin; DNA, Antisense; DNA, Complementary; DNA, Recombinant; Dose-Response Relationship, Drug; Fluorouracil; Gene Expression Regulation, Enzymologic; Genetic Vectors; Humans; Hydroxyurea; Male; Paclitaxel; Proline-Directed Protein Kinases; Prostatic Neoplasms; Protein Serine-Threonine Kinases; Transfection; Tumor Cells, Cultured | 2000 |
Doxazosin: a new cytotoxic agent for prostate cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Doxazosin; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Etoposide; Humans; Male; Paclitaxel; Prostatic Neoplasms; Tumor Cells, Cultured | 2000 |
Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene testosterone-repressed prostate message-2 in prostate cancer xenograft models.
Topics: Animals; Antineoplastic Agents, Phytogenic; Blotting, Northern; Blotting, Western; Clusterin; Disease Progression; DNA Fragmentation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Glycoproteins; Humans; Male; Mice; Mice, Nude; Molecular Chaperones; Neoplasm Transplantation; Oligonucleotides, Antisense; Paclitaxel; Phenotype; Prostate-Specific Antigen; Prostatic Neoplasms; Time Factors; Tumor Cells, Cultured | 2000 |
Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo.
Topics: Androgens; Animals; Antineoplastic Agents; Cell Division; Cell Survival; Clusterin; DNA Fragmentation; Dose-Response Relationship, Drug; Drug Synergism; Gene Expression Regulation, Neoplastic; Glycoproteins; Humans; In Situ Nick-End Labeling; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Mitoxantrone; Molecular Chaperones; Oligodeoxyribonucleotides, Antisense; Paclitaxel; Prostatic Neoplasms; RNA, Messenger; Thionucleotides; Tumor Cells, Cultured | 2000 |
Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Bone Neoplasms; Breast Neoplasms; Cell Adhesion; Cell Cycle; Cell Movement; Clodronic Acid; Collagen; Diphosphonates; Dose-Response Relationship, Drug; Drug Combinations; Flow Cytometry; Fluorometry; Humans; Ibandronic Acid; Imidazoles; Laminin; Male; Matrix Metalloproteinases; Neoplasm Invasiveness; Neoplasm Metastasis; Paclitaxel; Prostatic Neoplasms; Proteoglycans; Pyridines; Pyridinium Compounds; Tumor Cells, Cultured; Zinc; Zoledronic Acid | 2000 |
Rapid in vivo monitoring of chemotherapeutic response using weighted sodium magnetic resonance imaging.
Topics: Animals; Annexin A5; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Nucleus; Docetaxel; Etoposide; Flow Cytometry; Fluorescent Antibody Technique; Fluorescent Dyes; Humans; Magnetic Resonance Imaging; Male; Mice; Neoplasm Transplantation; Paclitaxel; Phantoms, Imaging; Prostatic Neoplasms; Sodium; Sodium Chloride; Taxoids; Time Factors; Treatment Outcome; Tumor Cells, Cultured | 2000 |
Polymeric micellar paclitaxel phosphorylates Bcl-2 and induces apoptotic regression of androgen-independent LNCaP prostate tumors.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Electrophoresis, Agar Gel; Gentian Violet; Humans; Immunoenzyme Techniques; In Situ Nick-End Labeling; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Micelles; Orchiectomy; Paclitaxel; Phosphorylation; Prostate-Specific Antigen; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured | 2000 |
Fibroblast growth factors: an epigenetic mechanism of broad spectrum resistance to anticancer drugs.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Division; Culture Media, Conditioned; Doxorubicin; Drug Resistance, Neoplasm; Fibroblast Growth Factor 1; Fibroblast Growth Factor 2; Fluorouracil; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Paclitaxel; Prostatic Neoplasms; Rats; Suramin; Tumor Cells, Cultured | 2000 |
Cytoprotective effect of arginine deiminase on taxol-induced apoptosis in DU145 human prostate cancer cells.
Topics: Amino Acid Sequence; Animals; Apoptosis; Arginine; Astrocytes; Cell Line; Culture Media, Conditioned; Cycloheximide; Cytoprotection; DNA Fragmentation; G1 Phase; Humans; Hydrolases; L-Lactate Dehydrogenase; Lipopolysaccharides; Male; Molecular Sequence Data; Nitric Oxide; Paclitaxel; Prostatic Neoplasms; Protein Synthesis Inhibitors; Rats; Sequence Alignment; Sertoli Cells; Tumor Cells, Cultured | 2000 |
Colitis and docetaxel-based chemotherapy.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Colitis; Diarrhea; Docetaxel; Estramustine; Female; Humans; Male; Paclitaxel; Prostatic Neoplasms; Taxoids; Vinblastine; Vinorelbine | 2000 |
A peptidomimetic inhibitor of ras functionality markedly suppresses growth of human prostate tumor xenografts in mice. Prospects for long-term clinical utility.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Growth Inhibitors; Humans; Male; Methionine; Mice; Mice, Nude; Models, Chemical; Molecular Mimicry; Neoplasm Transplantation; Paclitaxel; Prostatic Neoplasms; ras Proteins; Transplantation, Heterologous; Tumor Cells, Cultured | 2000 |
Simultaneous estimation of T(G2+M), T(S), and T(pot) using single sample dynamic tumor data from bivariate DNA-thymidine analogue cytometry.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Phytogenic; Bromodeoxyuridine; DNA, Neoplasm; Female; Flow Cytometry; G2 Phase; Halogens; Interphase; Kinetics; Male; Mammary Neoplasms, Experimental; Mice; Mitosis; Orchiectomy; Paclitaxel; Prostatic Neoplasms; Rats; S Phase; Thymidine | 2000 |
The suppression of human prostate tumor growth in mice by the intratumoral injection of a slow-release polymeric paste formulation of paclitaxel.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Division; Chemistry, Pharmaceutical; Delayed-Action Preparations; Growth Inhibitors; Humans; Injections, Intralesional; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Ointments; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Tumor Cells, Cultured | 2000 |
Treatment of androgen-independent prostate cancer using antimicrotubule agents docetaxel and estramustine in combination: an experimental study.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Estramustine; Humans; Inhibitory Concentration 50; Male; Microtubules; Neoplasm Transplantation; Neoplasms, Hormone-Dependent; Paclitaxel; Prostatic Neoplasms; Rats; Taxoids; Tumor Cells, Cultured | 2000 |
Docetaxel (taxotere) extravasation: a report of five cases with treatment recommendations.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Edema; Erythema; Extravasation of Diagnostic and Therapeutic Materials; Hand; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prostatic Neoplasms; Taxoids | 2000 |
Synergism of cytotoxic effects of vinorelbine and paclitaxel in vitro.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Female; Humans; Male; Paclitaxel; Prostatic Neoplasms; Sarcoma; Tumor Cells, Cultured; Vinblastine; Vinorelbine | 2000 |
Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase.
Topics: Aminopterin; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Carboplatin; Cell Division; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; ErbB Receptors; Female; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Male; Maximum Tolerated Dose; Mice; Mice, Nude; Neoplasm Transplantation; Paclitaxel; Prostatic Neoplasms; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Taxoids; Time Factors; Tumor Cells, Cultured; Vinblastine; Vinorelbine; Vulvar Neoplasms | 2000 |
Different docetaxel-induced apoptotic pathways are present in prostate cancer cell lines LNCaP and PC-3.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Caspases; Clusterin; Docetaxel; Glycoproteins; Humans; Inhibitor of Apoptosis Proteins; Male; Microtubule-Associated Proteins; Molecular Chaperones; Neoplasm Proteins; Paclitaxel; Prostatic Neoplasms; Proteins; Survivin; Taxoids; Tumor Cells, Cultured | 2001 |
Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel.
Topics: Adenoviridae; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line; Cell Survival; DNA, Viral; Docetaxel; Dose-Response Relationship, Drug; Drug Synergism; Humans; Immunoblotting; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Paclitaxel; Prostatic Neoplasms; Taxoids; Time Factors; Treatment Outcome; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Virus Replication; Xenograft Model Antitumor Assays | 2001 |
Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Apoptosis Regulatory Proteins; Blotting, Western; Dose-Response Relationship, Drug; Drug Synergism; Humans; Male; Membrane Glycoproteins; Paclitaxel; Prostatic Neoplasms; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha; Up-Regulation | 2001 |
Synergistic chemosensitization and inhibition of progression to androgen independence by antisense Bcl-2 oligodeoxynucleotide and paclitaxel in the LNCaP prostate tumor model.
Topics: Androgens; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Division; DNA Primers; Drug Synergism; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Oligonucleotides, Antisense; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured | 2001 |
A new prodrug of paclitaxel: synthesis of Protaxel.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Division; Drug Stability; Drug Tolerance; Female; Half-Life; Humans; Hydrogen-Ion Concentration; Male; Maximum Tolerated Dose; Mice; Mice, Inbred BALB C; Mice, Nude; Ovarian Neoplasms; Paclitaxel; Prodrugs; Prostatic Neoplasms; Rats; Rats, Sprague-Dawley; Solubility; Taxoids; Xenograft Model Antitumor Assays | 2001 |
Modulation of docetaxel-induced apoptosis and cell cycle arrest by all- trans retinoic acid in prostate cancer cells.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Cycle; Cyclin D1; Docetaxel; Down-Regulation; Drug Interactions; Humans; Male; Paclitaxel; Prostatic Neoplasms; Taxoids; Tretinoin; Tumor Cells, Cultured | 2001 |
Combination therapy in hormone-refractory prostate cancer.
Topics: Anti-Inflammatory Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Docetaxel; Estramustine; Humans; Hydrocortisone; Male; Paclitaxel; Prostatic Neoplasms; Taxoids | 2001 |
Use of antisense oligonucleotides targeting the antiapoptotic gene, clusterin/testosterone-repressed prostate message 2, to enhance androgen sensitivity and chemosensitivity in prostate cancer.
Topics: Androgen Antagonists; Animals; Antineoplastic Agents, Hormonal; Apoptosis; Calcium Channel Blockers; Cell Death; Clusterin; Disease Models, Animal; Drug Synergism; Glycoproteins; Humans; Male; Mice; Molecular Chaperones; Neoadjuvant Therapy; Oligonucleotides, Antisense; Orchiectomy; Paclitaxel; Prostatic Neoplasms; Up-Regulation; Xenograft Model Antitumor Assays | 2001 |
Antitumor activity of antisense clusterin oligonucleotides is improved in vitro and in vivo by incorporation of 2'-O-(2-methoxy)ethyl chemistry.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Blotting, Northern; Clusterin; Electrophoresis, Capillary; Glycoproteins; Half-Life; Humans; Male; Mice; Molecular Chaperones; Neoplasm Proteins; Oligonucleotides, Antisense; Paclitaxel; Prostatic Neoplasms; RNA, Messenger; Tetrazolium Salts; Thiazoles; Tumor Cells, Cultured | 2001 |
Nontoxic doses of suramin enhance activity of paclitaxel against lung metastases.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Culture Media, Conditioned; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Humans; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Paclitaxel; Prostatic Neoplasms; Rats; Suramin; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2001 |
Therapeutic implications of enhanced G(0)/G(1) checkpoint control induced by coculture of prostate cancer cells with osteoblasts.
Topics: Antineoplastic Agents; Apoptosis; Cell Communication; Cell Cycle; Cell Division; Coculture Techniques; Culture Media, Conditioned; Doxorubicin; G1 Phase; Humans; Male; Neoplasms, Hormone-Dependent; Osteoblasts; Paclitaxel; Prostatic Neoplasms; Resting Phase, Cell Cycle; Thapsigargin; Tumor Cells, Cultured | 2001 |
Modulation of endogenous beta-tubulin isotype expression as a result of human beta(III)cDNA transfection into prostate carcinoma cells.
Topics: Antineoplastic Agents; Colchicine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Estramustine; Genetic Vectors; Humans; Male; Microtubules; Neoplasm Proteins; Paclitaxel; Prostatic Neoplasms; Protein Isoforms; Reverse Transcriptase Polymerase Chain Reaction; Transfection; Tubulin; Tumor Cells, Cultured; Vinblastine | 2001 |
Cell cycle checkpoint efficiency and cellular response to paclitaxel in prostate cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; CDC2 Protein Kinase; Cell Cycle; Cell Cycle Proteins; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; DNA, Neoplasm; Flow Cytometry; Humans; Male; Microtubules; Paclitaxel; Phosphorylation; Prostatic Neoplasms; Retinoblastoma Protein; Tumor Cells, Cultured | 2001 |
Antitumor efficacy of 26-fluoroepothilone B against human prostate cancer xenografts.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Epothilones; Humans; Infusions, Intravenous; Macrolides; Male; Mice; Mice, Nude; Paclitaxel; Prostatic Neoplasms; Transplantation, Heterologous; Tumor Cells, Cultured | 2001 |
Inhibition of potentially anti-apoptotic proteins by antisense protein kinase C-alpha (Isis 3521) and antisense bcl-2 (G3139) phosphorothioate oligodeoxynucleotides: relationship to the decreased viability of T24 bladder and PC3 prostate cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Cell Survival; Down-Regulation; Gene Deletion; Humans; Isoenzymes; Male; NF-kappa B; Oligodeoxyribonucleotides, Antisense; Paclitaxel; Prostatic Neoplasms; Protein Kinase C; Protein Kinase C-alpha; Proto-Oncogene Proteins c-bcl-2; Ribonuclease H; RNA, Messenger; Thionucleotides; Transcription Factor RelA; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2001 |
Enhanced transgene expression in androgen independent prostate cancer gene therapy by taxane chemotherapeutic agents.
Topics: Adenoviridae; Antineoplastic Agents, Phytogenic; Docetaxel; Gene Expression; Genetic Therapy; Humans; Male; Paclitaxel; Prostatic Neoplasms; Taxoids; Transgenes; Tumor Cells, Cultured | 2002 |
Combined modality radioimmunotherapy for human prostate cancer xenografts with taxanes and 90yttrium-DOTA-peptide-ChL6.
Topics: Animals; Combined Modality Therapy; Docetaxel; Heterocyclic Compounds; Humans; Male; Mice; Mice, Nude; Neoplasm Transplantation; Oligopeptides; Paclitaxel; Prostatic Neoplasms; Radiation-Sensitizing Agents; Radioimmunotherapy; Taxoids; Transplantation, Heterologous; Yttrium | 2002 |
Successful treatment of metastatic hormone-refractory prostate cancer with malignant pericardial tamponade using docetaxel.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cardiac Tamponade; Cisplatin; Combined Modality Therapy; Docetaxel; Humans; Male; Methylprednisolone; Middle Aged; Paclitaxel; Pericardial Effusion; Pericardiocentesis; Pleural Effusion; Prostatic Neoplasms; Taxoids | 2002 |
Antineoplastic effects of chemotherapeutic agents are potentiated by NM-3, an inhibitor of angiogenesis.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Aorta; Breast Neoplasms; Cell Movement; Coumarins; Cyclophosphamide; Drug Synergism; Endothelium, Vascular; Female; Fluorouracil; Growth Inhibitors; Humans; Isocoumarins; Male; Mice; Mice, Nude; Neovascularization, Pathologic; Paclitaxel; Prostatic Neoplasms; Rats; Rats, Sprague-Dawley; Xenograft Model Antitumor Assays | 2002 |
Severe interstitial pneumonitis associated with docetaxel administration.
Topics: Adrenal Cortex Hormones; Aged; Anti-Bacterial Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Fatal Outcome; Female; Humans; Lung Diseases, Interstitial; Male; Middle Aged; Paclitaxel; Prognosis; Prostatic Neoplasms; Respiration, Artificial; Taxoids; Uterine Neoplasms | 2002 |
[Globalization of anti-cancer therapies].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carboplatin; Cisplatin; Colorectal Neoplasms; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Neoplasms; Ovarian Neoplasms; Paclitaxel; Prostatic Neoplasms; Stomach Neoplasms | 2002 |
Protein kinase Cdelta amplifies ceramide formation via mitochondrial signaling in prostate cancer cells.
Topics: Acetophenones; Antineoplastic Agents, Phytogenic; Apoptosis; Benzopyrans; Caspase Inhibitors; Caspases; Cell Fractionation; Ceramides; Enzyme Inhibitors; Etoposide; Flow Cytometry; Humans; Isoenzymes; Male; Mitochondria; Paclitaxel; Prostatic Neoplasms; Protein Kinase C; Protein Kinase C-delta; Signal Transduction; Sphingomyelins; Tumor Cells, Cultured | 2002 |
Inhibition of angiogenesis by the antiepidermal growth factor receptor antibody ImClone C225 in androgen-independent prostate cancer growing orthotopically in nude mice.
Topics: Androgens; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Apoptosis; Blood Vessels; Cell Cycle Proteins; Cell Division; Cetuximab; Cyclin-Dependent Kinase Inhibitor p27; Dose-Response Relationship, Drug; Epidermal Growth Factor; ErbB Receptors; Humans; Interleukin-8; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Metastasis; Neoplasm Transplantation; Neovascularization, Pathologic; Paclitaxel; Phosphorylation; Prostatic Neoplasms; RNA, Messenger; Tumor Cells, Cultured; Tumor Suppressor Proteins; Tyrosine; Up-Regulation; Xenograft Model Antitumor Assays | 2002 |
Nonredundant antioxidant defense by multiple two-cysteine peroxiredoxins in human prostate cancer cells.
Topics: Animals; Antibody Specificity; Antineoplastic Agents; Antioxidants; Cysteine; Doxorubicin; Etoposide; Humans; Hydrogen Peroxide; Immune Sera; Male; Mice; Oxidative Stress; Paclitaxel; Peroxidases; Peroxiredoxin III; Peroxiredoxins; Prostatic Neoplasms; Protein Isoforms; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 2002 |
Taxol blocks processes essential for prostate tumor cell (PC-3 ML) invasion and metastases.
Topics: Alkaloids; Animals; Antineoplastic Agents, Phytogenic; Cell Movement; Gelatinases; Humans; Male; Mice; Mice, SCID; Microbial Collagenase; Neoplasm Invasiveness; Neoplasm Metastasis; Paclitaxel; Pepsin A; Prostatic Neoplasms; Proteins | 1992 |
Combined antimicrotubule activity of estramustine and taxol in human prostatic carcinoma cell lines.
Topics: Alkaloids; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cell Cycle; Drug Screening Assays, Antitumor; Estramustine; Flow Cytometry; Humans; Male; Micronucleus Tests; Microtubules; Paclitaxel; Prostatic Neoplasms; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1992 |
Diethylstilbestrol induces metaphase arrest and inhibits microtubule assembly.
Topics: Alkaloids; Brain; Cell Line; Diethylstilbestrol; Humans; Male; Metaphase; Microtubules; Paclitaxel; Prostatic Neoplasms; Tubulin | 1985 |
Morphological studies on the effect of taxol on cultured human prostatic cancer cells.
Topics: Adenocarcinoma; Alkaloids; Dimethyl Sulfoxide; Humans; Male; Microscopy, Electron; Paclitaxel; Prostatic Neoplasms; Tumor Cells, Cultured | 1987 |
Brevifoliol ester induces apoptosis in prostate cancer cells by activation of caspase pathway.
Topics: Acetic Acid; Animals; Antineoplastic Agents; Apoptosis; Benzoic Acid; Drug Screening Assays, Antitumor; Esterification; Esters; Humans; Male; Mice; Molecular Docking Simulation; Neoplasms, Experimental; PC-3 Cells; Plant Extracts; Prostatic Neoplasms; Taxoids; Taxus | 2020 |
Novel taxa-4(20),12-diene and 2(3→20)abeotaxane from needles of Taxus canadensis.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Female; Humans; Magnetic Resonance Spectroscopy; Male; Molecular Structure; Plant Extracts; Plant Leaves; Prostatic Neoplasms; Taxoids; Taxus; Treatment Failure; Uterine Cervical Neoplasms | 2011 |
Treatment of PC-3 and DU145 prostate cancer cells by prenylflavonoids from hop (Humulus lupulus L.) induces a caspase-independent form of cell death.
Topics: Amino Acid Chloromethyl Ketones; Caspase 3; Caspase Inhibitors; Caspases; Cell Death; Cell Line, Tumor; Cell Survival; Cysteine Proteinase Inhibitors; Dose-Response Relationship, Drug; Flavanones; Flavonoids; Humans; Humulus; Male; Molecular Structure; Plant Extracts; Propiophenones; Prostatic Neoplasms; Xanthones | 2008 |